



(86) Date de dépôt PCT/PCT Filing Date: 2007/02/09
(87) Date publication PCT/PCT Publication Date: 2007/08/16
(45) Date de délivrance/Issue Date: 2019/06/18
(85) Entrée phase nationale/National Entry: 2008/08/07
(86) N° demande PCT/PCT Application No.: NZ 2007/000029
(87) N° publication PCT/PCT Publication No.: 2007/091904
(30) Priorité/Priority: 2006/02/10 (NZ545243)

(51) Cl.Int./Int.Cl. *C12Q 1/68* (2018.01),
C12Q 1/6809 (2018.01), *C12Q 1/6886* (2018.01),
G01N 33/48 (2006.01), *G01N 33/574* (2006.01)
(72) Inventeur/Inventor:
GUILFORD, PARRY JOHN, NZ
(73) Propriétaire/Owner:
PACIFIC EDGE BIOTECHNOLOGY LTD., NZ
(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : PROPORTIONS D'EXPRESSION DE GENES DANS L'URINE POUR DETECTER UN CANCER
(54) Title: URINE GENE EXPRESSION RATIOS FOR DETECTION OF CANCER

(57) **Abrégé/Abstract:**

This invention relates to methods for determining the presence of cancer in a subject based on the analysis of the expression levels of an under-expressed tumour marker (TM) and at least one other TM. Specifically, this invention relates to the determination of a cancer, particularly bladder cancer, by performing ratio, regression or classification analysis of the expression levels of at least one under-expressed TM, particularly an under-expressed bladder TM (BTM), and at least one over-expressed TM, particularly an over-expressed BTM. In various aspects, the invention relates to kits and devices for carrying out these methods.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2007 (16.08.2007)

PCT

(10) International Publication Number
WO 2007/091904 A1

(51) International Patent Classification:
C12Q 1/68 (2006.01) *G01N 33/574* (2006.01)

(21) International Application Number:
PCT/NZ2007/000029

(22) International Filing Date: 9 February 2007 (09.02.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
545243 10 February 2006 (10.02.2006) NZ

(71) Applicant (for all designated States except US): **PACIFIC
EDGE BIOTECHNOLOGY LIMITED** [NZ/NZ]; T D
Scott & Co Ltd, Level 6, Otago House, 481 Moray Place,
Dunedin (NZ).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **GUILFORD, Parry
John** [NZ/NZ]; 38 Riccarton Road East, East Taieri,
Dunedin (NZ).

(74) Agent: **BALDWINS**; P O Box 852, Wellington (NZ).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS,
LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: URINE GENE EXPRESSION RATIOS FOR DETECTION OF CANCER

(57) Abstract: This invention relates to methods for determining the presence of cancer in a subject based on the analysis of the expression levels of an under-expressed tumour marker (TM) and at least one other TM. Specifically, this invention relates to the determination of a cancer, particularly bladder cancer, by performing ratio, regression or classification analysis of the expression levels of at least one under-expressed TM, particularly an under-expressed bladder TM (BTM), and at least one over-expressed TM, particularly an over-expressed BTM. In various aspects, the invention relates to kits and devices for carrying out these methods.

WO 2007/091904 A1

URINE GENE EXPRESSION RATIOS FOR DETECTION OF CANCER**TECHNICAL FIELD**

This invention relates to detection of cancer. Specifically, the invention relates to the use of markers for the detection of bladder cancer. More specifically, this invention relates to use of an under-expressed marker in combination with at least one other marker for the detection of bladder cancer.

BACKGROUND

Survival of cancer patients is greatly enhanced when the cancer is treated early. In the case of bladder cancer, patients diagnosed with early stage disease have 5-year survival rates of >90%, compared to approximately 15-30% for patients diagnosed with advanced disease. Therefore, developments that lead to early diagnosis of bladder cancer can lead to an improved prognosis for the patients. The established method for detecting bladder cancer using urine samples is cytology. However, cytology is known to be only about 75% sensitive for detecting invasive bladder cancer and only about 25% sensitive for detecting superficial bladder cancer (Lotan and Roehrborn, Urology 61, 109-118 (2003)).

Identification of specific markers for cancer in urine can provide a valuable approach for the early diagnosis of cancer, leading to early treatment and improved prognosis. Specific cancer markers also provide a means for monitoring disease progression, enabling the efficacy of surgical, radiotherapeutic and chemotherapeutic treatments to be monitored.

At present, the most reliable method for detecting bladder cancer is cystoscopy accompanied by histology of biopsied lesions. However, this technique is time consuming, invasive and its sensitivity is only approximately 90%, meaning that about 10 percent of cancers are not detected using these methods. Of the non-invasive methodologies, urine cytology, which detects exfoliated malignant cells microscopically, is the current preferred method. Although cytology has a specificity of about 95%, it has poor sensitivity (9-25%) for low-grade lesions, is extremely dependent on sample quality and suffers from high inter-observer variability.

Several urine protein markers are known. Tests for these markers offer better sensitivity than cytology, but tend to suffer from sub-optimal specificity because elevated levels of these markers are also commonly observed in patients with non-malignant diseases including inflammation, urolithiasis and benign prostatic hyperplasia. For example, NMP22, which

detects a specific nuclear matrix protein, has a sensitivity of 47-87% and a specificity of 58-91%.

One drawback associated with urine testing is that individual marker levels can vary significantly with: (i) different urine collection methods (catheterised, voided, urine pellets); (ii) the diurnal timing of urine sampling; (iii) the point of sampling during voiding (e.g. midstream vs end sample); and (iv) urine concentration associated with varying fluid intake, kidney function or diseases that affect plasma volume. These variations have the potential to lead to false positive and false negative tests. Although some of this variation can be reduced using strict standard operating procedures, patient compliance with these procedures can be unreliable. The effect of varying urine concentration can, in some instances, be accounted for by assessing marker levels relative to urinary creatinine, however, this increases the cost and complexity of testing, particularly when sample preparation or storage methods differ for marker detection and creatinine measurement.

There is a need for simple tools for the early detection and diagnosis of cancer. This invention provides further methods, devices and kits based on markers, specifically ratios, regression or classification analysis of bladder cancer markers, to aid in the detection and diagnosis of bladder cancer.

SUMMARY OF THE INVENTION

The present invention provides for a method for determining the presence of a cancer in a subject, comprising:

- (a) providing a sample from the subject;
- (b) detecting the expression level of at least two tumour marker (TM) family members in said sample, wherein at least one TM is an under-expressed TM;
- (c) establishing whether the patient has cancer according to a predetermined threshold.

Step (c) can be preformed by determining the ratio of expression of said TMs, or by performing regression or classification analysis on the TM expression levels.

The TM can be a BTM. The cancer to be detected can be bladder cancer, and in certain embodiments at least one of the TMs is an over-expressed BTM. The over-expressed BTM may be selected from the group outlined in Figure 11 or Figure 12.

- 3 -

In certain embodiments at least one under-expressed TM is a BTM selected from the group outlined in Figure 3 or Figure 4.

5 In other embodiments of the present invention the step of detecting is carried out by detecting over expression of BTM mRNA, a BTM protein, or a BTM peptide.

The sample can be any one of biopsy, blood, serum, peritoneal washes, cerebrospinal fluid, urine and stool samples

10 The present invention also provides for a device for detecting a TM, comprising:
a substrate having a TM capture reagent thereon; and
a detector associated with said substrate, said detector capable of detecting a TM associated with said capture reagent, wherein the TM is an under-expressed TM.

15 The TM can be a BTM.

The TM capture reagent can be an oligonucleotide or an antibody.

20 In certain embodiments the TM can be a BTM selected from the group outlined in Figure 3 or Figure 4.

The present invention also provides for a kit for determining the presence of a cancer in a subject, comprising:

25 a substrate;
at least two TM capture reagents, wherein at least one TM is an under-expressed TM;
and
instructions for use.

30 The TM can be a BTM.

The TM capture reagent may be a TM -specific oligonucleotide or a TM -specific antibody.

The TM detected by the kit may be a BTM selected from the group outlined in Figure 3 or Figure 4.

35

At least one of the TMs detected by the kit may be an over-expressed TM or an over-expressed BTM. The over-expressed BTM may be selected from the group outlined in Figure 11 or Figure 12.

5 BRIEF DESCRIPTION OF THE FIGURES

This invention is described with reference to specific embodiments thereof and with reference to the Figures, in which:

- 10 Figure 1 depicts a table showing the characteristics of urine samples used in the qPCR analyses.
- Figure 2 depicts a table of primers and oligonucleotide probes of markers for qPCR analysis of bladder cancer according to the present invention.
- 15 Figure 3 depicts a table of under-expressing bladder tumour markers identified using microarray methods on samples of bladder cancer.
- Figure 4 depicts a table of under-expressing bladder tumour markers identified using microarray methods on samples of bladder cancer that have insignificant expression in whole blood, but high expression in normal bladder tissue.
- 20 Figure 5 depicts box and whisker plots showing the ratios of three bladder transitional cell carcinoma (TCC) markers (HoxA13, IGFBP5, and MDK) with the under expressing marker LTB4DH for urine samples from patients with either non-malignant urological disease or TCC. The boxes define the 25th, 50th and 75th percentiles and the horizontal bars mark the adjacent values. Outliers are shown by circles. The unfilled boxes represent samples from non-malignant disease controls and the shaded boxes represent samples from patients with TCC.
- 25 Figure 6 shows examples of the sensitivities and specificities of TCC detection for tests that include LTB4DH. (a). single tests; (b). combination tests using LTB4DH and two of the three markers HoxA13, IGFBP5, and MDK.
- 30

- 5 -

Figure 7a-c shows ROC curves for the sensitivity and specificity of detection of TCC in urine samples using ratios that include LTB4DH. 7a. IGFBP5/LTB4DH; 7b. MDK/LTB4DH; 7c. HoxA13/LTB4DH.

Figure 8a-f shows scatter plots for combination tests, a-c using LTB4DH and two of the three markers HoxA13, IGFBP5, and MDK, and d-f repeated using BAG1 for LTB4DH. 8a. MDK/LTB4DH and IGFBP5/LTB4DH; 8b. MDK/LTB4DH and HoxA13/LTB4DH; 8c. IGFBP5/LTB4DH and HoxA13/LTB4DH; 8d. MDK/BAG1 and IGFBP5/BAG1; 8e. MDK/BAG1 and HoxA13/BAG1; 8f. IGFBP5/BAG1 and HoxA13/BAG1.

Figure 9a-b shows scatter plots showing the correlation between ΔC_t for IGFBP5 and ΔC_t ratios for IGFBP5/LTB4DH and urine creatinine concentration. 9a. Urine samples from patients with TCC 9b. Urine samples from patients with non-malignant disease

Figure 10a-f depicts self-self scatter plots showing the distribution of voided and catheterised urine samples from TCC patients analysed using the bladder tumour markers MDK, IGFBP5 and HoxA13 alone or in ratios with LTB4DH.

Figure 11 shows known over-expressed markers from invasive bladder tumours.

Figure 12 shows known over-expressed markers from superficial bladder tumours.

Figure 13 shows the clinical characteristics of low grade TCC samples and controls used in ROC curve analysis.

Figure 14 shows the results of a ROC Curve analysis. Illustration of the increased test accuracy obtained when LTB4DH is used in ratios with HoxA13 and IGFBP5.

Figure 15 shows the results of a Linear Discriminate Analysis of BTMs, with and without LTB4DH, for the detection of TCC.

DETAILED DESCRIPTION

Definitions

The term "marker" means a molecule that is associated quantitatively or qualitatively with the presence of a biological phenomenon. Examples of "markers" include a polynucleotide, such

- 6 -

as a gene, gene fragment, RNA, or RNA fragment; or a gene product, including a polypeptide such as a peptide, oligopeptide protein or protein fragment; or related metabolites, by products or other identifying molecules, such as antibodies or antibody fragments whether related directly or indirectly to a mechanism underlying the phenomenon.

5 The markers of the invention include the nucleotide sequences (e.g. GenBank sequences) as disclosed herein, in particular the full length sequences, any coding sequences, non-coding sequences and fragments, or any compliments thereof, and any measurable marker thereof as defined above.

10 The term "sensitivity" means the proportion of individuals with the disease who test (by the model) positive. Thus, increased sensitivity means fewer false negative test results.

The term "specificity" means the proportion of individuals without the disease who test (by the model) negative. Thus, increased specificity means fewer false positive test results.

15

The term "expression" includes production of polynucleotides and polypeptides, in particular, the production of RNA (e.g., mRNA) from a gene or portion of a gene, and includes the production of a polypeptide encoded by an RNA or gene or portion of a gene, and includes appearance of a detectable material associated with expression. For example, the formation

20

of a complex, for example, from a polypeptide-polypeptide interaction, polypeptide-nucleotide interaction, or the like, is included within the scope of the term "expression". Another example, the binding of a binding ligand, such as a hybridization probe or antibody, to a gene or other polynucleotide, a polypeptide or a protein fragment and the visualization of the binding ligand. Thus, the density of a spot on a microarray, on a hybridization blot such as a

25

Northern blot, or on an immunoblot, such as a Western blot, or on a bead array, or by PCR analysis, is included within the term "expression" of the underlying biological molecule.

The term "over expression" is used where the expression of a marker in one cell, or cell type, is greater than that of another equivalent cell, or cell type.

30

The term "under expression" is used where the expression of a marker in one cell, or cell type, is less than that of another equivalent cell, or cell type.

35

The term "TM" or "tumour marker" or "TM family member" means a marker that is associated with a particular cancer. The term TM also includes combinations of individual markers, whose combination improves the sensitivity and specificity of detecting cancer. It is to be

- 7 -

understood that the term TM does not require that the marker be specific only for a particular tumour. Rather, expression of TM can be altered in other types of cells, diseased cells, tumours, including malignant tumours.

- 5 A TM can be identified by extracting RNA from a tissue sample from a patient suspected of having bladder cancer, applying the RNA or cDNA copy to a microarray having a number of oligonucleotides thereon, permitting the sample RNA to hybridize to the oligonucleotides on the array, and then quantifying the level of measured RNA bound to the each array spot. A marker is considered to be a under expressing TM if its presence is below a threshold of at least about 1.2 times that found in normal, non-malignant tissue using microarray methods. Alternatively, the threshold can be below about 2 times normal, about 3 times less than normal, 4 times or even about 5 times less than normal. By "normal" we mean less than the 90th percentile of the normal population. In other cases, normal can mean a level of presence of the 95th percentile (i.e., about 2 Standard Deviations (SD) from the mean), and in 15 other cases, less than about 97.5th percentile (i.e., about 3 SD) or the 99th percentile.

The term "under expressing TM" means a marker that shows lower expression in bladder tumours than in non-malignant bladder tissue.

- 20 The term "over expressing TM" means a marker that shows higher expression in bladder tumours than in non-malignant tissue.

The term "BTM" or "bladder tumour marker" or "BTM family member" means a TM that is associated with bladder cancer. The term BTM also includes combinations of individual 25 markers, whose combination improves the sensitivity and specificity of detecting bladder cancer. It is to be understood that the term BTM does not require that the marker be specific only for bladder tumours. Rather, expression of BTM can be altered in other types of cells, diseased cells, tumours, including malignant tumours.

- 30 The term "under expressing BTM" means a marker that shows lower expression in bladder tumours than in non-malignant bladder tissue.

The term "over expressing BTM" means a marker that shows higher expression in bladder tumours than in non-malignant tissue.

- 8 -

The term "qPCR" means quantitative polymerase chain reaction. The term "qPCR" or "QPCR" refers to quantitative polymerase chain reaction as described, for example, in PCR Technique: Quantitative PCR, J.W. Larrick, ed., Eaton Publishing, 1997, and A-Z of Quantitative PCR, S. Bustin, ed., IUL Press, 2004.

5

The term "TCC" means transitional cell carcinoma of the bladder. TCCs constitute ~95% of all bladder cancers.

10

15

20

As used herein "antibodies" and like terms refer to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. These include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fc, Fab, Fab', and Fab2 fragments, and a Fab expression library. Antibody molecules relate to any of the classes IgG, IgM, IgA, IgE, and IgD, which differ from one another by the nature of heavy chain present in the molecule. These include subclasses as well, such as IgG1, IgG2, and others. The light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all classes, subclasses, and types. Also included are chimeric antibodies, for example, monoclonal antibodies or fragments thereof that are specific to more than one source, e.g., a mouse or human sequence. Further included are camelid antibodies, shark antibodies or nanobodies.

25

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by abnormal or unregulated cell growth. Cancer and cancer pathology can be associated, for example, with metastasis, interference with the normal functioning of neighbouring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.

30

The term "tumour" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

35

The term "microarray" refers to an ordered or unordered arrangement of capture agents, preferably polynucleotides (e.g., probes) or polypeptides on a substrate. See, e.g., Microarray Analysis, M. Schena, John Wiley & Sons, 2002; Microarray Biochip Technology, M. Schena, ed., Eaton Publishing, 2000; Guide to Analysis of DNA Microarray Data, S.

Knudsen, John Wiley & Sons, 2004; and Protein Microarray Technology, D. Kambhampati, ed., John Wiley & Sons, 2004.

5 The term "oligonucleotide" refers to a polynucleotide, typically a probe or primer, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA: DNA hybrids, and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available, or by a variety of other methods, including in vitro expression systems, recombinant techniques,
10 and expression in cells and organisms.

The term "polynucleotide," when used in the singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. This includes, without limitation, single- and double-stranded DNA,
15 DNA including single- and double- stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. Also included are triple-stranded regions comprising RNA or DNA or both RNA and DNA. Specifically included are mRNAs, cDNAs, and genomic DNAs, and
20 any fragments thereof. The term includes DNAs and RNAs that contain one or more modified bases, such as tritiated bases, or unusual bases, such as inosine. The polynucleotides of the invention can encompass coding or non-coding sequences, or sense or antisense sequences. It will be understood that each reference to a "polynucleotide" or like term, herein, will include the full-length sequences as well as any fragments, derivatives, or variants
25 thereof.

"Polypeptide," as used herein, refers to an oligopeptide, peptide, or protein sequence, or fragment thereof, and to naturally occurring, recombinant, synthetic, or semi-synthetic molecules. Where "polypeptide" is recited herein to refer to an amino acid sequence of a
30 naturally occurring protein molecule, "polypeptide" and like terms, are not meant to limit the amino acid sequence to the complete, native amino acid sequence for the full-length molecule. It will be understood that each reference to a "polypeptide" or like term, herein, will include the full-length sequence, as well as any fragments, derivatives, or variants thereof.

35 "Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing

temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired
5 homologous between the probe and hybridisable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. Additional details and explanation of stringency of hybridization reactions, are found e.g., in Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

10

"Stringent conditions" or "high stringency conditions", as defined herein, typically: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ a denaturing agent during hybridization, such as formamide, for example, 50% (v/v) formamide
15 with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5X SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5X, Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in
20 0.2X SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash comprising 0.1X SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and
25 include the use of washing solution and hybridization conditions (e. g., temperature, ionic strength, and % SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5X SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm
30 DNA, followed by washing the filters in 1X SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The practice of the present invention will employ, unless otherwise indicated, conventional
35 techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained

*Trademark

fully in the literature, such as, Molecular Cloning: A Laboratory Manual, 2nd edition, Sambrook et al., 1989; Oligonucleotide Synthesis, MJ Gait, ed., 1984; Animal Cell Culture, R.I. Freshney, ed., 1987; Methods in Enzymology, Academic Press, Inc.; Handbook of Experimental Immunology, 4th edition, D .M. Weir & CC. Blackwell, eds., Blackwell Science Inc., 1987; Gene Transfer Vectors for Mammalian Cells, J.M. Miller & M.P. Calos, eds., 1987; Current Protocols in Molecular Biology, F.M. Ausubel et al., eds., 1987; and PCR: The Polymerase Chain Reaction, Mullis et al., eds., 1994.

Description of Embodiments of the Invention

Using a combination of microarray analysis and quantitative polymerase chain reaction (qPCR), markers for transitional cell carcinoma of the bladder (TCC) that are under-expressed in tumours have been identified. It has surprisingly been found that ratios between these markers and other bladder tumour markers (BTM), especially markers that are over expressed in tumours, are diagnostic for bladder cancer.

The ratios (rather than measuring an absolute level of a marker) identifies a simple gene expression 'signature' that typifies bladder cancer cells, and surprisingly is more robust to variations in sampling techniques or urine concentration. Moreover, the combination of an under-expressed marker and an over-expressed marker maximizes the differential between samples from patients and non-malignant controls, increasing the test reliability. The under-expressed markers described here have been selected on the basis of (i) strong and consistent down-regulation in TCC, (ii) high expression in normal tissue, and (iii) insignificant expression in whole blood to minimize the risk of false positives in patients presenting with hematuria.

As an alternative to determining the ration of the two BTM,s it has also been found that the under-expressed and over-expressed BTMs can be analysed in regression analyses or classification techniques including linear discriminate analysis, and the results of these analyses are also indicative of the presence of bladder cancer.

The test involves the measuring of at least two TM markers, such as a BTM, in a sample from a patient suspected of having a cancer or at risk of having cancer, wherein at least one of the TMs is an under-expressed TM. The ratio of the under-expressed TM and the other TM is indicative of the presence of cancer. The second TM can be any TM as known in the art, but preferably is an over-expressed BTM. Figure 3 shows a number of under-expressed markers suitable for use in the present invention.

- 12 -

The test is best preformed using an under-expressed TM in combination with an over-expressed TM. Any over-expressed TM can be used, for example. Known over expressed BTMs identified from invasive bladder tumours (defined here as tumours $\geq$ stage 1), are outlined in figure 11, and over-expressed BTMs identified from superficial bladder tumours (defined here as Stage Ta and Tis tumours) are shown in figure 12.

It has also been surprisingly established that preferred under-expressed BTMs for use in the present invention are ones that are not significantly elevated in whole blood, and are present in sufficiently high copy numbers in both tumour cells and non-malignant bladder cells. Preferred under-expressed BTMs are outlined in figure 4.

Cancer markers can be detected in a sample using any suitable technique, and can include, but are not limited to, oligonucleotide probes, qPCR or antibodies raised against cancer markers.

It will be appreciated that the sample to be tested is not restricted to a sample of the tissue suspected of being a tumour. The marker may be secreted into the serum, sloughed from cell membranes, released from lysed cells or associated with cells lost into the urine. Therefore, a sample can include any bodily sample, and includes biopsies, blood, serum, peritoneal washes, cerebrospinal fluid, urine and stool samples.

It will also be appreciate that the present invention is not restricted to the detection of cancer in humans, but is suitable for the detection of cancer in any animal, including, but not limited to dogs, cats, horses, cattle, sheep, deer, pigs and any other animal known to get cancer.

General Approaches to Cancer Detection

The following approaches are non-limiting methods that can be used to measure TMs. Following measurement of individual TMs, ratios between high and low expressing BTM family members are determined. These ratios are used to predict the presence or absence cancer.

Alternatively, the high and low expressing TMs are used in regression or classification analyses. The results of these analyses are also used to predict the presence or absence cancer.

General methodologies for determining expression levels are outlined below, although it will be appreciated that any method for determining expression levels would be suitable.

Quantitative PCR (qPCR)

5 Quantitative PCR (qPCR) can be carried out on tumour samples, on serum, plasma and urine samples using BTM specific primers and probes. In controlled reactions, the amount of product formed in a PCR reaction (Sambrook, J., E Fritsch, E. and T Maniatis, Molecular Cloning: A Laboratory Manual 3rd. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (2001)) correlates with the amount of starting template. Quantification of the PCR product
10 can be carried out by stopping the PCR reaction when it is in log phase, before reagents become limiting. The PCR products are then electrophoresed in agarose or polyacrylamide gels, stained with ethidium bromide or a comparable DNA stain, and the intensity of staining measured by densitometry. Alternatively, the progression of a PCR reaction can be measured using PCR machines such as the Applied Biosystems' Prism 7000 or the Roche
15 LightCycler which measure product accumulation in real-time. Real-time PCR measures either the fluorescence of DNA intercalating dyes such as Sybr Green into the synthesized PCR product, or the fluorescence released by a reporter molecule when cleaved from a quencher molecule; the reporter and quencher molecules are incorporated into an oligonucleotide probe which hybridizes to the target DNA molecule following DNA strand
20 extension from the primer oligonucleotides. The oligonucleotide probe is displaced and degraded by the enzymatic action of the Taq polymerase in the next PCR cycle, releasing the reporter from the quencher molecule. In one variation, known as Scorpion®, the probe is covalently linked to the primer.

Reverse Transcription PCR (RT-PCR)

25 RT-PCR can be used to compare RNA levels in different sample populations, in normal and tumour tissues, with or without drug treatment, to characterize patterns of expression, to discriminate between closely related RNAs, and to analyze RNA structure.

30 For RT-PCR, the first step is the isolation of RNA from a target sample. The starting material is typically total RNA isolated from human tumours or tumour cell lines, and corresponding normal tissues or cell lines, respectively. RNA can be isolated from a variety of samples, such as tumour samples from breast, lung, colon (e.g., large bowel or small bowel), colorectal, gastric, esophageal, anal, rectal, prostate, brain, liver, kidney, pancreas, spleen,
35 thymus, testis, ovary, uterus, bladder etc., tissues, from primary tumours, or tumour cell lines, and from pooled samples from healthy donors. If the source of RNA is a tumour, RNA can

be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g., formalin-fixed) tissue samples.

5 The first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction. The two most commonly used reverse transcriptases are avian myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukaemia virus reverse transcriptase (MMLV-RT). The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression
10 profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, CA, USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.

15 Although the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5'-3' nuclease activity but lacks a 3'-5' proofreading endonuclease activity. Thus, TaqMan (q) PCR typically utilizes the 5' nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5' nuclease activity can be used.

20 Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are
25 located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye
30 provides the basis for quantitative interpretation of the data.

TaqMan RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700 Sequence Detection System (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany).
35 In a preferred embodiment, the 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700tam Sequence Detection System. The system consists

- 15 -

of a thermocycler, laser, charge-coupled device (CCD), camera, and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fibre optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for
5 analyzing the data.

5' nuclease assay data are initially expressed as Ct, or the threshold cycle. As discussed above, fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The point when the fluorescent
10 signal is first recorded as statistically significant is the threshold cycle.

Real-time Quantitative PCR (qPCR)

A more recent variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorogenic probe (i.e., TaqMan
15 probe). Real time PCR is compatible both with quantitative competitive PCR and with quantitative comparative PCR. The former uses an internal competitor for each target sequence for normalization, while the latter uses a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. Further details are provided, e.g., by Held et al., Genome Research 6: 986-994 (1996).

20 Expression levels can be determined using fixed, paraffin-embedded tissues as the RNA source. According to one aspect of the present invention, PCR primers and probes are designed based upon intron sequences present in the gene to be amplified. In this embodiment, the first step in the primer/probe design is the delineation of intron sequences
25 within the genes. This can be done by publicly available software, such as the DNA BLAT software developed by Kent, W. J., Genome Res. 12 (4): 656-64 (2002), or by the BLAST software including its variations. Subsequent steps follow well established methods of PCR primer and probe design.

30 In order to avoid non-specific signals, it is useful to mask repetitive sequences within the introns when designing the primers and probes. This can be easily accomplished by using the Repeat Masker program available on-line through the Baylor College of Medicine, which screens DNA sequences against a library of repetitive elements and returns a query sequence in which the repetitive elements are masked. The masked sequences can then be
35 used to design primer and probe sequences using any commercially or otherwise publicly available primer/probe design packages, such as Primer Express (Applied Biosystems);

MGB assay-by-design (Applied Biosystems); Primer3 (Steve Rozen and Helen J. Skaletsky (2000) Primer3 on the WWW for general users and for biologist programmers in: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, NJ, pp 365-386).

5

The most important factors considered in PCR primer design include primer length, melting temperature (T_m), and G/C content, specificity, complementary primer sequences, and 3' end sequence. In general, optimal PCR primers are generally 17-30 bases in length, and contain about 20-80%, such as, for example, about 50-60% G+C bases. Melting
 10 temperatures between 50 and 80°C, e.g., about 50 to 70°C, are typically preferred. For further guidelines for PCR primer and probe design see, e.g., Dieffenbach, C. W. et al., General Concepts for PCR Primer Design in: PCR Primer, A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1995, pp. 133-155; Innis and Gelfand, Optimization of PCRs in: PCR Protocols, A Guide to Methods and Applications, CRC Press, London, 1994,
 15 pp. 5-11; and Plasterer, T. N. Primerselect: Primer and probe design. Methods Mol. Biol. 70: 520-527 (1997).

Microarray Analysis

20 Differential expression can also be identified, or confirmed using the microarray technique. Thus, the expression profile of CCPMs can be measured in either fresh or paraffin-embedded tumour tissue, using microarray technology. In this method, polynucleotide sequences of interest (including cDNAs and oligonucleotides) are plated, or arrayed, on a microchip substrate. The arrayed sequences (i.e., capture probes) are then hybridized with
 25 specific polynucleotides from cells or tissues of interest (i.e., targets). Just as in the RT-PCR method, the source of RNA typically is total RNA isolated from human tumours or tumour cell lines, and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of primary tumours or tumour cell lines. If the source of RNA is a primary tumour, RNA can be extracted, for example, from frozen or archived formalin fixed paraffin-
 30 embedded (FFPE) tissue samples and fixed (e.g., formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.

In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA clones are applied to a substrate. The substrate can include up to 1, 2, 5, 10, 15, 20, 25, 30, 35, 40,
 35 45, 50, or 75 nucleotide sequences. In other aspects, the substrate can include at least 10,000 nucleotide sequences. The microarrayed sequences, immobilized on the microchip,

are suitable for hybridization under stringent conditions. As other embodiments, the targets for the microarrays can be at least 50, 100, 200, 400, 500, 1000, or 2000 bases in length; or 50-100, 100-200, 100-500, 100-1000, 100-2000, or 500-5000 bases in length. As further embodiments, the capture probes for the microarrays can be at least 10, 15, 20, 25, 50, 75, 80, or 100 bases in length; or 10-15, 10-20, 10-25, 10-50, 10-75, 10-80, or 20-80 bases in length.

Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance. With dual colour fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. An exemplary protocol for this is described in detail in Example 4.

The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93 (2): 106-149 (1996)). Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix^{*} GenChip technology, Illumina microarray technology or Incyte's microarray technology. The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumour types.

30 RNA Isolation, Purification, and Amplification

General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., Current Protocols of Molecular Biology, John Wiley and Sons (1997). Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp and Locker, Lab Invest. 56: A67 (1987), and De Sandres et al., BioTechniques 18: 42044 (1995). In particular, RNA isolation can be performed using purification kit, buffer set, and protease from commercial

*Trademark

- 18 -

manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns. Other commercially available RNA isolation kits include MasterPure Complete DNA and RNA Purification Kit (EPICENTRE (D, Madison, WI), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumour can be isolated, for example, by cesium chloride density gradient centrifugation.

The steps of a representative protocol for profiling gene expression using fixed, paraffin-embedded tissues as the RNA source, including mRNA isolation, purification, primer extension and amplification are given in various published journal articles (for example: T. E. Godfrey et al. J. Molec. Diagnostics 2: 84-91 (2000); K. Specht et al., Am. J. Pathol. 158: 419-29 (2001)). Briefly, a representative process starts with cutting about 10 µm thick sections of paraffin-embedded tumour tissue samples. The RNA is then extracted, and protein and DNA are removed. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR. Finally, the data are analyzed to identify the best treatment option(s) available to the patient on the basis of the characteristic gene expression pattern identified in the tumour sample examined.

Immunohistochemistry and Proteomics

Immunohistochemistry methods are also suitable for detecting the expression levels of the proliferation markers of the present invention. Thus, antibodies or antisera, preferably polyclonal antisera, and most preferably monoclonal antibodies specific for each marker, are used to detect expression. The antibodies can be detected by direct labeling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as, biotin, or an enzyme such as horse radish peroxidase or alkaline phosphatase. Alternatively, unlabeled primary antibody is used in conjunction with a labeled secondary antibody, comprising antisera, polyclonal antisera or a monoclonal antibody specific for the primary antibody. Immunohistochemistry protocols and kits are well known in the art and are commercially available.

Proteomics can be used to analyze the polypeptides present in a sample (e.g., tissue, organism, or cell culture) at a certain point of time. In particular, proteomic techniques can be used to assess the global changes of polypeptide expression in a sample (also referred to as expression proteomics). Proteomic analysis typically includes: (1) separation of individual

- 19 -

polypeptides in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identification of the individual polypeptides recovered from the gel, e.g., by mass spectrometry or N-terminal sequencing, and (3) analysis of the data using bioinformatics. Proteomics methods are valuable supplements to other methods of gene expression profiling, and can be used, alone or in combination with other methods, to detect the products of the proliferation markers of the present invention.

Hybridization Methods Using Nucleic Acid Probes Selective for a Marker

These methods involve binding the nucleic acid probe to a support, and hybridizing under appropriate conditions with RNA or cDNA derived from the test sample (Sambrook, J., E Fritsch, E. and T Maniatis, *Molecular Cloning: A Laboratory Manual* 3rd. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (2001)). These methods can be applied to BTM derived from a tumour tissue or fluid sample. The RNA or cDNA preparations are typically labeled with a fluorescent or radioactive molecule to enable detection and quantification. In some applications, the hybridizing DNA can be tagged with a branched, fluorescently labeled structure to enhance signal intensity (Nolte, F.S., *Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens*. *Adv. Clin. Chem.* 33, 201-35 (1998)). Unhybridized label is removed by extensive washing in low salt solutions such as 0.1x SSC, 0.5% SDS before quantifying the amount of hybridization by fluorescence detection or densitometry of gel images. The supports can be solid, such as nylon or nitrocellulose membranes, or consist of microspheres or beads that are hybridized when in liquid suspension. To allow washing and purification, the beads may be magnetic (Haukanes, B-I and Kvam, C., *Application of magnetic beads in bioassays*. *Bio/Technology* 11, 60-63 (1993)) or fluorescently-labeled to enable flow cytometry (see for example: Spiro, A., Lowe, M. and Brown, D., *A Bead-Based Method for Multiplexed Identification and Quantitation of DNA Sequences Using Flow Cytometry*. *Appl. Env. Micro.* 66, 4258-4265 (2000)).

A variation of hybridization technology is the QuantiGene Plex® assay (Genospectra, Fremont) which combines a fluorescent bead support with branched DNA signal amplification. Still another variation on hybridization technology is the Quantikine® mRNA assay (R&D Systems, Minneapolis). Methodology is as described in the manufacturer's instructions. Briefly the assay uses oligonucleotide hybridization probes conjugated to Digoxigenin. Hybridization is detected using anti-Digoxigenin antibodies coupled to alkaline phosphatase in colorimetric assays.

Additional methods are well known in the art and need not be described further herein.

Enzyme-Linked Immunological Assays (ELISA)

Briefly, in sandwich ELISA assays, a polyclonal or monoclonal antibody against the BTM is bound to a solid support (Crowther, J.R. The ELISA guidebook. Humana Press: New Jersey (2000); Harlow, E. and Lane, D., Using antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (1999)) or suspension beads. Other methods are known in the art and need not be described herein further. Monoclonal antibodies can be hybridoma-derived or selected from phage antibody libraries (Hust M. and Dubel S., Phage display vectors for the in vitro generation of human antibody fragments. Methods Mol Biol. 295:71-96 (2005)). Non-specific binding sites are blocked with non-target protein preparations and detergents. The capture antibody is then incubated with a preparation of urine or tissue containing the BTM antigen. The mixture is washed before the antibody/antigen complex is incubated with a second antibody that detects the target BTM. The second antibody is typically conjugated to a fluorescent molecule or other reporter molecule that can either be detected in an enzymatic reaction or with a third antibody conjugated to a reporter (Crowther, Id.). Alternatively, in direct ELISAs, the preparation containing the BTM can be bound to the support or bead and the target antigen detected directly with an antibody-reporter conjugate (Crowther, Id.).

Methods for producing monoclonal antibodies and polyclonal antisera are well known in the art and need not be described herein further.

Immunodetection

The methods can also be used for immunodetection of marker family members in sera or plasma from bladder cancer patients taken before and after surgery to remove the tumour, immunodetection of marker family members in patients with other cancers, including but not limited to, colorectal, pancreatic, ovarian, melanoma, liver, oesophageal, stomach, endometrial, and brain and immunodetection of marker family members in urine and stool from bladder cancer patients.

BTMs can also be detected in tissues or urine using other standard immunodetection techniques such as immunoblotting or immunoprecipitation (Harlow, E. and Lane, D., Using antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor (1999)). In immunoblotting, protein preparations from tissue or fluid containing the BTM are electrophoresed through polyacrylamide gels under denaturing or non-denaturing conditions. The proteins are then transferred to a membrane support such as nylon. The BTM is then reacted directly or indirectly with monoclonal or polyclonal antibodies as described for

- 21 -

immunohistochemistry. Alternatively, in some preparations, the proteins can be spotted directly onto membranes without prior electrophoretic separation. Signal can be quantified by densitometry.

- 5 In immunoprecipitation, a soluble preparation containing the BTM is incubated with a monoclonal or polyclonal antibody against the BTM. The reaction is then incubated with inert beads made of agarose or polyacrylamide with covalently attached protein A or protein G. The protein A or G beads specifically interact with the antibodies forming an immobilized complex of antibody-BTM-antigen bound to the bead. Following washing the bound BTM can
10 be detected and quantified by immunoblotting or ELISA.

Threshold Determination

- For tests using down-regulated BTMs in either ratios or regression analyses, thresholds will be derived that will enable a sample to be called either positive or negative for TCC. These
15 thresholds will be determined by the analysis of cohorts of patients who are being investigated for the presence of TCC. Thresholds may vary for different test applications; for example, thresholds for use of the test in population screening will be determined using cohorts of patients who are largely free of urological symptoms, and these thresholds may be different to those used in tests for patients who are under surveillance for TCC recurrence, or
20 those being investigated for the presence of urological symptoms such as hematuria. A threshold could be selected to provide a practical level of test specificity in the required clinical setting; that is, a specificity that allows reasonable sensitivity without excessive numbers of patients receiving false positive results. This specificity may be within the range of 80-90%. An alternative method to obtain a test threshold is to plot sensitivity against
25 specificity for different test thresholds (ROC curves) then select the point of inflexion of the curve.

- As an alternative to single thresholds, the test may use test intervals which provide different degrees of likelihood of presence of disease and which have different clinical consequences
30 associated with them. For example, a test may have three intervals; one associated with a high (eg 90%) risk of the presence of TCC, a second associated with a low risk of TCC and a third regarded as being suspicious of disease. The "suspicious" interval could be associated with a recommendation for a repeat test in a defined period of time.

Methods for Detecting Bladder Cancer Markers in Urine

In several embodiments, assays for BTM can be desirably carried out on urine samples. In general, methods for assaying for oligonucleotides, proteins and peptides in these fluids are known in the art. However, for purposes of illustration, urine levels of a BTM can be
5 quantified using a sandwich-type enzyme-linked immunosorbent assay (ELISA). For plasma or serum assays, a 5 μ L aliquot of a properly diluted sample or serially diluted standard BTM and 75 μ L of peroxidase-conjugated anti-human BTM antibody are added to wells of a microtiter plate. After a 30-minute incubation period at 30°C, the wells are washed with 0.05% Tween^{*} 20 in phosphate-buffered saline (PBS) to remove unbound antibody. Bound
10 complexes of BTM and anti-BTM antibody are then incubated with o-phenyldiamine containing H₂O₂ for 15 minutes at 30°C. The reaction is stopped by adding 1 M H₂SO₄, and the absorbance at 492 nm is measured with a microtiter plate reader. It can be appreciated that anti-BTM antibodies can be monoclonal antibodies or polyclonal antisera.

15 Because many proteins are either (1) secreted by cells, (2) cleaved from cell membranes, (3) lost from cells upon cell death or (4) contained within sloughed cells, it will be appreciated that BTMs may also be detected in the urine. Additionally, diagnosis of bladder cancer can be determined by measuring either expression of BTMs in a sample, or accumulation of BTMs in a sample. Prior art methods of diagnosis include cystoscopy, cytology and
20 examination of cells extracted during these procedures. Such methods have relied upon identification of tumour cells in the urine or in a brush sample of urothelium, or in other cases, in biopsy specimens of the bladder wall. These methods suffer from several types of errors, including sampling error, errors in identification between observers, and the like.

25 Antibodies to Bladder Tumour Markers

In additional aspects, this invention includes manufacture of antibodies against BTMs. Using methods described herein, novel BTMs can be identified using microarray and/or qPCR methods. Once a putative marker is identified, it can be produced in sufficient amount to be suitable for eliciting an immunological response. In some cases, a full-length BTM can be
30 used, and in others, a peptide fragment of a BTM may be sufficient as an immunogen. The immunogen can be injected into a suitable host (e.g., mouse, rabbit, etc) and if desired, an adjuvant, such as Freund's complete adjuvant, Freund's incomplete adjuvant can be injected to increase the immune response. It can be appreciated that making antibodies is routine in the immunological arts and need not be described herein further. As a result, one can
35 produce antibodies against BTMs identified using methods described herein.

*Trademark

- 23 -

In yet further embodiments, antibodies can be made against the protein or the protein core of the tumour markers identified herein or against an oligonucleotide sequence unique to a BTM. Although certain proteins can be glycosylated, variations in the pattern of glycosylation can, in certain circumstances, lead to mis-detection of forms of BTMs that lack usual glycosylation patterns. Thus, in certain aspects of this invention, BTM immunogens can include deglycosylated BTM or deglycosylated BTM fragments. Deglycosylation can be accomplished using one or more glycosidases known in the art. Alternatively, BTM cDNA can be expressed in glycosylation-deficient cell lines, such as prokaryotic cell lines, including *E. coli* and the like.

Vectors can be made having BTM-encoding oligonucleotides therein. Many such vectors can be based on standard vectors known in the art. Vectors can be used to transfect a variety of cell lines to produce BTM-producing cell lines, which can be used to produce desired quantities of BTM for development of specific antibodies or other reagents for detection of BTMs or for standardizing developed assays for BTMs.

Kits

Based on the discoveries of this invention, several types of test kits can be envisioned and produced. First, kits can be made that have a detection device pre-loaded with a detection molecule (or "capture reagent"). In embodiments for detection of BTM mRNA, such devices can comprise a substrate (e.g., glass, silicon, quartz, metal, etc) on which oligonucleotides as capture reagents that hybridize with the mRNA to be detected is bound. In some embodiments, direct detection of mRNA can be accomplished by hybridizing mRNA (labeled with cy3, cy5, radiolabel or other label) to the oligonucleotides on the substrate. In other embodiments, detection of mRNA can be accomplished by first making complementary DNA (cDNA) to the desired mRNA. Then, labeled cDNA can be hybridized to the oligonucleotides on the substrate and detected.

Antibodies can also be used in kits as capture reagents. In some embodiments, a substrate (e.g., a multiwell plate) can have a specific BTM capture reagent attached thereto. In some embodiments, a kit can have a blocking reagent included. Blocking reagents can be used to reduce non-specific binding. For example, non-specific oligonucleotide binding can be reduced using excess DNA from any convenient source that does not contain BTM oligonucleotides, such as salmon sperm DNA. Non-specific antibody binding can be reduced using an excess of a blocking protein such as serum albumin. It can be appreciated that numerous methods for detecting oligonucleotides and proteins are known in the art, and any

- 24 -

strategy that can specifically detect BTM associated molecules can be used and be considered within the scope of this invention.

In addition to a substrate, a test kit can comprise capture reagents (such as probes), washing solutions (e.g., SSC, other salts, buffers, detergents and the like), as well as detection moieties (e.g., cy3, cy5, radiolabels, and the like). Kits can also include instructions for use and a package.

BTM ratios Used for Detection of Bladder Cancer I

In one series of embodiments, reagents for the testing the BTM LTBDH4 in combination with over-expressing BTMs can be incorporated into a kit for the testing of unfractionated urine or urine cell sediments to detect bladder cancer. The urine samples could be collected from patients with diagnosed bladder cancer who require monitoring for disease progression or treatment response, individuals with urological symptoms including macroscopic or microscopic hematuria, or asymptomatic individuals. For patients or individuals being tested with a kit that measures the BTMs in unfractionated urine, approximately 2mls of urine can be taken for testing. For tests on the urine pellet, >10mls of urine can be collected.

A suitable kit includes: (i) instructions for use and result interpretation, (ii) software for interpretation of multiple gene analyses, including any regression analysis classifier or formula (iii) reagents for the stabilization and purification of RNA from unfractionated urine or urine pellets, (iv) reagents for the synthesis of cDNA including dNTPs and reverse transcriptase, and (v) reagents for the quantification of the BTM cDNA. In one form, these reagents would be used for quantitative PCR and would include specific exon-spanning oligonucleotide primers, a third oligonucleotide labeled with a probe for detection, Taq polymerase and the other buffers, salts and dNTPs required for PCR. The kit can also use other methods for detection of the transcripts such as direct hybridization of the BTM RNA with labeled probes or branched DNA technology; and (vi) oligonucleotides and probe for the detection of transcripts from a highly transcribed gene, such as β actin, to serve as a quality control measure.

Evaluation of Progression of Bladder Cancer Using BTM ratios

To evaluate the progression of bladder tumours, samples of tissue are obtained by biopsy of bladder wall or samples of urine are collected over time from a patient having bladder cancer.

Evaluation of the ratio of BTMs or combinations thereof are made for samples taken at

different times. BTM ratios within a specified range are indicative of progression of bladder cancer.

Evaluation of Therapy of Bladder Cancer Using BTM ratios

- 5 To evaluate the efficacy of therapy for bladder tumours, samples of tissue and/or urine are obtained before treatment is initiated. The baseline levels of one or more BTMs are determined, as are ratios of various BTMs with respect to each other. Treatment is initiated, and can include any therapy known in the art, including surgery, radiation therapy or chemotherapy as appropriate to the type and stage of the disease. During the course of
- 10 therapy, samples of tissue and/or urine are collected and analyzed for the presence and amount of BTMs. Ratios of various BTMs are determined and results are compared to: (1) the patient's baseline levels before treatment or (2) normal values obtained from a population of individuals not having bladder cancer.

15 Use of BTM Ratios to Monitor the Progression of TCC Therapies

- In addition to the rapid diagnosis and early detection of TCC, BTM marker ratios detected in either tissue, serum or urine can be used to monitor a patient's response to therapy. In these applications, urine and/or serum samples can be taken at intervals following the initiation of systemic, intravesicular or intravascular chemotherapy, radiotherapy or immunotherapy. A
- 20 change in marker ratio can indicate a reduction in tumour size, indicative of effective treatment. The rate of change can be used to predict the optimum therapeutic dose for each patient or treatment.

Use of BTM Regression Analyses

- 25 In addition to the BTM ratios, regression or classification analyses that include high and low expressing BTM family members can be used for the applications described above.

Markers evaluated are selected from known human genes. The genes evaluated are indicated in Figures 3 and 4. Included in Figures 3 and 4 are the name of the gene, the

30 HUGO identifier, MWG oligo number, NCBI mRNA reference sequence number and the protein reference number.

EXAMPLES

- 35 The examples described herein are for purposes of illustrating embodiments of the invention and are not intended to limit the scope of the invention. Other embodiments, methods and

- 26 -

types of analyses are within the scope of persons of ordinary skill in the molecular diagnostic arts and need not be described in detail hereon. Other embodiments within the scope of the art that are based on the teachings herein are considered to be part of this invention.

5 **Methods**

Tumour Collection

Bladder tumour samples and non-malignant urothelium samples were collected from surgical specimens resected at Kyoto University Hospital, Japan.

10 **Urine Collection**

Urine samples from non-malignant controls and bladder cancer patients were obtained from Kyoto University Hospital, Japan. Healthy control samples were obtained from Japanese volunteers (figure 1).

15 **RNA Extraction**

Tumour tissues were homogenized in a TriReagent: water (3:1) mix, then chloroform extracted. Total RNA was then purified from the aqueous phase using the RNeasy™ procedure (Qiagen). RNA was also extracted from 16 cancer cell lines and pooled to serve as a reference RNA.

20

RNA was extracted from urine by mixing the urine sample with an equal volume of lysis buffer (5.64M guanidine-HCl, 0.5% sarkosyl, 50mM sodium acetate (pH 6.5) and 1mM β -mercaptoethanol; pH adjusted to 7.0 with 1.5M Hepes pH 8). Due to the low amounts of RNA in urine, 7.5ugs of total bacterial RNA was added to the urine/lysis buffer mix to act as a carrier. Total RNA was then extracted using Trizol and the RNeasy™ procedure. RNA preparations were further purified prior to cDNA synthesis using the Qiagen QIAquick™ PCR purification kit.

25

RNA was extracted from the blood of three healthy volunteers by performing a Trizol/RNeasy™ extraction on cells enriched from whole blood using sedimentation in 3.6% dextran.

30

Microarray Slide Preparation

Epoxy coated glass slides (MWG Biotech) were printed with ~30,000 50mer oligonucleotides (MWG Biotech) using a Gene Machines microarraying robot, according to the manufacturer's protocol.

35

RNA Labeling and Hybridization

cDNA was transcribed from 5µg total RNA using Superscript II™ reverse transcriptase (Invitrogen) in reactions containing 5-(3-aminoallyl)- 2' deoxyuridine –5'-triphosphate. The reaction was then de-ionised in a Microcon column before being incubated with Cy3 or Cy5 in bicarbonate buffer for 1 hour at room temperature. Unincorporated dyes were removed using a Qiaquick column (Qiagen) and the sample concentrated to 15 µl in a SpeedVac. Cy3 and Cy5 labeled cDNAs were then mixed with Ambion ULTRAhyb™ buffer, denatured at 100°C for 2 min and hybridized to the microarray slides in hybridisation chambers at 42°C for 16 hours. The slides were then washed and scanned twice in an Axon 4000A™ scanner at two power settings.

Microarray Analysis of Cancer Marker Genes

RNA from 53 bladder tumours and 20 non-malignant ("normal") bladder tissue samples were labeled with Cy5 and hybridized in duplicate or triplicate with Cy3 labeled reference RNA. After normalization, the change in expression in each of 29,718 genes was then estimated by fold change and statistical probability.

Normalisation Procedure

Median fluorescence intensities detected by Genepix™ software were corrected by subtraction of the local background intensities. Spots with a background corrected intensity of less than zero were excluded. To facilitate normalization, intensity ratios and overall spot intensities were log-transformed. The logged intensity ratios were corrected for dye and spatial bias using local regression implemented in the LOCFIT™ package. Logged intensity ratios were regressed simultaneously with respect to overall spot intensity and location. The residuals of the local regression provided the corrected logged fold changes. For quality control, ratios of each normalized microarray were plotted in respect to spot intensity and localization. The plots were subsequently visually inspected for any remaining artifacts. Additionally, an ANOVA model was applied for the detection of pin-tip bias. All results and parameters of the normalization were inserted into a Postgres-database for statistical analysis.

Statistical Analysis

To improve the comparison of measured fold changes between arrays, log2 (ratios) were scaled to have the same overall standard deviation per array. This standardization reduced the average within-tissue class variability. A rank-test based on fold changes was then used to improve the noise robustness. This test consists of two steps: (i) calculation of the rank of

- 28 -

fold change (Rfc) within arrays and ii) subtraction of the median (Rfc) for normal tissue from the median (Rfc) for tumour tissue. The difference of both median ranks defines the score of the fold change rank. Three additional statistical tests were also performed on standardized data: 1) Two sample student's t-test, 2) the Wilcoxon test and 3) Statistical Analysis of
5 Microarrays (SAM). The most significantly down-regulated genes determined by each of the statistical methods (rank fold change, t-test, Wilcoxon test, and SAM) were given a rank score for each test. All rank scores were then added into one summated rank score.

cDNA Synthesis from Urine RNA

10 Total urine RNA was annealed to gene-specific primers for each of the bladder tumour markers by incubating at 70°C then cooling on ice for 2 mins in 50ul reactions containing forward primers at 0.01µg/µl. Each cDNA reaction contained annealed RNA and 4µl of 5x Superscript II reverse transcriptase buffer (Invitrogen, USA), 2µl of 0.1M DTT (Invitrogen, USA), 0.5µl of RNase out (40U/µL), (Invitrogen, USA), 4µl of 10 mM dNTP (Invitrogen, USA)
15 and 0.5µl of Superscript II reverse transcriptase (200U/µl), (Invitrogen, USA) in a final volume of 20µl. Reactions were incubated at 42°C for 1 hour, 10 minutes at 70°C and 1 minute at 80°C. Reactions were cleaned prior to qPCR with Qiagen QIAquick PCR purification columns (Qiagen, Victoria, Australia) and stored at -80°C.

20 Quantitative Real-Time PCR

Real-time or quantitative PCR (qPCR) is used for absolute or relative quantitation of PCR template copy number. Taqman™ probe and primer sets were designed using Primer Express V 2.0™ (Applied Biosystems). Where possible, all potential splice variants were included in the resulting amplicon, with amplicon preference given to regions covered by the
25 MWG-Biotech-derived microarray oligonucleotide. Primer and probe sequences are shown in Figure 2. Alternatively, if the target gene was represented by an Assay-on-Demand™ expression assay (Applied Biosystems) covering the desired amplicons, these were used. In the in-house designed assays, primer concentration was titrated using a SYBR green labeling protocol and cDNA made from the reference RNA. Amplification was carried out on
30 an ABI Prism™ 7000 sequence detection system under standard cycling conditions. When single amplification products were observed in the dissociation curves, standard curves were generated over a 625 fold concentration range using optimal primer concentrations and 5'FAM - 3'TAMRA phosphate Taqman™ probe (Proligo) at a final concentration of 250 nM. Assays giving standard curves with regression coefficients over 0.98 were used in
35 subsequent analyses.

Assays were performed in 96 well plates. Each plate contained a reference cDNA standard curve, over a 625-fold concentration range. For the urine qPCR, total RNA extracted from ~0.5mls unfractionated urine was used in each reaction. The ΔC_t (target gene C_t – mean reference cDNA C_t) was calculated for each marker, and used in subsequent ratios, regression or classification analysis.

Expression of Markers in Blood

The expression of the markers shown in figures 3 and 4 in whole blood was determined *in silico*. Microarray probes were linked to UniGene clusters via the GenBank accession numbers of their target mRNAs, and the tissue expression profile from UniGene used to determine the number of expressed sequence tags (ESTs) in blood libraries. Only genes with 0 or 1 expressed sequence tags (EST) are shown in figure 4. To confirm the low expression of LTB4DH in whole blood, RT-qPCR was carried out on total RNA extracted from whole blood using the primers and probes shown in Figure 2. No significant expression was observed (results not shown).

Identification of Down Regulated Bladder Cancer Markers

To identify down-regulated markers of bladder cancer, we performed microarray studies on RNA from 53 bladder tumours and 20 non-malignant bladder tissue samples using 30,000 oligonucleotide chips. Figure 3 shows the statistical analysis of microarray data for 300 genes that show significant downregulation in bladder cancer tissue compared to non-malignant tissue. Figure 3 includes the HUGO gene name and symbol, the protein reference sequence number, the NCBI mRNA reference sequence number, the MWG Biotech probe oligonucleotide number, the median fold change in gene expression between tumour and non-malignant tissue, the results of an original unadjusted Student's t-test, the results of the 2-sample Wilcoxon test, the results of the SAM test, and the summated rank score.

Identification of Preferred Under-Expressed Bladder Tumour Markers for Use in Urine Tests for Bladder Cancer

Because urinary hematuria is a common co-occurrence with bladder cancer, it is an advantage that bladder cancer markers are not significantly elevated in whole blood. In addition, because the downregulated markers are being used in ratios, regression or classification analysis, it is an advantage that they be present in sufficiently high copy numbers in both tumour cells and non-malignant bladder cells to enable reliable detection in urine. To identify suitable markers, we screened the genes in Figure 3 for a subset that had little or no representation in blood EST libraries, and had higher than median expression in

non-malignant tissue. Median expression was estimated by ranking the 30,000 oligonucleotides on the array by their median intensity in the samples analysed in the microarray study. Markers that met the criteria are shown in Figure 4. Figure 4 includes the HUGO gene name and symbol, the protein reference sequence number, the NCBI mRNA reference sequence number, the median fold change, the rank score, the median rank of microarray spot intensity in tumour tissue and non-malignant tissue, and the number of ESTs present in blood EST libraries.

The down regulation observed in the array data was validated by qPCR for three genes shown in Figure 4, LTB4DH, BAG1 and FLJ21511. These genes were tested on total RNA from 10 tumour samples and 10 non-malignant samples. LTB4DH, BAG1 and FLJ21511 showed an average downregulation in bladder tumours compared to bladder non-malignant tissue of 2.5 fold, 1.4 fold and 6.1 fold, respectively, in these samples.

qPCR Analysis of Urine using LTB4DH

Urine from TCC patients and controls with non-malignant urological conditions was collected by either voiding or catheterisation. Total RNA was extracted from the voided urine of 42 controls and the voided or catheterised urine of 37 TCC patients and used in quantitative RT-PCR using primers and probes for LTB4DH and three over-expressed markers, IGFBP5, MDK and HoxA13. The ΔC_t ratios were determined for IGFBP5/LTB4DH, MDK/LTB4DH and HoxA13/LTB4DH. This data is illustrated by the box plots in Figure 5, which show a clear difference in the spread of data between the urine samples from controls and TCC patients for each of the three tests. The most accurate test was IGFBP5/LTB4DH which demonstrated sensitivity and specificity of 87% and 88% in this sample cohort, respectively (Fig. 6a). To illustrate the correspondence between sensitivity and specificity for each of these tests, ROC curves are shown in Figure 7. The areas under the curve for IGFBP5/LTB4DH, MDK/LTB4DH and HoxA13/LTB4DH are 0.9223, 0.9199, and 0.7497, respectively. These areas, which measure test accuracy, indicate that all three ratios with LTB4DH are useful tests, in particular IGFBP5/LTB4DH and MDK/LTB4DH.

To increase the sensitivity and specificity of TCC detection, combinations of two tests were used. The optimal sensitivities and specificities of these test combinations are shown in Figure 6b. Figure 8a-f shows the separation of data in 2 dimensional space for each of the three tests using LTB4DH and BAG1. This data shows that combinations of two or more tests that include either of the downregulated BTMs LTB4DH or BAG1, are able to achieve sensitivities and specificities of over 90%. Moreover, because these tests are measuring

simple gene expression signatures and not absolute levels of markers, they will be robust to variations in urine concentration.

To demonstrate the robustness of tests involving ratios with LTB4DH to urine concentration, the levels of IGFBP5 alone (ΔCt) and IGFBP5/LTB4DH were plotted as a function of urine concentration (Figure 9a-b) and trendlines fitted to the data. It can be seen that for both urine samples from non-malignant controls and patients with TCC, there is a decrease in the IGFBP5 ΔCt with increasing urine concentration that is absent in the IGFBP5/LTB4DH ratio. The effect is most pronounced with the non-malignant samples because of the absence of other influences such as tumour size and tumour heterogeneity in the expression of IGFBP5 and LTB4DH.

In some instances, when single markers are used in bladder cancer assays, the method of urine sample collection can affect the amount of marker detected due to variations in the number of exfoliated bladder cells collected. This bias could lead to false positive or false negative results in a small proportion of samples. The use of ratios including LTB4DH or other low-expressing genes should provide a method to compensate for different methods. To test this hypothesis, samples collected from TCC patients by either simple voiding (nine samples) or catheterisation (28 samples) were tested for the presence of TCC markers and LTB4DH. Analysis of the TCC markers alone showed that the voided samples were more heavily represented at the lower end of the range of data (higher Ct), consistent with a lower average number of exfoliated cells in these samples compared to the catheterised samples. This is illustrated in the self-self scatter plots for IGFBP5, MDK and HoxA13 in figure 10a-c. In contrast, when ratios between these markers and LTB4DH were calculated, the voided and catheterised samples were spread over similar ranges of Ct ratios (figure 10d-f), illustrating that the calculation of gene expression signatures between high expressing markers and low expressing markers such as LTB4DH compensate for variations in marker levels introduced by different urine sampling methodologies.

Urine samples from patients with low grade tumours are often borderline in their accumulation of BTMs due to the presence of only small numbers of exfoliated cells in these samples. These samples are therefore at high risk of being incorrectly classified due to variations in sampling method or urine concentration.

The utility of gene expression ratios that incorporate down-regulated genes for the detection of TCC is therefore likely to be pronounced when applied to the detection of low grade TCC.

To demonstrate this effect, a cohort of voided 43 urine samples from patients with low grade TCC and 123 controls were tested with the markers IGFBP5, HoxA13 and LTB4DH. The clinical characteristics of the cohort are summarised in Fig. 13. The qPCR data for IGFBP5 and HoxA13 were analysed alone and in ratios with LTB4DH using the area under the ROC curve as a measure of test accuracy (STATA statistics package). The results are summarized in Fig. 14. Using the IGFBP5 marker, LTB4DH increased the accuracy of detection of low grade (grade 1-2) stage Ta TCCs by 9% and low grade TCCs of any stage by 8%. The accuracy of HoXA13 testing of low grade stage Ta TCCs was increased by 3%.

Linear Discriminate Analysis of qPCR Data using LTB4DH

Linear discriminate analysis (LDA) is a statistical technique (Fisher R.A. "The Use of Multiple Measurements in Taxonomic Problems", Annals of Eugenics 7 179 (1936)) in which a linear combination of variables is generated, such that there is maximal separation between two or more groups. This linear combination of variables is termed the "linear discriminant", which is a linear function of the input variables that maximally separates the classes of the data set. The ability of LDA (or any other classification technique) to characterise a particular dataset, such as qPCR data, can be tested using cross-validation. In this method, part of the dataset is used to generate a classifier, and part of the dataset is used to measure the effectiveness of that classifier. The partitioning of the dataset into training and testing sets can be repeated multiple times (each time generating a new classifier). In k-fold cross-validation, the dataset is split k-wise, and each subset is used as the testing set in one of k rounds of training and validation. This can be extended to leave-one-out cross-validation (LOOCV) where each sample is classified according to a classifier generated from the remaining samples in the dataset ("leaving one out"; leaving out the sample which is being tested).

LDA and LOOCV were used to illustrate the utility of the downregulated BTM, LTB4DH, in improving the diagnosis of TCC. qPCR was first carried out on the cohort of control and TCC urine samples described in Figure 13 which were supplemented with an additional 30 grade 3 tumours (5 > stage 1, 13 =stage 1, 4=Tis, and 8=Ta). Combinations of the six genes LTB4DH, MDK, IGFBP5, HOXA13, TOP2a and CDC2 were tested for classifier performance, as judged by LOOCV. The posterior probability (that the sample "left out" was a TCC sample) was used to generate ROC curves using the ROCR package of the R statistical programming environment. The sensitivity of the classifier for a given specificity was obtained by reference to the appropriate ROC curve.

The sensitivity of detection of TCC using combinations of upregulated BTMs with and without LTB4DH was determined at a specificity of 85%. The results of this analysis are shown in Figure 15. It can be seen that the addition of LTB4DH to assays including combinations of the upregulated BTMs MDK, IGFBP5, Top2a, cdc2 and HoxA13 increased the overall
5 sensitivity by 1-2% and the sensitivity of detection of Stage Ta tumours, grade 1-2 tumours and grade 3 tumours by up to 3%.

Wherein in the foregoing description reference has been made to integers or components having known equivalents, such equivalents are herein incorporated as if individually set
10 fourth.

15

INDUSTRIAL APPLICABILITY

Methods for detecting BTM family members include detection of nucleic acids, proteins and peptides using microarray and/or real time PCR methods. The compositions and methods of this invention are useful in diagnosis of disease, evaluating efficacy of therapy, and for
20 producing reagents and test kits suitable for measuring expression of BTM family members.

CLAIMS

1. A method for determining the presence of a bladder cancer in a subject, the method comprising:
 - (a) providing a urine sample from the subject;
 - (b) detecting the expression level of at least two tumour markers (TM) in said urine sample, wherein at least one TM is an under-expressed TM selected from the group outlined in Figure 3 or 4 and at least one TM is an over-expressed TM selected from the group outlined in Figure 11 or Figure 12;
 - (c) determining the ratio of expression between said at least one under-expressed TM and said at least one over-expressed TM; and
 - (d) establishing whether the patient has cancer according to a predetermined threshold, wherein the predetermined threshold is established by determining the ratio of expression of said TMs from subjects with and without bladder cancer.
2. The method of claim 1 wherein the over-expressed TM is CDC2, MDK, HOXA13 or IGFBP5.
3. The method of claim 1 wherein the under-expressed TM is LTB4DH or BAG1.
4. The method of claim 1, wherein said step of detecting is carried out by detecting expression of: TM mRNA, a TM protein or a TM peptide.
5. A kit for determining the presence of a bladder cancer from a urine sample from a subject, the kit consisting of:
 - a substrate,
 - oligonucleotides or antibodies selected from:
 - (i) an oligonucleotide or antibody specific for an under-expressed TM selected from the group outlined in Figure 3 or 4 and an oligonucleotide or antibody specific for an over-expressed TM selected from the group outlined in Figure 11 or 12;
 - (ii) oligonucleotides or antibodies specific for all of the under-expressed TMs selected from the groups

outlined in Figure 3 or 4 and all of the over-expressed TMs selected from the group outlined in Figure 11 or 12; or

(iii) oligonucleotides or antibodies specific for the over-expressed TMs CDC2, MDK, HOXA13 and IGFBP5, and the under-expressed TMs LTB4DH and BAG 1; and

instructions for use.

6. The kit of claim 5 (i) wherein the over-expressed TM is CDC2, MDK, HOXA13 or IGFBP5, and the under-expressed TM is LTB4DH or BAG 1.

7. Use of one or more oligonucleotides specific for at least one under-expressed TM selected from the group outlined in Figure 3 or 4 and one or more oligonucleotides specific for at least one over-expressed TM selected from the group outlined in Figure 11 or 12,

for determining the presence of bladder cancer in a urine sample from a subject, wherein the ratio of expression between said at least one under-expressed TM and said at least one over-expressed TM is determined, and wherein whether said subject has cancer is established according to a predetermined threshold established by determining the ratio of expression of said TMs from subjects with and without bladder cancer.

8. Use of one or more antibodies specific for at least one under-expressed TM selected from the group outlined in Figure 3 or 4 and one or more antibodies specific for at least one over-expressed TM selected from the group outlined in Figure 11 or 12,

for determining the presence of bladder cancer in a urine sample from a subject, wherein the ratio of expression between said at least one under-expressed TM and said at least one over-expressed TM is determined, and wherein whether said subject has cancer is established according to a predetermined threshold established by determining the ratio of expression of said TMs from subjects with and without bladder cancer.

1/102

disease state	age	stage	grade
Prostate hyperplasia	73		
Urolithiasis	76		
normal	40		
Prostate hyperplasia	61		
Prostate hyperplasia	78		
Neurogenic bladder	72		
Prostate hyperplasia	68		
Urolithiasis	63		
normal	40		
Neurogenic bladder	76		
Prostate hyperplasia	69		
normal	24		
Prostate hyperplasia	65		
normal	24		
normal	37		
Urolithiasis	48		
normal	28		
Urolithiasis	23		
Neurogenic bladder	69		
normal	28		
normal	25		
Neurogenic bladder	78		
Normal	50		
normal	36		
normal	34		
Urolithiasis	85		
Neurogenic bladder	54		
Normal	53		
Prostate hyperplasia	55		
Prostate hyperplasia	76		
Infection	19		
Normal	64		
Normal	62		
Infection	62		
Neurogenic bladder	83		
normal lab	35		
Urolithiasis	76		
normal lab	40		
Urolithiasis	80		
Prostate hyperplasia	72		
Normal	70		
Urolithiasis	63		
TCC	82	-	-
TCC	69	2	3
TCC	52	a	1-2
Ureteral ca	77	3a	2~3
TCC	67	a	3
TCC	57	a	3
TCC	64	1	1
TCC	87	a	2
TCC	77	a	3
TCC	37	a	2
TCC	73	0	0
TCC	72	2	3

Fig. 1

2/102

disease state	age	stage	grade
TCC	76	a	2
TCC	74	a	3
TCC	38	a	2
TCC	86	a	2
TCC	77	a	3
TCC	78	1	3
TCC	72	-	-
TCC	72	1	2
TCC	71	a	2
TCC	64	1	1
TCC	81	a	1
TCC	67	a	2
TCC	75	a	2
TCC	76	a	2
TCC	70	a	3
TCC	78	is	3
TCC	76	2a	3
TCC	76	?ureteral	2=3
TCC	68	2	3
TCC	78	0	0
TCC	78	1	3
TCC	70	a	2>3
TCC	77	1	3>2
TCC	83	a	2
TCC	83	a	1

Fig. 1 (continued)

Name	Symbol	Forward Primer	Seq ID #	Reverse Primer	Seq ID #	Probe	Seq ID #
insulin-like growth factor binding protein 5	IGFBP5	AATTGTGACCGCAAAGGAT TCT	1	CAGCAGATGCCACGCTTG	2	AAGAGAAAGCAGTGCAAA CCTTCCCGT	3
homeo box A13	HOXA13	Taqman(R) Gene Expression Assay Hs00426284_m1					
midkine (neurite growth-promoting factor 2)	MDK	Taqman(R) Gene Expression Assay Hs00171064_m1					
Leukotriene B4 12-dehydrogenase	LTB4DH	TATAACAGAACCGGCCCA CTTC	4	CCCATTTTCAGCAAGTCCTT CA	5	CCAGGCCCCACCCCCAGAG ATTG	6
cell division cycle 2, G1 to S and G2 to M			7	TGT CTA CCC TTA TAC ACA ACT CCA TAG G	8	AGC CGG GAT CTA CCA TAC CCA TTG ACT AAC T	9
Topoisomerase (DNA) II alpha	TOP2A	CCG CCC AGA CAC CTA CAT TG	10	TGT ACA AAC CAG GAA CAA AAG TGA CT	11	TTC TGT GGA ATT AGT GAC CCA GCA AAT GTG	12
BCL2-associated athanogene	BAG1	Taqman(R) Gene Expression Assay Hs00185390_m1					
hypothetical protein FLJ21511	FLJ21511	Taqman(R) Gene Expression Assay Hs00228221_m1					

Fig. 2

4/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
ras homolog gene family, member B (RHOB), mRNA	NP_004031.1	NM_004040.2	mwghuman3 OK#A:08114	-2.684592	2.13794E- 10	2.25758E- 09	-10.53678	38	8789.5	4176	23
hypothetical protein FLJ21511 (FLJ21511), mRNA	NP_079363.1	NM_025087.1	mwghuman3 OK#A:00410	-2.080908	2.54894E- 11	3.22908E- 08	-6.925773	68	14455	9272.5	0
paired box gene 8 (PAX8), transcript variant PAX8A, mRNA	NP_003457.1	NM_003466.3	mwghuman3 OK#B:3648	-1.961896	4.71674E- 11	4.07014E- 08	-6.806281	82	19419	12999.5	0
UPF3 regulator of nonsense transcripts homolog A (yeast) (UPF3A), transcript variant 1, mRNA	NP_075387.1	NM_023011.2	mwghuman3 OK#A:06295	-3.84007	1.03703E- 13	3.34027E- 08	-7.811653	96.5	5663.5	1825	0
leukotriene B4 12- hydroxydehydr ogenase (LTB4DH), mRNA	NP_036344.1	NM_012212.2	mwghuman3 OK#B:8686	-5.034613	3.08873E- 10	1.41836E- 07	-6.436167	122.5	11340.5	3138	0

Fig. 3

5/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
RAB11 family interacting protein 2 (class I) (RAB11FIP2), mRNA	NP_055719.1	NM_014904.1	mwghuman3 OK#A:10479	-1.993629	4.57925E- 09	5.83951E- 08	-7.711624	156	19636.5	12951	0
TSC22 domain family, member 1 (TSC22D1), transcript variant 2, mRNA	NP_006013.1	NM_006022.2	mwghuman3 OK#A:00577	-2.133065	1.12033E- 07	1.8543E- 07	-7.698568	156.5	8415	6130	1
sulfite oxidase (SUOX), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA	NP_000447.2	NM_000456.2	mwghuman3 OK#A:05512	-1.622803	4.52404E- 10	5.29156E- 09	-6.728892	223	11312.5	8789.5	0
tetratricopeptid e repeat domain 21A (TTC21A), mRNA	NP_665698.1	NM_145755.1	mwghuman3 OK#B:6976	-2.976809	2.11314E- 07	4.28806E- 07	-6.286432	225	8375.5	3870.5	1

Fig. 3 (continued)

6/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
RAS p21 protein activator (GTPase activating protein) 1 (RASA1), transcript variant 2, mRNA	NP_072179.1	NM_022650.1	mwghuman3 OK#A:08292	-1.947454	3.74564E- 09	2.68048E- 06	-5.99299	235	6895.5	5277.5	7
ensembl genscan prediction		AC024384.3.1 07975.119435 .1	mwghuman3 OK#C:6641	-2.471322	4.47058E- 08	1.54585E- 06	-6.085076	255.5	3327.5	1537	
ensembl genscan prediction		AL031669.28. 1.94224.1	mwghuman3 OK#C:0930	-1.774123	6.77812E- 09	1.13272E- 06	-5.56116	288.5	4367	3218	
geminin, DNA replication inhibitor (GMNN), mRNA	NP_056979.1	NM_015895.3	mwghuman3 OK#A:03435	-2.046753	1.94846E- 07	4.07898E- 06	-5.99032	311	11844	8413.75	2
fatty acid binding protein 1, liver (FABP1), mRNA	NP_001434.1	NM_001443.1	mwghuman3 OK#A:09506	-1.985247	2.20148E- 06	6.83453E- 07	-6.750782	312.5	25595	19500.75	0
v-jun sarcoma virus 17 oncogene homolog (avian) (JUN), mRNA	NP_002219.1	NM_002228.3	mwghuman3 OK#A:04848	-3.222311	6.2171E- 07	4.59274E- 06	-6.383849	318.5	12139	5321.5	11

Fig. 3 (continued)

7/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
transmembran e and coiled- coil domains 4 (TMCO4), mRNA	NP_859070.2	NM_181719.2	mwghuman3 OK#B:3094	-1.799143	8.41415E- 09	3.21175E- -06	-5.702577	322.5	4584.5	3158	5
ensembl genscan prediction		AP002080.2.3 7398.74587.1	mwghuman3 OK#C:4035	-1.860121	5.75299E- 08	1.01121E- -07	-7.300326	332.5	4972.5	2643	
synaptotagmin- like 2 (SYTL2), transcript variant b, mRNA	NP_115755.2	NM_032379.3	mwghuman3 OK#B:9411	-2.343357	4.07526E- 10	9.87494E- -09	-7.993821	342	19920	12053.5	0
cyclin G1 (CCNG1), transcript variant 1, mRNA	NP_004051.1	NM_004060.3	mwghuman3 OK#B:5261	-1.83737	2.79204E- 08	4.64998E- -07	-6.214776	365	9269.5	4453	7
F-box protein 34 (FBXO34), mRNA	NP_060413.2	NM_017943.2	mwghuman3 OK#B:4885	-1.801846	1.15594E- 06	1.13272E- -06	-7.165506	365.5	17957.5	13192.75	5
hypothetical protein xp_097916 loc150582		XM_097916	mwghuman3 OK#B:6228	-2.291304	2.69775E- 08	3.84322E- -06	-5.299383	375	3591	1276	
RNA pseudouridylat e synthase domain containing 4 (RPUSD4), mRNA	NP_116184.1	NM_032795.1	mwghuman3 OK#B:6888	-1.588438	2.0145E- 10	1.14227E- -08	-8.404434	407	15747.5	11247	5

Fig. 3 (continued)

8/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
WD repeat domain 33 (WDR33), transcript variant 2, mRNA	NP_0010066 23.1	NM_0010066 22.1	mwghuman3 OK#A:08115	-1.765322	1.47232E- 07	1.45307E- 06	-6.190057	413	14876	13787.5	8
FLJ20859 gene (FLJ20859), transcript variant 1, mRNA	NP_0010251 62.1	NM_0010299 91.1	mwghuman3 OK#A:10470	-1.708985	8.133E-08	1.13272E- 06	-6.182853	420.5	3781	2693.75	
activating transcription factor 3 (ATF3), transcript variant 2, mRNA	NP_004015.3	NM_004024.3	mwghuman3 OK#A:00568	-3.134291	8.40437E- 06	1.51698E- 07	-7.446028	421	13832.5	5301.25	3
cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5), mRNA	NP_000768.1	NM_000777.2	mwghuman3 OK#A:04559	-2.482162	7.0225E- 08	1.9772E- 06	-4.813425	451.5	20350.5	12190.5	2
ensembl genscan prediction		AL161725.13. 1.181179.3	mwghuman3 OK#C:3443	-1.955495	1.19555E- 09	9.24336E- 06	-5.681512	455	2738.5	1799	
KIT ligand (KITLG), transcript variant b, mRNA	NP_000890.1	NM_000899.3	mwghuman3 OK#A:07355	-4.28251	3.8867E- 06	7.23184E- 07	-5.884133	470	19497	10599.75	2

Fig. 3 (continued)

9/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
decay accelerating factor for complement (CD55, Gromer blood group system) (DAF), mRNA	NP_000565.1	NM_000574.2	mwghuman3 OK#A:06760	-2.146033	1.44112E- 06	6.53282E- 06	-5.668164	471.5	9806.5	4753.25	10
solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 (SLC25A23), mRNA	NP_077008.2	NM_024103.2	mwghuman3 OK#A:05530	-1.465915	7.79426E- 09	8.80903E- 07	-5.741772	497	16285.5	12418.75	4
wingless-type MMTV integration site family, member 2B (WNT2B), transcript variant WNT- 2B1, mRNA	NP_004176.2	NM_004185.2	mwghuman3 OK#A:05696	-10.745275	2.92382E- 12	3.19726E- 07	-6.175471	501	10716	2016.25	0
protocadherin gamma subfamily A, 12 (PCDHGA12), transcript variant 1, mRNA	NP_003726.1	NM_003735.2	mwghuman3 OK#A:03393	-2.070447	2.89557E- 07	6.92439E- 06	-4.982742	511	2537	1931.5	0

Fig. 3 (continued)

10/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
ensembl genscan prediction		AC010828.3. 125573.1581 93.2	mwghuman3 OK#C:4737	-1.679465	2.34945E- 07	6.18322E- 07	-5.341693	511	26962	25287.75	
olfactory receptor, family 1, subfamily D, member 5 (OR1D5), mRNA	NP_055381.1	NM_014566.1	mwghuman3 OK#A:08766	-1.640751	5.38884E- 08	4.32856E- 06	-5.134756	539.5	1644	1134	0
G protein- coupled receptor 126 (GPR126), transcript variant b1, mRNA	NP_940971.1	NM_198569.1	mwghuman3 OK#B:2989	-2.181735	3.9002E- 07	1.05021E- 05	-5.047901	549	15965.5	8040.75	0
similar to ba408e5.4 novel protein dmpk-like cdc42-binding kinase beta cdc42bpb loc144850		XM_090553	mwghuman3 OK#B:9158	-4.265957	2.3863E- 08	5.29006E- 07	-6.259229	573	1784	632	
ubiquitin specific peptidase 9, Y- linked (fat facets-like, Drosophila) (USP9Y), mRNA	NP_004645.2	NM_004654.3	mwghuman3 OK#A:10655	-1.584065	3.40815E- 07	8.23838E- 06	-5.287284	587	10035.5	7858.25	1

Fig. 3 (continued)

11/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
ensembl genscan prediction		AC022554.2.1 1725.14597.1	mwghuman3 OK#C:7523	-2.800527	1.74508E- 07	6.41199E -07	-5.902891	597	3330	1296	
solute carrier family 35 (CMP-sialic acid transporter), member A1 (SLC35A1), mRNA	NP_006407. 1	NM_006416.2	mwghuman3 OK#B:6203	-1.879113	1.20877E- 06	5.48118E -06	-5.297694	606	20639	15436.75	1
cell line sc30 t receptor alpha chain v-j junctional region tcr v 29.1 j 11 coding sequence reported spans from nucleotide position		U14083	mwghuman3 OK#B:9790	-2.442854	9.94216E- 08	1.14277E -08	-7.365379	617	6673	2661.5	
chromosome 2 open reading frame 33 (C2orf33), mRNA	NP_064579. 3	NM_020194.4	mwghuman3 OK#A:06988	-1.615311	3.24982E- 07	9.24336E -06	-5.392632	624	11555.5	8868.25	4
ensembl genscan prediction		AC073108.7.1 14033.192530 .1	mwghuman3 OK#C:4991	-2.137812	1.453E-05	1.06394E -06	-6.345675	650.5	9963.5	5676.75	

Fig. 3 (continued)

12/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
UDP-N-acetyl- alpha-D- galactosamine: polypeptide N- acetylglactosa minyltransferas e 7 (GALNAc- T7) (GALNT7), mRNA	NP_059119. 1	NM_017423.1	mwghuman3 OK#A:01420	-1.401046	7.53042E- 08	1.13272E- 06	-6.143981	656.5	10573	8997.75	2
chromosome 11 open reading frame 1 (C11orf1), mRNA	NP_073598. 1	NM_022761.1	mwghuman3 OK#A:01834	-1.81726	1.38032E- 06	1.22937E- 05	-5.104229	673.5	12025.5	9585.25	0
heterogeneous nuclear ribonucleoprote in H2 (H') (HNRPH2), transcript variant 1, mRNA	NP_062543. 1	NM_019597.3	mwghuman3 OK#A:08547	-2.03901	2.40065E- 06	6.16248E- 06	-5.465662	684	777	472	9
Werner syndrome (WRN), mRNA	NP_000544. 1	NM_000553.2	mwghuman3 OK#A:03163	-1.605462	7.49706E- 08	6.16248E- 06	-4.681771	696	4585	4351.25	3
ensembl genscan prediction		AC040160.3.6 1245.138821. 5	mwghuman3 OK#C:7317	-4.953847	7.54477E- 12	1.43666E- 08	-6.602968	706.5	4523.5	744.5	

Fig. 3 (continued)

13/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	bloo d
adducin 3 (gamma) (ADD3), transcript variant 1, mRNA	NP_058432.1	NM_016824.3	mwghuman3 OK#B:5211	-2.092475	1.34331E- 05	1.16156E -05	-5.883251	716	7668.5	4808.75	8
hydroxysteroid dehydrogenase like 2 (HSDL2), mRNA	NP_115679.2	NM_032303.2	mwghuman3 OK#B:3888	-2.1317	9.39999E- 07	5.81228E -06	-5.58267	732.5	7276.5	5055	2
DNA-damage- inducible transcript 4 (DDIT4), mRNA	NP_061931.1	NM_019058.2	mwghuman3 OK#B:2115	-2.660775	6.68834E- 05	5.16818E -06	-5.969252	750	10960.5	5062.75	12
RNA binding protein, autoantigenic (hnRNP- associated with lethal yellow homolog (mouse)) (RALY), transcript variant 1, mRNA	NP_057951.1	NM_016732.1	mwghuman3 OK#A:06376	-1.901576	1.7076E- 07	4.32856E -06	-4.392163	750.5	977	386.5	26

Fig. 3 (continued)

14/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
acyl-CoA synthetase medium-chain family member 3 (ACSM3), transcript variant 1, mRNA	NP_005613.2	NM_005622.3	mwghuman3 OK#B:9076	-1.967123	1.7751E- 05	7.33836E -06	-5.050721	765.5	18906.5	12252.25	3
BCL2- associated athanogene (BAG1), mRNA	NP_004314.3	NM_004323.3	mwghuman3 OK#A:09581	-2.525417	2.13163E- 08	5.29006E -07	-5.934904	776	9031	4503.5	1
neural precursor cell expressed, developmentall y down- regulated 4 (NEDD4), transcript variant 1, mRNA	NP_006145.1	NM_006154.1	mwghuman3 OK#B:7862	-1.900818	3.7763E- 06	8.23334E -06	-5.249282	781	15497	12075	2
chromosome 7 open reading frame 19 (C7orf19), mRNA	NP_116220.1	NM_032831.1	mwghuman3 OK#B:2324	-1.780735	4.63759E- 06	0.000016 624	-5.43532	783	11586.5	6704.75	16
calpain 13 (CAPN13), mRNA	NP_653176.2	NM_144575.2	mwghuman3 OK#B:6754	-1.542431	4.41704E- 06	5.81228E -06	-4.843249	808.5	23318	19953.5	0
homeo box B2 (HOXB2), mRNA	NP_002136.1	NM_002145.2	mwghuman3 OK#A:01639	-2.702649	2.94498E- 11	5.08294E -08	-6.774876	814.5	11537.5	6408	3

Fig. 3 (continued)

15/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
coiled-coil domain containing 28A (CCDC28A), mRNA	NP_056254.1	NM_015439.2	mwghuman3 OK#B:3128	-1.960606	1.97345E- 06	5.48118E- 06	-5.330597	826	19022	14223.75	4
myofibrillogene sis regulator 1 (MR-1), transcript variant 1, mRNA	NP_056303.2	NM_015488.3	mwghuman3 OK#B:3179	-1.526799	1.22924E- 05	6.92439E- 06	-5.874478	832	13007	10755.75	6
guanine nucleotide binding protein (G protein), beta polypeptide 2- like 1 (GNB2L1), mRNA	NP_006089.1	NM_006098.4	mwghuman3 OK#C:0841	-1.789085	2.16356E- 06	4.35419E- 05	-4.900058	844.5	1710	1178	106
spectrin repeat containing, nuclear envelope 1 (SYNE1), transcript variant beta, mRNA	NP_056108.1	NM_015293.1	mwghuman3 OK#B:9104	-1.414534	7.52733E- 07	3.02433E- 06	-5.983107	851	20159.5	17233.75	64
ensembl genscan prediction		AL021155.1.1 .107603.5	mwghuman3 OK#C:7334	-1.766409	2.12121E- 06	2.01355E- 05	-4.468876	853	1264	847.5	

Fig. 3 (continued)

16/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
bone morphogenetic protein receptor, type IA (BMPR1A), mRNA	NP_004320.2	NM_004329.2	mwghuman3 OK#A:02484	-1.558632	2.22237E- 07	1.22937E- 05	-4.618211	874.5	5116	5037.5	4
IQ motif containing B1 (IQCB1), transcript variant 1, mRNA	NP_0010188 64.1	NM_0010235 70.1	mwghuman3 OK#B:4020	-1.646698	2.79495E- 05	1.62908E- 05	-5.169855	882.5	10922	8773.5	2
ensembl genscan prediction		AC069502.9.1 .18380.1	mwghuman3 OK#C:3663	-1.464573	6.94397E- 07	2.53657E- 05	-4.951029	901	21078	19035	
similar to death- associated protein (LOC92196), mRNA	NP_0010179 20.1	NM_0010179 20.1	mwghuman3 OK#B:6718	-2.553467	5.76345E- 07	7.76152E- 07	-5.221107	907	23255	15868	0
ensembl genscan prediction		AC012203.4.1 05191.123571 .1	mwghuman3 OK#C:4578	-1.438718	3.21936E- 05	4.85862E- 07	-5.989899	907	27071.5	25867.5	
ensembl genscan prediction mwg oligo matches these RefSeq numbers NM_000986		AL158153.8.4 5139.113162. 3	mwghuman3 OK#C:2173	-2.089238	4.80586E- 07	4.32856E- 06	-5.395407	909.5	1290	1010.25	

Fig. 3 (continued)

17/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
growth arrest and DNA- damage- inducible, alpha (GADD45A), mRNA	NP_001915.1	NM_001924.2	mwghuman3 OK#A:04346	-1.68216	7.53906E- 06	2.67916E -05	-4.924921	916.5	11634.5	8596.75	3
stress 70 protein chaperone, microsome- associated, 60kDa (STCH), mRNA	NP_008879.3	NM_006948.4	mwghuman3 OK#A:05064	-1.761334	4.58163E- 05	1.72268E -05	-5.784774	916.5	10794	6231.25	5
ensembl genscan prediction		Z84474.1.1.1 07526.2	mwghuman3 OK#C:0911	-1.884499	1.62444E- 08	2.23413E -06	-5.434325	933.5	1974	1488.5	
family with sequence similarity 44, member B (FAM44B), mRNA	NP_612378.1	NM_138369.1	mwghuman3 OK#B:4192	-1.357114	7.91633E- 07	1.64431E -06	-6.047548	942.5	15308.5	13004.75	1
ensembl genscan prediction		AC078789.15. 1.55074.2	mwghuman3 OK#C:6283	-1.786484	1.80836E- 06	3.70831E -05	-4.861731	948	25553.5	22990.75	
citrate lyase beta like (CLYBL), transcript variant 1, mRNA	NP_612124.3	NM_138280.3	mwghuman3 OK#B:8855	-1.444822	1.17336E- 06	5.16818E -06	-5.775319	953	21231	19330.25	1

Fig. 3 (continued)

18/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
ensembl gscan prediction		AP001015.3.6 6054.115655. 1	mwghuman3 OK#C:3998	-1.709242	1.48259E- 07	7.36585E- 05	-4.504002	972.5	3374.5	2739.5	
ensembl gscan prediction		AL159169.14. 1.86155.2	mwghuman3 OK#C:4465	-1.474035	8.96434E- 07	3.25437E- 06	-5.020854	998.5	28575	28030	
chromosome 6 open reading frame 130 (C6orf130), mRNA	NP_659500.1	NM_145063.2	mwghuman3 OK#B:4652	-1.674296	1.77778E- 05	3.32944E- 05	-4.846371	1011. 5	14804	10754.75	3
methyltransferase like 1 (METTL1), transcript variant 1, mRNA	NP_005362.1	NM_005371.3	mwghuman3 OK#A:00607	-1.464425	1.73108E- 07	5.48118E- 06	-5.447819	1026	943	645.5	2
nucleosome assembly protein 1-like 4 (NAP1L4), mRNA	NP_005960.1	NM_005969.3	mwghuman3 OK#A:00706	-1.902267	1.44614E- 05	6.99321E- 05	-4.962357	1042. 5	10336.5	8978.5	12
tumor protein D52 (TPD52), transcript variant 3, mRNA	NP_005070.1	NM_005079.2	mwghuman3 OK#A:05633	-1.55805	1.79544E- 06	3.15409E- 05	-4.599069	1070	19033	14646.75	4
EH-domain containing 4 (EHD4), mRNA	NP_644670.1	NM_139265.2	mwghuman3 OK#B:5911	-1.64935	1.97896E- 05	3.70831E- 05	-4.903865	1077	12134	9187.5	4

Fig. 3 (continued)

19/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
fibroblast growth factor receptor 4 (FGFR4), transcript variant 2, mRNA	NP_075252.2	NM_022963.2	mwghuman3 OK#B:8174	-2.638426	2.02402E- 06	3.21175E- -06	-6.251766	1087. 5	17096	9762.5	0
KIAA0674 (KIAA0674), mRNA	XP_376903.2	XM_376903.2	mwghuman3 OK#B:0240	-1.362276	3.68739E- 06	3.62055E- -06	-5.432041	1092. 5	10744	9097.25	4
chromosome 16 bac clone cif987sk-a- 363e6		U91321	mwghuman3 OK#B:5375	-1.568388	5.91844E- 05	6.53282E- -06	-6.349455	1114. 5	10576.5	6083.25	
ensembl gscan prediction		AC073610.11. 63494.102478 .3	mwghuman3 OK#C:1337	-1.828108	1.68631E- 06	1.30096E- -05	-5.253574	1114. 5	1434.5	737	
androgen receptor (AR), transcript variant 1, mRNA	NP_000035.2	NM_000044.2	mwghuman3 OK#A:01003	-1.575215	1.18973E- 07	1.54035E- -05	-4.291628	1120. 5	18067.5	15252.5	0
thyroid transcription factor 1 (TTF1), mRNA	NP_003308.1	NM_003317.3	mwghuman3 OK#A:07197	-1.466987	8.57665E- 07	1.54585E- -06	-6.023277	1124. 5	2139	1026.25	0

Fig. 3 (continued)

20/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
spectrin repeat containing, nuclear envelope 1 (SYNE1), transcript variant longest, mRNA	NP_892006.1	NM_182961.1	mwghuman3 OK#C:2340	-1.440164	6.37872E- 05	2.15085E -05	-5.805222	1124. 5	26092.5	21681.5	64
ensembl gscan prediction		AC019084.7.9 3515.134992. 2	mwghuman3 OK#C:5482	-1.55364	1.48892E- 06	7.77593E -06	-5.043927	1126. 5	8785.5	8789.5	
ensembl gscan prediction		AC026235.12. 9210.157122. 4	mwghuman3 OK#C:3969	-1.693854	8.74991E- 08	0.000122 803	-4.393663	1136. 5	804	493.5	
ensembl gscan prediction		AP002840.1.9 9623.121675. 1	mwghuman3 OK#C:5950	-1.784079	2.96992E- 05	7.75722E -05	-4.69759	1156	16693.5	14033.25	
CDC-like kinase 1 (CLK1), transcript variant 1, mRNA	NP_004062.2	NM_004071.2	mwghuman3 OK#A:07840	-2.034707	6.15281E- 05	6.99321E -05	-5.146308	1157. 5	12199	7934.75	4
lipin 1 (LPIN1), mRNA	NP_663731.1	NM_145693.1	mwghuman3 OK#B:8172	-1.851742	1.40757E- 07	2.98753E -05	-4.301729	1159. 5	3757	2609	2
lamin A/C (LMNA), transcript variant 2, mRNA	NP_005563.1	NM_005572.2	mwghuman3 OK#A:08943	-1.724223	9.63727E- 05	5.67358E -05	-5.305029	1162. 5	4447	3295	10
ensembl gscan prediction		AC079456.15. 119608.15149 0.1	mwghuman3 OK#C:3309	-1.39662	6.38081E- 06	4.32856E -06	-6.439308	1169. 5	26755.5	26493.5	

Fig. 3 (continued)

21/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
similar to riken cdha 1500002b03 clone mgc:12928 image:429841 4		BC007768	mwghuman3 OK#B:4242	-1.518362	5.21322E- 06	3.51403E- 05	-4.463332	1171	21159	20375	
ensembl genscan prediction		AC027086.2.2 3033.31927.1	mwghuman3 OK#C:6982	-1.659003	1.16113E- 11	3.82785E- 07	-6.295271	1172. 5	2757	2062.75	
hyaluronogluco saminidase 3 (HYAL3), mRNA	NP_003540.2	NM_003549.2	mwghuman3 OK#A:09529	-2.01277	6.70905E- 08	1.16156E- 05	-4.684969	1175	4326	3464.5	4
ensembl genscan prediction		AC083822.10. 126464.12912 2.1	mwghuman3 OK#C:9101	-1.479602	6.01319E- 06	2.53657E- 05	-4.526959	1177	22091.5	20578.5	
VprBP protein (VprBP), mRNA	NP_055518.1	NM_014703.1	mwghuman3 OK#B:0332	-1.720326	3.28082E- 05	2.40122E- 05	-5.246863	1178	17312.5	14031	0
nuclear RNA export factor 1 (NXF1), mRNA	NP_006353.2	NM_006362.3	mwghuman3 OK#B:1047	-1.485619	7.48559E- 05	1.62908E- 05	-5.176445	1195. 5	15210	14049.75	20
empty spiracles homolog 2 (Drosophila) (EMX2), mRNA	NP_004089.1	NM_004098.2	mwghuman3 OK#B:9279	-1.745086	9.4996E- 09	5.64117E- 07	-5.709572	1199. 5	19380	10749.25	0
homeo box D8 (HOXD8), mRNA	NP_062458.1	NM_019558.2	mwghuman3 OK#B:3465	-1.41555	6.70306E- 08	2.1019E- 06	-5.674131	1206	9672.5	7512.25	0

Fig. 3 (continued)

22/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
pro2591 predicted protein of hq2591		AF119886	mwghuman3 OK#B:1001	-1.487408	7.83971E- 05	1.30297E- -05	-4.929888	1212	27543.5	26699	0
ensembl gscan prediction		AC016432.3.1 6946.19371.1	mwghuman3 OK#C:6058	-3.528975	4.33482E- 13	5.08294E- -08	-6.731611	1216. 5	3962.5	1303	
ensembl gscan prediction		AF286885.1.7 6372.115954. 3	mwghuman3 OK#C:7800	-1.83051	1.14443E- 05	5.11795E- -05	-4.359199	1218	21163.5	21224.5	
zinc finger protein 25 (KOX 19) (ZNF25), mRNA	NP_659448.1	NM_145011.2	mwghuman3 OK#C:1648	-1.473477	6.43814E- 09	4.35863E- -07	-5.84264	1253. 5	21026.5	19171	1
zinc finger protein 626 (ZNF626), mRNA	NP_660340.1	NM_145297.2	mwghuman3 OK#B:4148	-1.773183	2.31455E- 06	6.63845E- -05	-4.294361	1266	14806.5	10341	1
growth arrest and DNA- damage- inducible, beta (GADD45B), mRNA	NP_056490.1	NM_015675.1	mwghuman3 OK#A:00537	-1.950707	0.0002000 32	2.03519E- -05	-5.558029	1270. 5	13309	8615.5	5
nebullette (NEBL), transcript variant 1, mRNA	NP_006384.1	NM_006393.1	mwghuman3 OK#A:10459	-1.513391	1.95755E- 05	3.15409E- -05	-4.789714	1276	22936	20052.5	1

Fig. 3 (continued)

23/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
hypothetical protein pro2832 pro2832		NM_018541	mwghuman3 OK#A:00371	-1.457098	3.06355E- 05	6.99321E- 05	-5.164495	1289. 5	16692.5	14266.5	
ring finger protein 44 (RNF44), mRNA	NP_055716.1	NM_014901.4	mwghuman3 OK#A:10680	-1.353366	7.76079E- 07	2.37433E- 06	-5.842265	1292	6288.5	4664.5	1
REX1, RNA exonuclease 1 homolog (S. cerevisiae) (REXO1), mRNA	NP_065746.2	NM_020695.2	mwghuman3 OK#B:8218	-1.36867	1.73225E- 05	2.38069E- 05	-5.111364	1305. 5	4933	3309.5	6
pyrimidinergic receptor P2Y, G-protein coupled, 4 (P2RY4), mRNA	NP_002556.1	NM_002565.3	mwghuman3 OK#A:00433	-1.732075	5.0193E- 08	2.68048E- 06	-5.510614	1309	18307	12139.5	0
ensembl genscan prediction		AL023804.2.1 .96460.1	mwghuman3 OK#C:5405	-1.533348	1.03637E- 06	2.806E- 05	-4.693772	1313	28610	27980.5	
ensembl genscan prediction		AL139823.3.4 9422.51911.1	mwghuman3 OK#C:8800	-1.894452	4.41409E- 05	0.000129 14	-4.650026	1320	11214.5	7548	
similar to hypothetical protein (LOC440804), mRNA	XP_036936.3	XM_036936.3	mwghuman3 OK#B:4832	-4.049648	5.38047E- 11	1.51698E- 07	-6.579174	1332	3647	996.5	0

Fig. 3 (continued)

24/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
chromosome X open reading frame 41 (CXorf41), mRNA	NP_775765.1	NM_173494.1	mwghuman3 OK#C:1526	-1.448331	1.77872E- 05	2.53657E- 05	-5.140193	1334	27414	24062.75	0
chromosome 20 open reading frame 152 (C20orf152), mRNA	NP_543024.1	NM_080834.1	mwghuman3 OK#B:3251	-1.948612	6.84261E- 06	1.82138E- 05	-4.987586	1349	10775	8652.5	0
ensembl genscan prediction		AL390766.11. 35686.142382 .1	mwghuman3 OK#C:4546	-1.516487	5.60986E- 05	4.81914E- 05	-4.642986	1352	28469.5	27078.25	
phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI) (PYGL), mRNA	NP_002854.3	NM_002863.3	mwghuman3 OK#A:04342	-2.190281	5.14475E- 06	0.000269 936	-4.316788	1388. 5	10289.5	7222	21
ensembl genscan prediction		AC013764.3.1 17501.157349 .1	mwghuman3 OK#C:3627	-1.671949	8.77886E- 06	7.36585E- 05	-4.28185	1395. 5	1205	826.5	
folliculin-like 4 (FSTL4), mRNA	NP_055897.1	NM_015082.1	mwghuman3 OK#B:0510	-1.544042	4.79688E- 05	4.35419E- 05	-4.607654	1405. 5	17051	12319	0

Fig. 3 (continued)

25/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
chromosome 14 open reading frame 168 (C14orf168), mRNA	NP_113615.1	NM_031427.1	mwghuman3 OK#B:4011	-1.512002	1.56095E- 05	5.97939E- 05	-4.695177	1414	15738	14705.75	1
aldehyde dehydrogenas e 7 family, member A1 (ALDH7A1), mRNA	NP_001173.1	NM_001182.2	mwghuman3 OK#A:08361	-1.837545	4.80787E- 07	0.000105 506	-3.903403	1433	20103.5	14345.5	2
ensembl genscan prediction		AC010904.9.3 83.204857.4	mwghuman3 OK#C:7433	-1.40403	4.74755E- 05	3.07694E- 05	-4.852328	1444	27423.5	25979.25	
kalikrein 8 (neuropilin/ova sin) (KLK8), transcript variant 2, mRNA	NP_653088.1	NM_144505.1	mwghuman3 OK#B:0129	-2.091505	3.56009E- 06	2.61655E- 06	-5.991679	1449. 5	8391	6488	0
leucine zipper, down-regulated in cancer 1-like (LDOC1L), mRNA	NP_115663.2	NM_032287.2	mwghuman3 OK#B:8710	-1.501021	2.6566E- 06	1.22937E- 05	-4.280727	1454. 5	16509.5	14157	0
two pore segment channel 1 (TPCN1), mRNA	NP_060371.2	NM_017901.3	mwghuman3 OK#B:7759	-1.497443	4.32588E- 06	3.32944E- 05	-4.567011	1460. 5	17545	11635.75	8

Fig. 3 (continued)

26/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
hypothetical protein MGC11242 (MGC11242), mRNA	NP_077296.1	NM_024320.2	mwghuman3 OK#A:05130	-1.527839	2.70218E- 05	1.72268E -05	-4.004461	1463. 5	17565	13134.5	0
phosphofurin acidic cluster sorting protein 1 (PACS1), mRNA	NP_060496.2	NM_018026.2	mwghuman3 OK#B:7703	-1.494259	5.23361E- 05	7.36585E -05	-4.899266	1482. 5	9352	7757.75	19
hypothetical protein xp_036406 loc91138		XM_036406	mwghuman3 OK#B:8080	-1.533764	1.02161E- 05	4.59223E -05	-4.93538	1486. 5	15372.5	14652	
KIAA1274 (KIAA1274), mRNA	NP_055246.1	NM_014431.1	mwghuman3 OK#B:8047	-1.41942	7.87044E- 05	2.27276E -05	-5.659345	1488. 5	8059	5065	0
ensembl gscan prediction		AC090651.1.9 901.36661.2	mwghuman3 OK#C:6027	-1.525691	2.39913E- 05	7.36585E -05	-4.620984	1489. 5	21092	20253	
hypothetical protein FLJ13111 (FLJ13111), mRNA	NP_079358.1	NM_025082.1	mwghuman3 OK#A:02690	-1.496988	3.69096E- 05	7.08197E -05	-4.489468	1494	4861	7579.25	10
glycophorin C (Gerbich blood group) (GYPC), transcript variant 1, mRNA	NP_002092.1	NM_002101.3	mwghuman3 OK#A:01278	-1.628829	9.49623E- 06	0.000135 784	-4.110107	1502	8042	6771	2

Fig. 3 (continued)

27/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
hypothetical LOC401510 (LOC401510), mRNA	XP_376843.2	XM_376843.2	mwghuman3 OK#B:6807	-1.402922	3.03035E- 06	0.000105 506	-4.471835	1504	13882.5	11233.25	0
ensembl genscan prediction		AC068282.4.1 68870.201224 .1	mwghuman3 OK#C:1421	-1.273265	1.4683E- 06	4.32856E -06	-5.673395	1505. 5	4650	3232.25	
phospholipase A2, group IVA (cytosolic, calcium- dependent) (PLA2G4A), mRNA	NP_077734.1	NM_024420.1	mwghuman3 OK#C:2726	-1.656839	1.32347E- 05	2.82936E -05	-4.522341	1508. 5	17687.5	14140.5	5
platin 1 (I isoform) (PLS1), mRNA	NP_002661.1	NM_002670.1	mwghuman3 OK#A:06551	-1.626206	5.67628E- 05	2.98753E -05	-4.952263	1509. 5	20943	14040.5	1
neurobeachin- like 1 (NBEAL1), mRNA	NP_945183.1	NM_198945.1	mwghuman3 OK#C:8646	-1.528665	7.51176E- 06	2.82936E -05	-5.005478	1511. 5	23554.5	20060	3
alcohol dehydrogenas e 4 (class II), pi polypeptide (ADH4), mRNA	NP_000661.2	NM_000670.3	mwghuman3 OK#A:04002	-1.485933	6.40488E- 05	7.36585E -05	-4.608649	1520. 5	22288	20240.75	0

Fig. 3 (continued)

28/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
clone rp5-94718 on chromosome 1p34.1-36.11. contains ests. gsss and stss. part of novel cub sushi scr repeat domain containing p		AL355178	mwghuman3 OK#B:9614	-1.466888	8.43097E- 06	3.15409E -05	-4.397922	1529	4947.5	4650.25	
cytochrome b5 reductase 3 (CYB5R3), transcript variant M, mRNA	NP_000389.1	NM_000398.4	mwghuman3 OK#A:01423	-1.497796	0.0001216 06	9.05266E -05	-5.28459	1531. 5	9574.5	6353.5	9
clone flb5634 pro1477 predicted protein of hq1477		AF130059	mwghuman3 OK#B:1074	-1.699661	1.17568E- 05	3.32944E -05	-4.802532	1535	5685	3946.75	10
zinc finger, DHHC-type containing 2 (ZDHHC2), mRNA	NP_057437.1	NM_016353.2	mwghuman3 OK#A:03494	-1.588633	8.03858E- 06	0.000105 506	-4.741236	1536	13684.5	10087.5	0
cone-rod homeobox (CRX), mRNA	NP_000545.1	NM_000554.2	mwghuman3 OK#A:09219	-3.022299	2.51326E- 05	9.24336E -06	-5.849282	1548	16588.5	7500.5	0

Fig. 3 (continued)

29/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
chromosome 14 open reading frame 154 (C14orf154), transcript variant 1, mRNA	NP_115609.2	NM_032233.2	mwghuman3 OK#B:2665	-1.704609	8.00302E- 05	0.000166 293	-4.427372	1561. 5	16629	15080.75	5
hypothetical protein xp_098665 loc155085		XM_098665	mwghuman3 OK#B:6056	-1.672814	4.27782E- 05	0.000142 749	-4.312941	1566. 5	8795	6847.25	
clone hq0117 pro0117		AF090895	mwghuman3 OK#B:0914	-1.888405	1.18377E- 05	9.05266E- 05	-4.735768	1570. 5	20158	14933.5	4
prostate and breast cancer overexpressed 1 (PBOV1), mRNA	NP_067648.1	NM_021635.1	mwghuman3 OK#A:05114	-1.610345	5.40979E- 06	8.1682E- 05	-4.437567	1571. 5	22494.5	19845.75	0
esterase D/fo mylglutath ione hydrolase (ESD), mRNA	NP_001975.1	NM_001984.1	mwghuman3 OK#C:2641	-1.535083	6.75303E- 06	4.84259E- 05	-4.777065	1574	8049	4838.75	6
ATG4 autophagy related 4 homolog B (S. cerevisiae) (ATG4B), transcript variant 1, mRNA	NP_037457.3	NM_013325.4	mwghuman3 OK#B:2748	-1.348856	8.59727E- 06	1.6224E- 05	-4.71932	1575	15166	16712.25	13

Fig. 3 (continued)

30/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
NADPH oxidase 1 (NOX1), transcript variant NOH- 1Lv, mRNA	NP_039249.1	NM_013955.1	mwghuman3 OK#B:1370	-1.903809	5.04367E- 06	2.65189E- 05	-3.799677	1585. 5	18807.5	17371.5	0
ensembl genscan prediction		AL445675.9.1 .171985.3	mwghuman3 OK#C:8741	-1.774793	2.60881E- 05	0.000182 916	-4.133137	1598	22483.5	18071.5	
putative nuclear protein ORF1-FL49 (ORF1-FL49), mRNA	NP_115788.1	NM_032412.2	mwghuman3 OK#B:7958	-1.499659	6.10749E- 05	3.32944E- 05	-4.457256	1610. 5	8598	4986	8
THUMP domain containing 1 (THUMPD1), mRNA	NP_060206.2	NM_017736.3	mwghuman3 OK#B:2088	-1.313257	4.11592E- 07	6.53282E- 06	-5.325518	1651. 5	14877	15313.5	0
glutaminyl- peptide cyclotransferas e (glutaminyl cyclase) (QPCT), mRNA	NP_036545.1	NM_012413.3	mwghuman3 OK#A:09422	-1.769571	4.69509E- 07	0.000122 803	-3.882851	1651. 5	11960	8357.75	2
PHD finger protein 23 (PHF23), mRNA	NP_077273.1	NM_024297.1	mwghuman3 OK#A:02678	-1.398461	1.43961E- 05	0.000109 884	-4.356774	1657. 5	10656.5	9355.75	0

Fig. 3 (continued)

31/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
nasopharyngeal carcinoma associated gene protein-8 (NAG8), mRNA	NP_055226.1	NM_014411.2	mwghuman3 OK#B:1482	-1.388055	2.38325E-05	5.10584E-05	-4.601658	1660	15731.5	12161	0
ensembl genscan prediction		AC013487.5.1 02379.117540.1	mwghuman3 OK#C:3348	-1.465932	0.0001448 57	2.37433E-06	-6.225756	1662	14711	9423	
ensembl genscan prediction		AC079757.5.5 4037.62672.1	mwghuman3 OK#C:3844	-1.486502	2.69625E-05	4.12788E-05	-4.765229	1684. 5	25678.5	23575.5	
hypothetical protein FLJ22313 (FLJ22313), mRNA	NP_071768.2	NM_022373.3	mwghuman3 OK#B:3974	-1.47429	0.0001047 25	5.67358E-05	-4.784258	1688. 5	8360.5	9165.25	2
holocytochrome c (cytochrome c heme-lyase) (HCCS), mRNA	NP_005324.2	NM_005333.2	mwghuman3 OK#A:04510	-2.084412	0.0003326 32	0.000211 886	-5.979649	1692. 5	10130.5	5488.25	4
dual specificity phosphatase 5 (DUSP5), mRNA	NP_004410.3	NM_004419.3	mwghuman3 OK#A:04028	-1.866767	5.52516E-05	2.27276E-05	-5.708882	1694. 5	16243.5	8885	2
hypothetical protein FLJ20245 (FLJ20245), mRNA	NP_060193.1	NM_017723.1	mwghuman3 OK#B:2083	-1.525601	6.09068E-05	0.000116 76	-4.325617	1697	16122	13101	3

Fig. 3 (continued)

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
protein kinase, AMP-activated, gamma 2 non- catalytic subunit (PRKAG2), mRNA	NP_057287.2	NM_016203.2	mwghuman3 OK#A:00771	-1.408092	1.41299E- 05	8.59969E- 05	-4.435082	1697. 5	16315.5	13437.25	5
clone rp11- 314a4 on chromosome 20. contains part of the eya2 eyes absent drosophila homolog 2 ests an sts and gsss starts i hypothetical protein pro1598 pro1598		AL359434	mwghuman3 OK#B:9638	-1.591958	1.67257E- 05	6.56055E- 05	-4.203762	1702	25348.5	23840.75	
NIMA (never in mitosis gene a)- related kinase 9 (NEK9), mRNA	NP_149107.3	NM_033116.3	mwghuman3 OK#B:0983	-1.446989	3.89533E- 06	1.30096E- 05	-5.339446	1716. 5	24112.5	22618.75	
glycine receptor, alpha 3 (GLRA3), mRNA	NP_006520.1	NM_006529.1	mwghuman3 OK#A:03690	-1.412224	0.0001037 63	4.35419E- 05	-4.78725	1722. 5	10134.5	7455.5	5
						8.1682E- 05	-4.59741	1726	9472.5	8083.25	2

Fig. 3 (continued)

33/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
ensembl genscan prediction		AC004408.1.1 .113252.2	mwghuman3 OK#C:9512	-1.54073	2.55537E- 06	1.54035E -05	-3.618774	1727	2977	2622.75	
ensembl genscan prediction		AP001655.2.1 48977.153525 .1	mwghuman3 OK#C:7868	-1.285997	2.64478E- 05	1.96829E -05	-4.601991	1746	28566	28245.5	
HERV-H LTR- associating 3 (HHLA3), transcript variant 3, mRNA	NP_0010317 22.1	NM_0010366 45.1	mwghuman3 OK#B:1046	-2.043346	8.67677E- 05	9.52067E -05	-3.941702	1759	13925.5	11798	0
ensembl genscan prediction		AL355497.14. 1.215397.9	mwghuman3 OK#C:7911	-3.056765	1.10766E- 06	3.82785E -07	-6.916789	1760	5672.5	2481.25	
fibronectin leucine rich transmembran e protein 3 (FLRT3), transcript variant 1, mRNA	NP_037413.1	NM_013281.2	mwghuman3 OK#A:05822	-4.204569	1.4941E- 08	9.99201E -07	-6.042443	1770	18156	9231.25	0
cyp3a5 allele cyp3a5*3 alternatively spliced		AF355802	mwghuman3 OK#B:1830	-1.371576	7.33293E- 06	1.91497E -05	-4.362299	1784	26198.5	24518.25	

Fig. 3 (continued)

34/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
microfibrillar- associated protein 3-like (MFAP3L), transcript variant 1, mRNA	NP_067679.5	NM_021647.5	mwghuman3 OK#B:0217	-1.987417	0.0001373 75	1.98715E -06	-4.959479	1785	22262	18475.25	3
cell division cycle associated 7 (CDCA7), transcript variant 1, mRNA	NP_114148.2	NM_031942.3	mwghuman3 OK#B:4810	-1.959598	9.26637E- 05	0.000150 05	-4.246093	1788	14826	12577.25	1
WD repeat domain 61 (WDR61), mRNA	NP_079510.1	NM_025234.1	mwghuman3 OK#B:1624	-1.531798	0.0001544 91	0.000105 506	-4.38785	1801. 5	9756.5	8041.75	3
protein kinase, AMP-activated, beta 1 non- catalytic subunit (PRKAB1), mRNA	NP_006244.2	NM_006253.4	mwghuman3 OK#A:04996	-1.514877	9.29449E- 05	0.000105 506	-4.4366	1805. 5	16011.5	13954	3
zinc finger, A20 domain containing 2 (ZA20D2), mRNA	NP_005998.1	NM_006007.1	mwghuman3 OK#A:10213	-1.857923	2.78106E- 06	2.67916E -05	-4.781221	1808. 5	6856.5	4563.25	13
similar to pro2852 loc93374		XM_050978	mwghuman3 OK#B:7206	-1.359998	8.48914E- 05	6.30077E -05	-5.206744	1817	19166	16438	

Fig. 3 (continued)

35/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
catalase (CAT), mRNA	NP_001743.1	NM_001752.2	mwghuman3 OK#C:3530	-2.225675	8.1938E- 07	6.92439E- 06	-4.777325	1820	7219.5	4208.75	31
peptidylprolyl isomerase (cyclophilin)- like 2 (PPIL2), transcript variant 2, mRNA	NP_680480.1	NM_148175.1	mwghuman3 OK#B:6262	-1.384263	4.77437E- 07	4.59274E- 06	-5.396075	1834. 5	3806	3514	5
periaxin (PRX), transcript variant 2, mRNA	NP_870998.1	NM_181882.1	mwghuman3 OK#A:01781	-1.399169	1.03356E- 05	6.63845E- 05	-4.549994	1838	19643.5	17122.5	0
breast carcinoma amplified sequence 3 (BCAS3), mRNA	NP_060149.2	NM_017679.2	mwghuman3 OK#A:01576	-1.41274	2.55423E- 07	3.64015E- 06	-4.03611	1839	15754.5	17960.25	2
HtrA serine peptidase 2 HTRA2	AAF66598.1	AF141307.1	mwghuman3 OK#B:1170	-1.284282	2.27894E- 05	1.86362E- 05	-4.071282	1850	22760.5	20044.75	
ensembl genscan prediction		AC012095.13. 12848.17419. 1	mwghuman3 OK#C:7012	-1.517696	0.0001343 14	0.000172 435	-4.407333	1854	26139.5	25010.5	
formin binding protein 4 (FNBP4), mRNA	NP_056123.1	NM_015308.1	mwghuman3 OK#B:8897	-1.360042	0.0001194 22	2.15085E- 05	-5.532889	1855	17142	14814.25	11

Fig. 3 (continued)

36/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
aldehyde dehydrogenas e 1 family, member L1 (ALDH1L1), mRNA	NP_036322.2	NM_012190.2	mwghuman3 OK#A:07479	-2.396851	2.32809E- 05	0.000157 701	-3.740555	1856. 5	13469	8189.5	3
ensembl genscan prediction		AP001487.3.8 5282.114407. 1	mwghuman3 OK#C:8733	-1.603991	4.09016E- 06	5.97939E -05	-4.353485	1870	3882	3994.75	
ensembl genscan prediction		AC015651.18. 1.191583.4	mwghuman3 OK#C:2191	-1.392136	5.55423E- 07	1.72268E -05	-4.562358	1873. 5	2463	1928.25	
OTU domain containing 5 (OTUD5), mRNA	NP_060072.1	NM_017602.2	mwghuman3 OK#B:7999	-1.721318	3.42749E- 06	1.37651E -05	-5.356883	1894. 5	1453	1011	14
ensembl genscan prediction		AC026668.5.8 4589.93793.1	mwghuman3 OK#C:5546	-1.668723	3.74924E- 06	2.40122E -05	-5.209366	1899	3201	1676.5	
chromosome 20 open reading frame 121 (C20orf121), mRNA	NP_077307.1	NM_024331.2	mwghuman3 OK#A:03031	-1.520517	5.93503E- 08	1.82138E -05	-4.163768	1906	8788	6894	2
pyruvate dehydrogenas e kinase, isozyme 4 (PDK4), mRNA	NP_002603.1	NM_002612.2	mwghuman3 OK#A:07564	-1.735687	1.72294E- 05	1.22937E -05	-5.445156	1911. 5	18067	13997.25	1

Fig. 3 (continued)

37/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
KIAA1049 protein (KIAA1049), mRNA	NP_055787.1	NM_014972.1	mwghuman3 OK#B:2555	-1.400381	1.30483E- 05	7.36585E- 05	-4.350759	1913. 5	10972	8868.5	12
DnaJ (Hsp40) homolog, subfamily B, member 6 (DNAJB6), transcript variant 1, mRNA	NP_490647.1	NM_058246.3	mwghuman3 OK#A:04664	-1.455502	9.60314E- 05	0.000150 05	-4.286094	1917	3609	2895.5	14
lectin, galactoside- binding, soluble, 3 (galectin 3) (LGALS3), mRNA	NP_002297.1	NM_002306.1	mwghuman3 OK#A:10306	-1.93733	6.69527E- 06	2.55121E- 05	-4.690215	1923	2753	1803.5	6
PTPRF interacting protein, binding protein 2 (liprin beta 2) (PPFIBP2), mRNA	NP_003612.1	NM_003621.1	mwghuman3 OK#B:0552	-1.881545	1.28489E- 06	2.98753E- 05	-4.14602	1937. 5	6372.5	4594.5	2
polymerase (DNA directed), lambda (POLL), mRNA	NP_037406.1	NM_013274.2	mwghuman3 OK#B:1279	-1.399567	3.5582E- 05	2.98753E- 05	-4.793654	1938	15108.5	11461.25	8

Fig. 3 (continued)

38/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
growth differentiation factor 15 (GDF15), mRNA	NP_004855.1	NM_004864.1	mwghuman3 OK#A:07217	-2.483648	0.0002241 34	0.000257 25	-4.296268	1944	6377	3127.5	2
hypothetical protein xp_089809 loc159765		XM_089809	mwghuman3 OK#B:6474	-1.381507	9.90157E- 07	2.40122E- 05	-4.093057	1949	11626.5	11522.5	
leucine rich repeat and sterile alpha motif containing 1 (LRSAM1), transcript variant 1, mRNA	NP_612370.3	NM_138361.3	mwghuman3 OK#B:4416	-2.034574	0.0001840 31	0.000233 537	-4.13512	1959. 5	7671.5	4421.75	1
trafficking protein particle complex 6A (TRAPPC6A), mRNA	NP_077013.1	NM_024108.1	mwghuman3 OK#A:02117	-1.452954	2.44741E- 06	2.53657E- 05	-3.509555	1985	1279	1294	8
ensembl genscan prediction		AL357146.10. 1.82494.1	mwghuman3 OK#C:3608	-1.287782	1.49736E- 05	6.05474E- 05	-4.826559	1989	28444.5	26083.25	
hypothetical protein MGC14327 (MGC14327), mRNA	NP_444273.1	NM_053045.1	mwghuman3 OK#B:4427	-1.504495	0.0001502 58	0.000174 117	-4.521635	1992	16805	15440.5	4

Fig. 3 (continued)

39/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
similar to kinesin family member 5b clone mgc:15265 image:429779 3		BC009353	mwghuman3 OK#B:4438	-1.51682	0.0001882 14	0.000192 131	-4.531075	1992	23071.5	21809.75	
potassium channel tetramerisation domain containing 3 (KCTD3), mRNA	NP_057205.2	NM_016121.3	mwghuman3 OK#A:04386	-1.358006	1.34593E- 05	5.38262E- 05	-4.810824	1994. 5	17479.5	13203.75	3
ensembl genscan prediction		AC018425.3.1 53134.186975 .1	mwghuman3 OK#C:3925	-1.496534	0.0001495 25	0.000192 131	-4.315259	1997	25336	25414.75	
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 (GNAI1), mRNA	NP_002060.4	NM_002069.4	mwghuman3 OK#A:10201	-1.631361	5.34686E- 06	0.000433 377	-3.885346	2003	16803.5	14082	1
microtubule- associated protein 4 (MAP4), transcript variant 1, mRNA	NP_002366.2	NM_002375.3	mwghuman3 OK#B:4355	-1.468752	0.0001551 87	0.000257 25	-4.423897	2004	10052	9080	11

Fig. 3 (continued)

40/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
nucleolar protein family 6 (RNA- associated) (NOL6), transcript variant alpha, mRNA	NP_075068.2	NM_022917.4	mwghuman3 OK#A:07182	-1.30257	1.12604E- 06	3.70831E- 05	-4.767639	2009	10513	8821	7
cerebral endothelial cell adhesion molecule 1 (CEECAM1), mRNA	NP_057258.2	NM_016174.3	mwghuman3 OK#A:10231	-1.516413	4.80848E- 05	0.000109 198	-3.667581	2014	16662.5	13757.75	0
ubiquinol- cytochrome c reductase, complex III subunit VII, 9.5kDa (UQCRQ), nuclear gene encoding mitochondrial protein, mRNA	NP_055217.2	NM_014402.3	mwghuman3 OK#B:8060	-1.71221	4.79681E- 05	4.35419E- 05	-5.049156	2014	4199.5	2985.25	14
hypothetical protein xp_092745 loc164337		XM_092745	mwghuman3 OK#B:3255	-1.386871	3.26973E- 05	0.000165 718	-4.513374	2041	19510	15741.25	

Fig. 3 (continued)

41/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
hypothetical protein FLJ22965 (FLJ22965), mRNA	NP_071384.1	NM_022101.2	mwghuman3 OK#A:09776	-1.903469	7.16955E- 05	0.000475 592	-4.078844	2041. 5	2596	2337	0
chromosome 9 open reading frame 102 (C9orf102), transcript variant 1, mRNA	NP_064592.1	NM_020207.2	mwghuman3 OK#B:6956	-1.369819	3.05523E- 05	0.000105 506	-4.676244	2049	16457.5	13970	0
sphingosine-1- phosphate phosphatase 1 (SGPP1), mRNA	NP_110418.1	NM_030791.2	mwghuman3 OK#B:1809	-1.477332	4.90035E- 05	0.000142 749	-4.328137	2062. 5	20094	17541.5	1
pleckstrin and Sec7 domain containing 3 (PSD3), transcript variant 1, mRNA	NP_056125.2	NM_015310.2	mwghuman3 OK#B:9515	-1.395381	2.70551E- 05	0.000142 896	-3.953529	2072	14023	13223.25	1
hypothetical protein LOC283874 (LOC283874), mRNA	NP_0010127 49.1	NM_0010127 31.1	mwghuman3 OK#B:2101	-1.376341	1.45793E- 05	2.67916E -05	-5.079903	2090. 5	23511.5	23000	1

Fig. 3 (continued)

42/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
zinc finger, FYVE domain containing 21 (ZFYVE21), mRNA	NP_076976.1	NM_024071.2	mwghuman3 OK#A:05642	-1.579562	0.0001142 53	0.000342 648	-4.238027	2094	2994.5	2740.25	0
forkhead box E1 (thyroid transcription factor 2) (FOXE1), mRNA	NP_004464.2	NM_004473.3	mwghuman3 OK#A:07899	-1.678652	1.3104E- 05	0.000192 131	-3.837954	2107	7269	5293.75	0
ensembl genscan prediction		AL158168.17. 82811.114103 .1	mwghuman3 OK#C:5892	-1.54059	5.72345E- 05	8.88591E- 06	-4.136599	2114	28578	27753.75	
similar to per- hexamer repeat protein 5 loc149135		XM_089208	mwghuman3 OK#B:9694	-1.363387	0.0001055 64	3.77672E- 05	-3.9371	2131	27002.5	27249.5	
zinc finger, matrin type 1 (ZMAT1), transcript variant 3, mRNA	NP_115817.1	NM_032441.1	mwghuman3 OK#C:0106	-1.423696	0.0001562 67	0.000211 886	-4.538065	2134. 5	20339.5	17190.25	2
endoplasmic reticulum to nucleus signalling 2 (ERN2), mRNA	NP_150296.2	NM_033266.2	mwghuman3 OK#B:9444	-1.735187	1.98165E- 05	2.70994E- 05	-4.509363	2135	24789	18903	0

Fig. 3 (continued)

43/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
ring finger protein 38 (RNF38), transcript variant 1, mRNA	NP_073618.3	NM_022781.3	mwghuman3 OK#B:5588	-1.302965	2.50283E- 06	2.15085E- 05	-4.986001	2138	24546.5	22148.75	1
Myc-induced mitochondria protein (mimitin), mRNA	NP_777549.1	NM_174889.2	mwghuman3 OK#B:3716	-1.474873	8.439E-05	0.000359 234	-4.207401	2151. 5	9215	7030.25	1
TGF beta- inducible nuclear protein 1 (TINP1), mRNA	NP_055701.1	NM_014886.2	mwghuman3 OK#A:06520	-1.655993	0.0003187 59	0.000571 767	-4.796546	2153	7530	5545.5	6
similar to developmental pluripotency associated 5; embryonal stem cell specific gene 1 (LOC341912), mRNA	XP_292301.3	XM_292301.3	mwghuman3 OK#B:8134	-1.639786	7.64251E- 07	4.32856E- 06	-5.437632	2155	18581.5	12815.25	1
dehydrogenas e/reductase (SDR family) member 3 (DHRS3), mRNA	NP_004744.2	NM_004753.4	mwghuman3 OK#B:0738	-1.439285	4.39582E- 05	0.000222 464	-3.974197	2166. 5	4626	3570	3

Fig. 3 (continued)

44/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
flavin containing monooxygenas e 4 (FMO4), mRNA	NP_002013.1	NM_002022.1	mwghuman3 OK#B:2927	-1.804252	0.0001959 67	0.000222 464	-4.159771	2173. 5	21428	18241	1
ensembl genscan prediction		AC022526.4.9 087.13827.1	mwghuman3 OK#C:9081	-1.518222	0.0001264 09	0.000174 117	-4.437239	2174	25713.5	23316	
serologically defined colon cancer antigen 8 (SDCCAG8), mRNA	NP_006633.1	NM_006642.1	mwghuman3 OK#B:4992	-1.359218	5.81032E- 06	1.22937E- 05	-4.628131	2177. 5	18648	16566	4
CDC14 cell division cycle 14 homolog B (S. cerevisiae) (CDC14B), transcript variant 2, mRNA	NP_201588.1	NM_033331.1	mwghuman3 OK#B:0753	-1.438486	0.0001500 76	0.000245 124	-4.702655	2178. 5	23322	22971	2
myeloid/lymph oid or mixed- lineage leukemia (trithorax homolog, Drosophila); translocated to, 3 (MLLT3), mRNA	NP_004520.1	NM_004529.1	mwghuman3 OK#A:00725	-1.503791	3.87447E- 05	0.000311 603	-4.282874	2188	20164.5	17462	4

Fig. 3 (continued)

45/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
cytochrome P450, family 27, subfamily A, polypeptide 1 (CYP27A1), nuclear gene encoding mitochondrial protein, mRNA	NP_000775.1	NM_000784.2	mwghuman3 OK#A:07422	-1.399906	4.05019E- 05	3.91276E- 05	-4.065883	2197	20714	13781.5	10
pre-tnk cell associated protein 1f6 3' end		L17326	mwghuman3 OK#B:9025	-1.643879	5.92984E- 08	3.84322E- 06	-5.055927	2201	6449.5	4787.5	
hepcidin antimicrobial peptide (HAMP), mRNA	NP_066998.1	NM_021175.2	mwghuman3 OK#A:06397	-1.279742	2.53831E- 05	1.72268E- 05	-4.893297	2205. 5	3722.5	3385.25	0
ensembl genscan prediction		AC078819.13. 1.41283.1	mwghuman3 OK#C:7792	-1.349603	2.94705E- 06	7.88194E- 05	-4.262185	2213	21381.5	17800.75	
hypothetical protein BC009862 (LOC90113), mRNA	XP_291077.3	XM_291077.3	mwghuman3 OK#B:3668	-1.769275	0.0003405 69	0.000454 027	-4.413577	2221. 5	6261.5	5176	0
elongation factor, RNA polymerase II, 2 (ELL2), mRNA	NP_036213.1	NM_012081.3	mwghuman3 OK#A:00356	-1.499648	5.40285E- 05	0.000157 701	-4.384409	2223. 5	14138	11702.5	4

Fig. 3 (continued)

46/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
FGFR1 oncogene partner (FGFR1OP), transcript variant 1, mRNA	NP_008976.1	NM_007045.2	mwghuman3 OK#B:4675	-1.513357	9.11409E- 05	0.000233 537	-4.085108	2228. 5	19894	19145.25	0
ensembl genscan prediction		AC025953.2.1 16948.127472 .1	mwghuman3 OK#C:6647	-2.043219	0.0001551 45	0.000283 207	-3.955032	2231	21041	17429.5	
EH domain binding protein 1 (EHBP1), mRNA	NP_056067.1	NM_015252.2	mwghuman3 OK#B:0385	-1.35833	2.50342E- 06	6.99321E -05	-4.628579	2249. 5	13151.5	12131	5
propionyl Coenzyme A carboxylase, alpha polypeptide (PCCA), mRNA	NP_000273.2	NM_000282.2	mwghuman3 OK#B:3551	-1.505038	6.411E-05	0.000110 999	-4.042034	2251	16323	13459	5
ensembl genscan prediction		AL138499.4.1 .185713.1	mwghuman3 OK#C:4137	-1.655664	1.65577E- 05	8.59969E -05	-3.700791	2252. 5	6728	6542.5	
ensembl genscan prediction		AC025937.3.2 8407.38498.1	mwghuman3 OK#C:9420	-5.821331	1.29566E- 11	3.14688E -07	-6.568115	2255. 5	3524	1068.5	

Fig. 3 (continued)

47/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
myocilin, trabecular meshwork inducible glucocorticoid response (MYOC), mRNA	NP_000252.1	NM_000261.1	mwghuman3 OK#A:09642	-1.364785	4.61814E- 05	2.61402E- 05	-4.638227	2263	23815.5	22357.25	0
hspc074		AF161337	mwghuman3 OK#B:1281	-1.61806	1.54965E- 06	1.54035E- 05	-4.426706	2264. 5	1792	1727	3
epoxide hydrolase 2, cytoplasmic (EPHX2), mRNA	NP_001970.2	NM_001979.4	mwghuman3 OK#A:08300	-1.416398	5.8666E- 06	5.81228E- 06	-4.695716	2267. 5	19752.5	16857	3
centromere protein C 1 (CENPC1), mRNA	NP_001803.2	NM_001812.2	mwghuman3 OK#A:10535	-1.578112	0.0001833 56	0.000192 131	-4.258306	2275	19346.5	14107.25	4
poly(A) polymerase beta (testis specific) (PAPOLB), mRNA	NP_064529.4	NM_020144.4	mwghuman3 OK#A:00034	-1.533242	0.0001793 94	0.000311 603	-4.111646	2284	24777	23772.75	1
oligonucleotide /oligosaccharid e-binding fold containing 1 (OBFC1), mRNA	NP_079204.1	NM_024928.3	mwghuman3 OK#A:07366	-1.597262	0.0001519 06	0.000150 05	-4.339099	2292	15940.5	11655	4

Fig. 3 (continued)

48/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
tripartite motif- containing 10 (TRIM10), transcript variant 1, mRNA	NP_006769.1	NM_006778.2	mwghuman3 OK#A:10515	-1.750912	5.52205E- 05	0.000135 784	-4.621742	2296. 5	4089.5	1565.5	0
Rap2-binding protein 9 (RPIB9), mRNA	NP_612147.1	NM_138290.1	mwghuman3 OK#B:7696	-1.451227	1.03873E- 06	1.37651E -05	-5.068475	2297	24136.5	22036.5	1
fksg17		NM_032031	mwghuman3 OK#B:1656	-1.576144	0.0001418 34	0.000233 537	-4.037961	2320. 5	2050	1701.75	1
G protein- coupled receptor 83 (GPR83), mRNA	NP_057624.2	NM_016540.2	mwghuman3 OK#A:05359	-1.472466	6.54909E- 05	0.000182 916	-3.811779	2322. 5	18971.5	15879.25	0
ensembl genscan prediction		AC078987.9.1 35718.144151 .1	mwghuman3 OK#C:4632	-1.300374	2.50018E- 05	1.72268E -05	-4.918105	2322. 5	25018.5	21332.5	
LIM homeobox 9 (LHX9), transcript variant 1, mRNA	NP_064589.2	NM_020204.2	mwghuman3 OK#B:8634	-1.374971	4.6951E- 06	9.24336E -06	-5.312469	2333. 5	16158	13872.25	0
pellino homolog 1 (Drosophila) (PELI1), mRNA	NP_065702.2	NM_020651.2	mwghuman3 OK#A:10770	-1.492094	8.8328E- 06	8.23838E -06	-5.23835	2336	22421.5	17524.5	7

Fig. 3 (continued)

49/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
hypothetical LOC401500 (LOC401500), mRNA	XP_379629.1	XM_379629.1	mwghuman3 OK#B:6223	-1.325858	2.27785E- 05	4.12788E- 05	-4.402696	2336. 5	26315	25320.25	0
TSC22 domain family, member 3 (TSC22D3), transcript variant 2, mRNA	NP_004080.2	NM_004089.3	mwghuman3 OK#B:0462	-1.491298	5.41371E- 05	1.72268E- 05	-5.010311	2350. 5	18693.5	13200.5	43
G protein- coupled receptor 51 (GPR51), mRNA	NP_005449.5	NM_005458.5	mwghuman3 OK#A:04815	-1.389185	0.0001017 06	2.98753E- 05	-4.845168	2361	3420	2489.25	0
chromosome 10 open reading frame 61 (C10orf61), transcript variant 2, mRNA	NP_056446.1	NM_015631.2	mwghuman3 OK#B:3105	-1.555923	0.0001770 95	0.000297 088	-4.510054	2366. 5	10134	8091.5	3.
jumonji domain containing 2C (JMJD2C), mRNA	NP_055876.1	NM_015061.1	mwghuman3 OK#B:8433	-1.317474	6.41124E- 05	0.000142 749	-4.870495	2366. 5	24516.5	22272.75	11
zinc finger protein 547 (ZNF547), mRNA	NP_775902.2	NM_173631.2	mwghuman3 OK#B:6716	-1.63256	0.0002511 74	0.000257 25	-3.984452	2370	19484	19537	2

Fig. 3 (continued)

50/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
hypothetical protein FLJ20032 (FLJ20032), mRNA	NP_060098.2	NM_017628.2	mwghuman3 OK#B:2068	-1.74414	6.61052E- 05	0.000105 506	-4.166213	2374	15233.5	9767.75	16
ensembl genscan prediction		AC064877.3.1 21131.166993 .1	mwghuman3 OK#C:7466	-1.319284	4.28953E- 05	2.03519E -05	-4.802131	2374	27348	26740.25	
ensembl genscan prediction		AC027755.2.8 1287.97090.1	mwghuman3 OK#C:3411	-1.439071	0.0001259 01	0.000331 474	-4.145868	2378. 5	14385.5	10781.5	
KIAA0690 (KIAA0690), mRNA	NP_055994.1	NM_015179.2	mwghuman3 OK#B:7202	-1.642414	0.0001739 36	0.000433 377	-4.08872	2380	14459	11844.25	10
SH3 domain binding glutamic acid- rich protein like 2 (SH3BGRL2), mRNA	NP_113657.1	NM_031469.1	mwghuman3 OK#B:1794	-1.995457	0.0002796 76	0.000376 568	-4.033794	2381	9893.5	6985.75	3
cdna: flj21394 fis clone col03536 unnamed protein product		AK025047	mwghuman3 OK#B:2580	-2.258109	0.0004473 76	0.000359 234	-4.071961	2387. 5	17288	11926.75	0
hypothetical protein xp_039231 loc91565		XM_039231	mwghuman3 OK#B:6431	-1.337232	2.70835E- 05	0.000174 117	-4.141157	2398	24099.5	20885	

Fig. 3 (continued)

51/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
GPI anchored molecule like protein (GML), mRNA	NP_002057.1	NM_002066.1	mwghuman3 OK#A:02108	-1.438045	0.0000724 93	0.000129 14	-4.162956	2405	16818	14265.75	0
small nuclear RNA activating complex, polypeptide 5, 19kDa (SNAPC5), mRNA	NP_006040.1	NM_006049.1	mwghuman3 OK#B:0945	-1.323754	1.74702E- 05	0.000184 787	-4.006319	2444	17556.5	17969.25	6
ensembl genscan prediction		AC027689.10. 1.180573.5	mwghuman3 OK#C:9758	-1.644263	0.0002550 65	2.98753E -05	-3.674603	2451	16829.5	10684.25	
mitochondrial tumor suppressor 1 (MTUS1), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA	NP_0010019 24.1	NM_0010019 24.1	mwghuman3 OK#B:7775	-1.715161	0.0003036 63	0.000269 936	-4.435392	2461. 5	17489	15873	0
ensembl genscan prediction		AL049829.4.1 .196292.3	mwghuman3 OK#C:4548	-1.402914	1.70061E- 06	2.49927E -06	-5.01844	2471	28131	26784	
ensembl genscan prediction		AC084842.1.7 903.10639.1	mwghuman3 OK#C:7638	-1.400793	0.0008120 94	7.36585E -05	-5.107784	2475. 5	14235.5	11061.25	

Fig. 3 (continued)

52/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
SAFB-like, transcription modulator (SLTM), transcript variant 1, mRNA	NP_079031.2	NM_024755.2	mwghuman3 OK#B:2154	-1.309539	2.00445E- 05	0.000122 803	-4.680439	2477. 5	12490	12280	12
guanine nucleotide binding protein (G protein), alpha activating activity polypeptide, olfactory type (GNAL), transcript variant 2, mRNA	NP_002062.1	NM_002071.1	mwghuman3 OK#A:06286	-1.836112	0.0003002 6	0.000498 109	-4.10637	2478	19959	16690.75	0
similar to cg14182 product loc146175		XM_085352	mwghuman3 OK#B:7365	-1.746066	0.0001949 23	0.000433 377	-3.812815	2487	14791.5	9814.5	
PH domain and leucine rich repeat protein phosphatase (PHLPP), mRNA	NP_919431.1	NM_194449.1	mwghuman3 OK#B:2242	-2.043619	0.0003079 45	0.000498 109	-4.006924	2500	15125	10009.75	7

Fig. 3 (continued)

53/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
autism susceptibility candidate 2 (AUTS2), mRNA	NP_056385.1	NM_015570.1	mwghuman3 OK#B:0110	-1.807633	0.0003692 99	0.000382 814	-4.213775	2503	18404	14412.75	8
hypothetical protein xp_097338 loc147909		XM_097338	mwghuman3 OK#B:5652	-1.428873	1.32234E- 06	2.67916E -05	-4.387947	2513	4388	2991.75	
leucine-rich repeat- containing G protein-coupled receptor 4 (LGR4), mRNA	NP_060960.1	NM_018490.1	mwghuman3 OK#A:06106	-1.519205	7.81416E- 05	0.000122 803	-3.810559	2514. 5	21417.5	19684	2
ensembl prediction		ENSG0000001 13407	mwghuman3 OK#C:2560	-1.740805	1.93346E- 05	9.52811E -05	-4.388894	2525	8797.5	6359.5	
programmed cell death 1 (PDCD1), mRNA	NP_005009.1	NM_005018.1	mwghuman3 OK#B:9147	-1.519488	1.50412E- 06	3.41028E -06	-5.713059	2537	8575	7118.5	0
cadherin 20, type 2 (CDH20), mRNA	NP_114097.2	NM_031891.2	mwghuman3 OK#B:7584	-1.393019	1.91884E- 05	2.73302E -05	-4.362445	2538	15588	12275.75	0

Fig. 3 (continued)

54/102

Gene name/ symbol	protein accession	mRNA ref seq accession	MWG Probe name	median fold change	t-test	Wilcoxon test	SAM	rank score	tumour tissue median intensity rank	non- malignant tissue median intensity rank	blood
glycine dehydrogenas e (decarboxylatin g; glycine decarboxylase, glycine cleavage system protein P) (GLDC), mRNA	NP_000161.1	NM_000170.1	mwghuman3 OK#B:8959	-1.405054	9.33312E- 05	0.000116 76	-4.398207	2542. 5	6039	4550.5	1
protease, serine, 35 (PRSS35), mRNA	NP_699193.1	NM_153362.1	mwghuman3 OK#B:3364	-1.451818	0.0002370 39	0.000257 25	-4.319803	2545	16909	14109	0
ensembl genscan prediction		AC008134.3.1 .175132.1	mwghuman3 OK#C:3643	-1.601839	0.0003788 4	0.000286 633	-4.042534	2545	27071.5	25825	
ATP-binding cassette, sub- family A (ABC1), member 12 (ABCA12), transcript variant 1, mRNA	NP_775099.2	NM_173076.2	mwghuman3 OK#B:3505	-1.653773	0.0002371 78	0.000475 592	-3.927921	2561. 5	19931	18593.5	0
suppressor of hairy wing homolog 3 (Drosophila) (SUHW3), mRNA	NP_060136.1	NM_017666.2	mwghuman3 OK#B:2904	-1.678106	0.0001863 59	0.000546 156	-3.864729	2568	17527	15364.5	1

Fig. 3 (continued)

55/102

Gene name/symbol	protein accession	mRNA ref seq accession	median fold change	rank score	tumour issue median intensity rank	non-malignant tissue median intensity rank	blood EST number
hypothetical protein FLJ21511 (FLJ21511), mRNA	NP_079363.1	NM_025087.1	-2.080908	68	14455	9272.5	0
paired box gene 8 (PAX8), transcript variant PAX8A, mRNA	NP_003457.1	NM_003466.3	-1.961896	82	19419	12999.5	0
UPF3 regulator of nonsense transcripts homolog A (yeast) (UPF3A), transcript variant 1, mRNA	NP_075387.1	NM_023011.2	-3.84007	96.5	5663.5	1825	0
leukotriene B4 12-hydroxydehydrogenase (LTB4DH), mRNA	NP_036344.1	NM_012212.2	-5.034613	122.5	11340.5	3138	0
RAB11 family interacting protein 2 (class I) (RAB11FIP2), mRNA	NP_055719.1	NM_014904.1	-1.993629	156	19636.5	12951	0
TSC22 domain family, member 1 (TSC22D1), transcript variant 2, mRNA	NP_006013.1	NM_006022.2	-2.133065	156.5	8415	6130	1
sulfite oxidase (SUOX), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA	NP_000447.2	NM_000456.2	-1.622803	223	11312.5	8789.5	0
tetratricopeptide repeat domain 21A (TTC21A), mRNA	NP_665698.1	NM_145755.1	-2.976809	225	8375.5	3870.5	1
synaptotagmin-like 2 (SYTL2), transcript variant b, mRNA	NP_115755.2	NM_032379.3	-2.343357	342	19920	12053.5	0
wingless-type MMTV integration site family, member 2B (WNT2B), transcript variant WNT-2B1, mRNA	NP_004176.2	NM_004185.2	-10.745275	501	10716	2016.25	0
protocadherin gamma subfamily A, 12 (PCDHGA12), transcript variant 1, mRNA	NP_003726.1	NM_003735.2	-2.070447	511	2537	1931.5	0
olfactory receptor, family 1, subfamily D, member 5 (OR1D5), mRNA	NP_055381.1	NM_014566.1	-1.640751	539.5	1644	1134	0
G protein-coupled receptor 126 (GPR126), transcript variant b1, mRNA	NP_940971.1	NM_198569.1	-2.181735	549	15965.5	8040.75	0
ubiquitin specific peptidase 9, Y-linked (fat facets-like, Drosophila) (USP9Y), mRNA	NP_004645.2	NM_004654.3	-1.584065	587	10035.5	7858.25	1

Fig. 4

56/102

Gene name/symbol	protein accession	mRNA ref seq accession	median fold change	rank score	tumour issue median intensity rank	non-malignant tissue median intensity rank	blood EST number
chromosome 11 open reading frame 1 (C11orf1), mRNA	NP_073598.1	NM_022761.1	-1.81726	673.5	12025.5	9585.25	0
BCL2-associated athanogene (BAG1), mRNA	NP_004314.3	NM_004323.3	-2.525417	776	9031	4503.5	1
family with sequence similarity 44, member B (FAM44B), mRNA	NP_612378.1	NM_138369.1	-1.357114	942.5	15308.5	13004.75	1
fibroblast growth factor receptor 4 (FGFR4), transcript variant 2, mRNA	NP_075252.2	NM_022963.2	-2.638426	1087.5	17096	9762.5	0
thyroid transcription factor 1 (TTF1), mRNA	NP_003308.1	NM_003317.3	-1.466987	1124.5	2139	1026.25	0
VprBP protein (VprBP), mRNA	NP_055518.1	NM_014703.1	-1.720326	1178	17312.5	14031	0
empty spiracles homolog 2 (Drosophila) (EMX2), mRNA	NP_004089.1	NM_004098.2	-1.745086	1199.5	19380	10749.25	0
homeo box D8 (HOXD8), mRNA	NP_062458.1	NM_019558.2	-1.41555	1206	9672.5	7512.25	0
zinc finger protein 626 (ZNF626), mRNA	NP_660340.1	NM_145297.2	-1.773183	1266	14806.5	10341	1
ring finger protein 44 (RNF44), mRNA	NP_055716.1	NM_014901.4	-1.353366	1292	6288.5	4664.5	1
pyrimidinergic receptor P2Y, G-protein coupled, 4 (P2RY4), mRNA	NP_002556.1	NM_002565.3	-1.732075	1309	18307	12139.5	0
similar to hypothetical protein (LOC440804), mRNA	XP_036936.3	XM_036936.3	-4.049648	1332	3647	996.5	0
chromosome 20 open reading frame 152 (C20orf152), mRNA	NP_543024.1	NM_080834.1	-1.948612	1349	10775	8652.5	0
folistatin-like 4 (FSTL4), mRNA	NP_055897.1	NM_015082.1	-1.544042	1405.5	17051	12319	0
chromosome 14 open reading frame 168 (C14orf168), mRNA	NP_113615.1	NM_031427.1	-1.512002	1414	15738	14705.75	1
kalikrein 8 (neuropsin/ovasin) (KLK8), transcript variant 2, mRNA	NP_653088.1	NM_144505.1	-2.091505	1449.5	8391	6488	0
leucine zipper, down-regulated in cancer 1-like (LDOC1L), mRNA	NP_115663.2	NM_032287.2	-1.501021	1454.5	16509.5	14157	0
hypothetical protein MGC11242 (MGC11242), mRNA	NP_077296.1	NM_024320.2	-1.527839	1463.5	17565	13134.5	0
KIAA1274 (KIAA1274), mRNA	NP_055246.1	NM_014431.1	-1.41942	1488.5	8059	5065	0
hypothetical LOC401510 (LOC401510), mRNA	XP_376843.2	XM_376843.2	-1.402922	1504	13882.5	11233.25	0

Fig. 4 (continued)

57/102

Gene name/symbol	protein accession	mRNA ref seq accession	median fold change	rank score	tumour issue median intensity rank	non-malignant tissue median intensity rank	blood EST number
plastin 1 (I isoform) (PLS1), mRNA	NP_002661.1	NM_002670.1	-1.626206	1509.5	20943	14040.5	1
zinc finger, DHHC-type containing 2 (ZDHHC2), mRNA	NP_057437.1	NM_016353.2	-1.588633	1536	13684.5	10087.5	0
cone-rod homeobox (CRX), mRNA	NP_000545.1	NM_000554.2	-3.022299	1548	16588.5	7500.5	0
PHD finger protein 23 (PHF23), mRNA	NP_077273.1	NM_024297.1	-1.398461	1657.5	10656.5	9355.75	0
nasopharyngeal carcinoma associated gene protein-8 (NAG8), mRNA	NP_055226.1	NM_014411.2	-1.388055	1660	15731.5	12161	0
HERV-H LTR-associating 3 (HHLA3), transcript variant 3, mRNA	NP_001031722.1	NM_001036645.1	-2.043346	1759	13925.5	11798	0
fibronectin leucine rich transmembrane protein 3 (FLRT3), transcript variant 1, mRNA	NP_037413.1	NM_013281.2	-4.204569	1770	18156	9231.25	0
cell division cycle associated 7 (CDCA7), transcript variant 1, mRNA	NP_114148.2	NM_031942.3	-1.959598	1788	14826	12577.25	1
pyruvate dehydrogenase kinase, isozyme 4 (PDK4), mRNA	NP_002603.1	NM_002612.2	-1.735687	1911.5	18067	13997.25	1
leucine rich repeat and sterile alpha motif containing 1 (LRSAM1), transcript variant 1, mRNA	NP_612370.3	NM_138361.3	-2.034574	1959.5	7671.5	4421.75	1
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 (GNAI1), mRNA	NP_002060.4	NM_002069.4	-1.631361	2003	16803.5	14082	1
cerebral endothelial cell adhesion molecule 1 (CEECAM1), mRNA	NP_057258.2	NM_016174.3	-1.516413	2014	16662.5	13757.75	0
hypothetical protein FLJ22965 (FLJ22965), mRNA	NP_071384.1	NM_022101.2	-1.903469	2041.5	2596	2337	0
chromosome 9 open reading frame 102 (C9orf102), transcript variant 1, mRNA	NP_064592.1	NM_020207.2	-1.369819	2049	16457.5	13970	0
pleckstrin and Sec7 domain containing 3 (PSD3), transcript variant 1, mRNA	NP_056125.2	NM_015310.2	-1.395381	2072	14023	13223.25	1
zinc finger, FYVE domain containing 21 (ZFYE21), mRNA	NP_076976.1	NM_024071.2	-1.579562	2094	2994.5	2740.25	0
forkhead box E1 (thyroid transcription factor 2) (FOXE1), mRNA	NP_004464.2	NM_004473.3	-1.678652	2107	7269	5293.75	0

Fig. 4 (continued)

58/102

Gene name/symbol	protein accession	mRNA ref seq accession	median fold change	rank score	tumour issue median intensity rank	non-malignant tissue median intensity rank	blood EST number
Myc-induced mitochondria protein (mimitin), mRNA	NP_777549.1	NM_174889.2	-1.474873	2151.5	9215	7030.25	1
similar to developmental pluripotency associated 5; embryonal stem cell specific gene 1 (LOC341912), mRNA	XP_292301.3	XM_292301.3	-1.639786	2155	18581.5	12815.25	1
hepcidin antimicrobial peptide (HAMP), mRNA	NP_066998.1	NM_021175.2	-1.279742	2205.5	3722.5	3385.25	0
hypothetical protein BC009862 (LOC90113), mRNA	XP_291077.3	XM_291077.3	-1.769275	2221.5	6261.5	5176	0
tripartite motif-containing 10 (TRIM10), transcript variant 1, mRNA	NP_006769.1	NM_006778.2	-1.750912	2296.5	4089.5	1565.5	0
fksg17 fksg17		NM_032031	-1.576144	2320.5	2050	1701.75	1
LIM homeobox 9 (LHX9), transcript variant 1, mRNA	NP_064589.2	NM_020204.2	-1.374971	2333.5	16158	13872.25	0
G protein-coupled receptor 51 (GPR51), mRNA	NP_005449.5	NM_005458.5	-1.389185	2361	3420	2489.25	0
cdna: flj21394 fis clone col03536 unnamed protein product		AK025047	-2.258109	2387.5	17288	11926.75	0
GPI anchored molecule like protein (GML), mRNA	NP_002057.1	NM_002066.1	-1.438045	2405	16818	14265.75	0
programmed cell death 1 (PDCD1), mRNA	NP_005009.1	NM_005018.1	-1.519488	2537	8575	7118.5	0
cadherin 20, type 2 (CDH20), mRNA	NP_114097.2	NM_031891.2	-1.393019	2538	15588	12275.75	0
glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P) (GLDC), mRNA	NP_000161.1	NM_000170.1	-1.405054	2542.5	6039	4550.5	1
protease, serine, 35 (PRSS35), mRNA	NP_699193.1	NM_153362.1	-1.451818	2545	16909	14109	0

Fig. 4 (continued)




Fig. 5

a.	ratio	sensitivity (%)	specificity (%)
	MDK/LTB4DH	87	81
	IGFBP5/LTB4DH	87	88
	HoxA13/LTB4DH	65	81

b.	combination test	sensitivity (%)	specificity (%)
	MDK/LTB4DH and IGFBP5/LTB4DH	92	98
	MDK/LTB4DH and HoxA13/LTB4DH	88	86
	IGFBP5/LTB4DH and HoxA13/LTB4DH	83	98

Fig. 6






Figure 7. ROC curves showing the sensitivity and specificity of detection of TCC in urine samples from TCC patients and non-malignant controls using ratios with LTB4DH.



7a. IGFBP5/LTB4DH; 7b. MDK/LT4BDH; 7c. HoxA13/LTB4DH.

Fig. 7

62/102

Fig. 8a: Combination test with MDK/LTB4DH and IGFBP5/LTB4DH**Fig. 8b: Combination test with MDK/LTB4DH and HoxA13/LTB4DH**

63/102

Fig. 8c: Combination test with IGFBP5/LTB4DH and HoxA13/LTB4DH**Fig 8d: Combination Test with MDK/BAG1 and IGFBP5/BAG1**

64/102



Fig. 8e: Combination test with MDK/BAG1 and HoxA13/BAG1**Fig. 8f: Combination test with IGFBP5/BAG1 and HoxA13/BAG1**

Figure 8. Scatter plots showing the use of test combinations to discriminate between urine samples from TCC patients and controls with non-malignant disease. 8a. MDK/LTB4DH and IGFBP5/LTB4DH; 8b. MDK/LTB4DH and HoxA13/LTB4DH; 8c. IGFBP5/LTB4DH and HoxA13/LTB4DH; 8d. MDK/BAG1 and IGFBP5/BAG1; 8e. MDK/BAG1 and HoxA13/BAG1; 8f. IGFBP5/BAG1 and HoxA13/BAG1.

Fig. 9a: IGFBP5 and IGFBP5/LTB4DH vs creatinine concentration: TCC samples




Fig.9b: IGFBP5 and IGFBP5/LTB4DH versus creatinine concentration: non-malignant samples








Figure 9. Scatter plots showing the correlation between ΔCt for IGFBP5 and ΔCt ratios for IGFBP5/LTB4DH and urine creatinine concentration.
9a. Urine samples from patients with TCC.
9b. Urine samples from patients with non-malignant disease.

67/102

Fig. 10a: MDK - catheterised and voided samples**Fig. 10b: MDK/LTB4DH -catheterised and voided samples**

68/102

Fig. 10c: IGFBP5 - catheterised and voided samples**Fig. 10d: IGFBP5/LTB4DH -catheterised and voided samples**

69/102



Fig. 10e: HoxA13 - catheterised and voided samples**Fig. 10f: HoxA13/LTB4DH -catheterised and voided samples**

Figure 10a. Self-self scatter plots showing the distribution of voided and catheterised samples from TCC patients analysed using BTMs alone and BTMs in ratios with LTB4DH. 10a. MDK; 10b. MDK/LTB4DH; 10c. IGFBP5; 10d. IGFBP5/LTB4DH; 10e. HoxA13; 10f. HoxA13/LTB4DH.

70/102

Gene Name	HUGO	MWVG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
gamma-glutamyl hydrolase	GGH	mwghuman3 OK#A:03601	NM_003878.1	NP_003869.1	2.7	7.5	2.78E-08	3.63E-09	102	S
secreted phosphoprotein 1	SPP1	mwghuman3 OK#A:09441	NM_000582.2	NP_000573.1	5.1	28.6	3.04E-08	0.000000525	143.5	S
neurtin 1	NRN1	mwghuman3 OK#A:00658	NM_016588.2	NP_057672.1	3.9	54.8	1.93E-07	0.000000265	232	S
secreted protein, acidic, cysteine- rich (osteonectin)	SPARC	mwghuman3 OK#A:08092	NM_003118.2	NP_003109.1	2.5	6.9	2.9E-07	0.00000013	352.5	S
a disintegrin-like and metalloprotease (reprolysin type) with										
thrombospondin type 1 motif	ADAMTS10	mwghuman3 OK#B:1355	NM_030957.1	NP_112219.2	2.7	25.8	2.27E-06	0.000000856	465	S
contactin 1	CNTN1	mwghuman3 OK#A:01591	NM_175038.1	NP_778203.1	1.9	5.3	2.61E-06	0.00000196	805	S
tolloid-like 2	TLL2	mwghuman3 OK#A:02932	NM_012465.2	NP_036597.1	3.9	35.6	0.0000207	0.0000466	1019	S
protein disulfide isomerase- related	PDIR	mwghuman3 OK#A:03506	NM_006810.1	NP_006801.1	1.6	3.3	0.0000228	0.00000785	1044.5	S
fibrillin 1	FBN1	mwghuman3 OK#A:07105	NM_000138.2	NP_000129.2	2.1	7.9	2.822E-06	1.37393E-06	1072.5	S
KIAA0100 gene product		mwghuman3 OK#A:10762	NM_014680.2	NP_055495.2	1.5	2.3	1.65E-06	0.00000187	1100.5	S
calreticulin	CALR	mwghuman3 OK#A:10360	NM_004343.2	NP_004334.1	1.7	3.4	5.39E-06	0.00000518	1123.5	S
integrin, beta-like 1	ITGBL1	mwghuman3 OK#A:07933	NM_004791.1	NP_004782.1	1.9	10.5	0.0000293	0.0000224	1186	S
elastase 3B, pancreatic	ELA3B	mwghuman3 OK#B:3993	NM_007352.1	NP_031378.1	1.4	2.1	1.65E-06	0.00000785	1239.5	S
SPARC related modular calcium binding 2	SMOC2	mwghuman3 OK#B:0260	NM_022138.1	NP_071421.1	1.6	4.3	0.0000069	0.00000547	1280	S

Fig. 11

71/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
hexosaminidase A (alpha polypeptide)	HEXA	mwghuman3 OK#B:9777	NM_000520.2	NP_000511.1	1.9	14.6	0.0000183	0.0000325	1318.5	S
insulin-like growth factor binding protein 7	IGFBP7	mwghuman3 OK#A:03385	NM_001553.1	NP_001544.1	2.0	6.5	0.0000614	0.000059	1554.5	S
microfibrillar- associated protein 2	MFAP2	mwghuman3 OK#B:3055	NM_017459.1	NP_059453.1	1.6	4.9	0.0000388	0.0000466	1565.5	S
cartilage intermediate layer protein, nucleotide pyrophosphohydr olase	CILP	mwghuman3 OK#A:00019 mwghuman3 OK#B:3555 mwghuman3 OK#A:09199	NM_003613.1 NM_058199.2 NM_002345.2	NP_003604.2 NP_478106.1 NP_002336.1	1.5 2.3 2.6	2.7 20.7 25.0	0.0000323 0.0000508 0.0002509	0.0000254 0.0000254 6.62502E-05	1582 1704 1953	S S S
olfactomedin 1	OLFM1									
lumican midkine (neurite growth-promoting factor 2)	LUM MDK	mwghuman3 OK#A:01650 mwghuman3 OK#A:05073	NM_002391.2 NM_020163.1	NP_002382.1 NP_064548.1	1.8 1.4	8.9 2.2	0.0002901 7.236E-05	5.24719E-05 0.000116474	2897 2920	S S
semaphorin (LOC56920) protease, serine, 11	SEM2 PRSS11	mwghuman3 OK#B:1274 mwghuman3 OK#B:8770	NM_002775.2 NM_015170.1	NP_002766.1 NP_055985.1	1.5 3.2	5.4 60.9	0.0002849 0.0025727	9.32339E-05 0.000797894	3896.5 4138.5	S S
sulfatase 1 serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1	SULF1									
	SERPINH1	mwghuman3 OK#A:08615 mwghuman3 OK#B:4003	NM_001235.2 NM_000900.2	NP_001226.2 NP_000891.2	1.5 2.6	2.7 47.9	5.232E-05 0.0011611	0.000221711 0.001781907	4391 5134	S S
matrix Gla protein	MGP									

Fig. 11 (continued)

72/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
tissue inhibitor of metalloproteinase 1	TIMP1	mwghuman3 OK#A:08048	NM_003254.1	NP_003245.1	1.8	4.4	0.0010783	0.006400169	7533	S
EGF-like-domain, multiple 6	EGFL6	mwghuman3 OK#A:07688	NM_015507.2	NP_056322.2	1.5	3.4	0.0042021	0.00857023	8467	S
sperm associated antigen 11	SPAG11	mwghuman3 OK#B:1373	NM_058203.1	NP_478110.1	1.3	4.2	0.0015737	0.001050446	10950	S
insulin-like growth factor binding protein 5	IGFBP5	mwghuman3 OK#C:1077	NM_000599.2	NP_000590.1	1.7	6.5	0.0097847	0.03366216	10980.5	S
sema domain, immunoglobulin domain (Ig), short basic domain, secreted,	SEMA3F	mwghuman3 OK#A:07262	NM_004186.2	NP_004177.2	-1.1	17.2	0.4328626	0.5041839	NA	S
(semaphorin) 3F cell division cycle 2, G1 to S and G2 to M	CDC2	mwghuman3 OK#A:05382	NM_033379.2	NP_203698.1	5.3	16.5	1.67E-12	6.12E-11	8	
topoisomerase (DNA) II alpha ubiquitin-	TOP2A	mwghuman3 OK#B:7144	NM_001067.2	NP_001058.2	3.6	7.5	5.33E-11	1.32E-09	28.5	
conjugating enzyme E2C	UBE2C	mwghuman3 OK#A:01776	NM_181803.1	NP_861519.1	4.6	34.3	6.82E-10	1.01E-09	29.5	
stahtmin 1	STMN1	mwghuman3 OK#A:00925	NM_203401.1	NP_981946.1	3.2	11.4	7.66E-10	3.63E-09	44	
tubulin, alpha 4	TUBA4	mwghuman3 OK#B:2461	NM_025019.1	NP_079295.1	2.6	4.5	3.1E-09	1.32E-09	82.5	
histone 1, H1b high-mobility group box 2	HIST1H1B	mwghuman3 OK#A:05716	NM_005322.2	NP_005313.1	2.3	5.7	1.77E-11	4.42E-12	93	
	HMGB2	mwghuman3 OK#B:3649	NM_002129.2	NP_002120.1	2.6	5.6	7.85E-09	1.44E-08	95.5	
cyclin A2 cell division cycle associated 1	CCNA2	mwghuman3 OK#A:04253	NM_001237.2	NP_001228.1	2.9	8.4	3.87E-08	5.85E-09	129.5	
	CDCA1	mwghuman3 OK#B:9471	NM_145697.1	NP_663735.1	2.4	8.2	1.85E-09	5.85E-09	151.5	

Fig. 11 (continued)

73/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
hypothetical protein MGC5576		mwghuman3 OK#A:06786	NM_024056.2	NP_076961.1	2.1	4.6	6.35E-09	9.25E-09	171	
DEK oncogene	DEK	mwghuman3 OK#B:2969	NM_003472.2	NP_003463.1	2.4	6.2	1.11E-07	1.44E-08	173.5	
MLF1 interacting protein	MLF1IP	mwghuman3 OK#C:8850	NM_024629.2	NP_078905.2	2.3	4.6	2.22E-07	6.07E-08	209.5	
cell division cycle associated 8	CDCA8	mwghuman3 OK#A:07906	NM_018101.1	NP_060571.1	2.3	4.1	2.8E-07	4.99E-08	212	
hypothetical protein FLJ20647		mwghuman3 OK#A:03566	NM_017918.3	NP_060388.1	2.2	4.6	1.5E-07	0.000000109	216	
thymidylate synthetase	TYMS	mwghuman3 OK#A:10045	NM_001071.1	NP_001062.1	2.2	5.0	1.48E-07	2.72E-08	232.5	
SMC4 structural maintenance of chromosomes 4- like 1 (yeast)	SMC4L1	mwghuman3 OK#A:05648	NM_0010027 99.1	NP_0010027 99.1	2.4	5.7	5.7E-07	0.000000525	264.5	
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog	LYN	mwghuman3 OK#C:2653	NM_002350.1	NP_002341.1	1.9	4.5	8.07E-08	0.000000265	267	
high-mobility group box 3 prostaglandin I2 (prostacyclin) receptor	HMGB3	mwghuman3 OK#A:01602	NM_005342.1	NP_005333.1	1.9	5.0	2.13E-10	6.12E-11	268	
downstream neighbor of SON (DONSON)	PTGIR	mwghuman3 OK#A:00268	NM_000960.3	NP_000951.1	3.2	31.5	3.59E-07	4.09E-08	270.5	
hyaluronan- mediated motility receptor	DONSON	mwghuman3 OK#A:05883	NM_145795.1	NP_665738.1	1.8	3.3	2.74E-08	4.09E-08	279.5	
	HMMR	mwghuman3 OK#A:02702	NM_012485.1	NP_036617.1	2.7	6.8	1.84E-06	0.000000729	291	
claudin 6	CLDN6	mwghuman3 OK#A:08357	NM_021195.3	NP_067018.1	3.2	39.1	7.89E-07	6.07E-08	296.5	
histone 1, H1d	HIST1H1D	mwghuman3 OK#C:1892	NM_005320.2	NP_005311.1	2.1	4.8	4.46E-08	7.37E-08	306.5	

Fig. 11 (continued)

74/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
chromosome 10 open reading frame 3	C10orf3	mwghuman3 OK#A:01678	NM_018131.3	NP_060601.2	2.1	4.3	9.03E-08	6.07E-08	308.5	
kinetochore associated 1	KNTC1	mwghuman3 OK#A:05391	NM_014708.3	NP_055523.1	2.2	4.2	2.32E-07	0.000000265	325	
CDC28 protein kinase regulatory subunit 1B	CKS1B	mwghuman3 OK#C:0649	NM_001826.1	NP_001817.1	2.1	3.4	1.7E-08	4.99E-08	332	
ribonucleotide reductase M2 polypeptide	RRM2	mwghuman3 OK#B:3501	NM_001034.1	NP_001025.1	2.6	16.6	0.0000015	0.0000000856	344	
histone 1, H2bh	HIST1H2B	mwghuman3 OK#B:2977	NM_003524.2	NP_003515.1	3.1	15.3	0.0000011	0.0000000794	349	
serine/threonine kinase 6	STK6	mwghuman3 OK#A:04814	NM_198437.1	NP_940839.1	2.6	26.9	1.67E-06	7.37E-08	349.5	
M-phase phosphoprotein 1	MPHOSPH 1	mwghuman3 OK#A:09885	NM_016195.2	NP_057279.2	1.9	3.8	3.29E-07	0.00000137	359.5	
cyclin B2	CCNB2	mwghuman3 OK#A:03606	NM_004701.2	NP_004692.1	2.0	3.4	6.19E-07	7.37E-09	373.5	
G protein-coupled receptor 32	GPR32	mwghuman3 OK#A:03297	NM_001506.1	NP_001497.1	3.4	42.0	1.26E-06	0.0000000856	390	
endoglin	ENG	mwghuman3 OK#A:05668	NM_000118.1	NP_000109.1	1.9	5.3	4.49E-07	0.0000000525	418.5	
malignant fibrous histiocytoma amplified sequence 1	MFHAS1	mwghuman3 OK#A:04639	NM_004225.1	NP_004216.1	2.4	11.0	2.17E-07	0.0000000243	425	
histone 1, H1c arginine	HIST1H1C	mwghuman3 OK#A:07773	NM_005319.3	NP_005310.1	2.3	10.0	3.71E-07	0.0000000375	425	
vasopressin receptor 2	AVPR2	mwghuman3 OK#A:01219	NM_000054.2	NP_000045.1	2.3	22.3	8.93E-07	6.07E-08	427.5	
centromere protein F	CENPF	mwghuman3 OK#A:06471	NM_016343.2	NP_057427.3	1.7	2.6	2.51E-07	1.17564E-06	435.5	
homeo box A13	HOXA13	mwghuman3 OK#A:08971	NM_000522.2	NP_000513.2	1.7	3.5	2.61E-07	0.0000000619	439.5	

Fig. 11 (continued)

75/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
h4 histone family, member g		mwghuman3 OK#A:01329	XM_030144		3.0	13.2	2.33E-06	0.00000179	463	
MGC27121 gene		mwghuman3 OK#C:3953	NM_0010013 43.1	NP_0010013 43.1	3.6	46.3	1.891E-06	5.18452E-06	481.5	
nucleoside		mwghuman3 OK#A:03762	NM_000270.1	NP_000261.1	1.9	4.2	2.7E-07	0.000000375	497	
phosphorylase	NP									
asp (abnormal spindle)-like, microcephaly associated	ASPM	mwghuman3 OK#A:01367	NM_018136.2	NP_060606.2	2.4	14.5	7.55E-07	0.00000187	504.5	
hypothetical protein fj11871		mwghuman3 OK#A:10682	NM_025117		2.0	13.2	1.96E-06	0.000001	511	
likely ortholog of mouse limb-bud and heart gene	LBH	mwghuman3 OK#B:7280	NM_030915.1	NP_112177.1	1.7	4.7	2.64E-07	0.000000223	528	
nudix (nucleoside diphosphate linked moiety X)- type motif 1	NUDT1	mwghuman3 OK#A:05916	NM_198954.1	NP_945192.1	1.9	3.7	5.12E-08	0.000000444	546.5	
helicase, lymphoid-specific	HELLS	mwghuman3 OK#A:00387	NM_018063.3	NP_060533.2	1.8	4.3	5.874E-07	3.74678E-07	550	
ankyrin repeat and SOCS box- containing 9	ASB9	mwghuman3 OK#A:01131	NM_024087.1	NP_076992.1	1.7	5.9	1.27E-06	0.0000016	556	
MCM5										
minichromosome maintenance deficient 5	MCM5	mwghuman3 OK#A:07747	NM_006739.2	NP_006730.2	1.7	3.3	7.631E-08	1.55499E-07	557.5	
IGF-II mRNA- binding protein 2	IMP-2	mwghuman3 OK#A:09784	NM_006548.3	NP_006539.2	2.1	4.9	3.964E-06	1.17464E-05	575	
hypothetical protein	DKFZP566 M1046	mwghuman3 OK#B:8751	NM_032127.1	NP_115503.1	1.8	5.7	2.214E-06	1.37393E-06	594.5	
DKFZp566M1046		mwghuman3 OK#B:4654	NM_079836.1	NP_524575.1	1.8	3.9	6.73E-07	0.00000217	602	
tubulin, alpha 2 growth arrest- specific 2 like 3	GAS2L3	mwghuman3 OK#C:3659	NM_174942.1	NP_777602.1	2.0	5.6	7.484E-07	2.91943E-06	604	

Fig. 11 (continued)

76/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
hypothetical protein FLJ12442 MCM6		mwghuman3 OK#B:2460	NM_022908.1	NP_075059.1	1.7	2.9	1.54E-08	3.63E-09	614	
minichromosome maintenance deficient 6	MCM6	mwghuman3 OK#B:8147	NM_005915.4	NP_005906.2	2.2	5.7	5.43E-07	0.000000232	653.5	
docking protein 3	DOK3	mwghuman3 OK#B:2635	NM_024872.1	NP_079148.1	2.2	12.6	1.75E-06	4.99E-08	655	
WD repeat domain 18	WDR18	mwghuman3 OK#B:3546	NM_024100.2	NP_077005.2	2.0	8.7	9.89E-07	4.99E-08	677	
cytoskeleton associated		mwghuman3								
protein 2	CKAP2	OK#A:00670	NM_018204.2	NP_060674.2	1.8	4.3	3.106E-06	1.93626E-05	701.5	
kinesin family member 20A	KIF20A	mwghuman3 OK#A:07989	NM_005733.1	NP_005724.1	1.9	2.8	1.045E-06	1.07593E-07	707.5	
putative fap protein		mwghuman3 OK#B:5292	U63542		2.1	18.9	4.98E-06	0.0000045	718	
chromosome 6 open reading frame 32	C6orf32	mwghuman3 OK#A:04643	NM_015864.2	NP_056948.2	1.8	11.4	1.527E-07	1.29514E-07	721.5	
NIMA (never in mitosis gene a)- related kinase 2	NEK2	mwghuman3 OK#A:00847	NM_002497.2	NP_002488.1	2.0	3.5	1.023E-05	3.37794E-06	732	
cryptochrome 1 (photolyase-like)	CRY1	mwghuman3 OK#A:06219	NM_004075.2	NP_004066.1	1.8	3.0	6.04E-06	0.000001	744	
transglutaminase 2	TGM2	mwghuman3 OK#A:08571	NM_004613.2	NP_004604.2	2.0	6.3	1.498E-05	3.37794E-06	747	
discs, large homolog 7	DLG7	mwghuman3 OK#B:7380	NM_014750.3	NP_055565.2	2.0	5.9	1.353E-05	1.17464E-05	748	
eukaryotic translation initiation factor 2C	EIF2C2	mwghuman3 OK#C:2287	NM_012154.2	NP_036286.2	1.7	2.7	1.73E-08	9.25E-09	766	
DEP domain containing 1	DEPDC1	mwghuman3 OK#B:7337	NM_017779.3	NP_060249.2	2.0	4.6	1.722E-06	3.15648E-07	776	
histone 2, H4	HIST2H4	mwghuman3 OK#C:1932	NM_003548.2	NP_003539.1	1.7	2.7	3.279E-06	2.91943E-06	823	

Fig. 11 (continued)

77/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
baculoviral IAP repeat-containing 5 (survivin) MCM7	BIRC5	mwghuman3 OK#B:0833	NM_001168.1	NP_001159.1	2.6	54.8	4.87E-06	0.000000856	823	
minichromosome maintenance deficient 7 methylothioadenos ine	MCM7	mwghuman3 OK#B:7620	NM_182776.1	NP_877577.1	1.9	4.0	1.13E-06	0.0000103	829	
phosphorylase kinetochore associated 2 HSPC150 protein similar to ubiquitin- conjugating enzyme	MTAP KNTC2	mwghuman3 OK#B:8310 mwghuman3 OK#A:10053	AF109294.1 NM_006101.1	AAD19641.1 NP_006092.1	2.3 1.6	13.3 2.9	1.033E-05 1.169E-06	1.33979E-05 2.17032E-06	844.5 848	
SMC6 structural maintenance of chromosomes 6- like 1	HSPC150	mwghuman3 OK#A:00955	NM_014176.1	NP_054895.1	1.9	3.4	1.782E-05	1.73622E-05	849.5	
histone 1, H2bc ASF1 anti- silencing function 1 homolog B LDL receptor adaptor protein	SMC6L1 HIST1H2B C ASF1B ARH	mwghuman3 OK#A:05363 mwghuman3 OK#B:9593 mwghuman3 OK#A:04415 mwghuman3 OK#B:2491 mwghuman3 OK#A:02069 mwghuman3 OK#B:2212 mwghuman3 OK#A:00611	NM_024624.2 NM_003526.2 NM_018154.1 NM_015627.1 NM_005573.2 NM_018193.1 NM_018186.2	NP_078900.1 NP_003517.2 NP_060624.1 NP_056442.1 NP_005564.1 NP_060663.1 NP_060656.2	1.7 1.9 1.7 2.0 1.8 1.7 1.5	4.0 5.3 4.1 14.0 3.4 3.4 2.8	6.059E-06 7.93E-06 1.04E-06 4.01E-06 2.869E-05 4.715E-06 1.483E-06	1.28219E-05 1.73622E-05 0.0000016 0.000000155 1.52615E-05 8.99315E-06 1.00418E-06	852 870 872 872 891.5 894.5 913	
lamin B1 hypothetical protein FLJ10719 hypothetical protein FLJ10706 MAD2 mitotic arrest deficient- like 1	LMNB1 MAD2L1	mwghuman3 OK#A:06387	NM_002358.2	NP_002349.1	1.8	3.9	1.058E-05	2.87228E-05	913.5	

Fig. 11 (continued)

Fig. 11 (continued)

79/102

Gene Name	HUGO	MWVG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
SMC1 structural maintenance of chromosomes 1- like 1	SMC1L1	mwghuman3 OK#A:05798	NM_006306.2	NP_006297.2	1.6	2.9	4.98E-06	0.0000134	1061.5	
		mwghuman3 OK#C:0578	NM_033209.2	NP_149986.1	1.8	4.7	1.15E-06	0.000000375	1074	
Thy-1 co- transcribed RA-regulated nuclear matrix- associated protein	RAMP	mwghuman3 OK#A:03935	NM_016448.1	NP_057532.1	1.5	2.1	4.195E-07	7.28584E-07	1076	
		mwghuman3 OK#A:07244	NM_016594.1	NP_057678.1	1.8	5.0	0.0000122	0.0000287	1088.5	
FKBP11 chromosome 20 open reading frame 129	C20orf129	mwghuman3 OK#B:3650	NM_030919.1	NP_112181.1	1.6	2.4	2.438E-05	2.91943E-06	1106	
		mwghuman3 OK#B:4596	NM_003543.3	NP_003534.1	2.1	6.4	0.0000344	0.000059	1117	
histone 1, H4h cyclin-dependent kinase inhibitor 3 melanoma cell adhesion	CDKN3	mwghuman3 OK#A:05799	NM_005192.2	NP_005183.2	2.1	4.7	7.871E-05	1.93626E-05	1117.5	
molecule synuclein, alpha interacting protein nipsnap homolog 1	MCAM	mwghuman3 OK#A:10599	NM_006500.1	NP_006491.1	1.6	3.0	1.81E-06	0.0000045	1135.5	
		mwghuman3 OK#A:08103	NM_005460.1	NP_005451.1	1.7	2.7	0.0000151	0.0000236	1151.5	
adaptor-related protein complex 1, mu 1 subunit anillin, actin binding protein chromosome 6 open reading frame 69	NIPSNAP1	mwghuman3 OK#A:10699	NM_003634.1	NP_003625.1	2.4	21.5	0.0000194	0.0000153	1165.5	
AP1M1	AP1M1	mwghuman3 OK#B:1553	NM_032493.2	NP_115882.1	1.5	4.1	6.692E-06	8.99315E-06	1173.5	
		mwghuman3 OK#A:05280	NM_018685.2	NP_061155.2	2.6	7.7	0.0001	0.0000716	1177	
C6orf69	C6orf69	mwghuman3 OK#C:0854	NM_173562.3	NP_775833.2	1.6	3.6	3.55E-07	0.000000856	1187	

Fig. 11 (continued)

80/102

Gene Name transducer of regulated cAMP response element-binding protein MYC-associated zinc finger protein thioredoxin reductase 1 hypothetical protein xp_096695 chromosome 22 open reading frame 4 visinin-like 1 similar to Carboxypeptidas e N 83 kDa chain KIAA1598 hypothetical protein flj13501 DKFZP434O047 protein hypothetical protein FLJ38716 similar to hypothetical protein (L1H 3 region) hypothetical protein KIAA1875 primase, polypeptide 1	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
	TORC3	mwghuman3 OK#A:04006	NM_022769.1	NP_073606.2	1.6	2.8	1.51E-05	1.73622E-05	1187.5	
	MAZ	mwghuman3 OK#A:04363	NM_002383.1	NP_002374.1	1.6	3.5	0.0000117	0.0000325	1195.5	
	TXNRD1	mwghuman3 OK#A:02930	NM_182743.1	NP_877420.1	2.4	16.9	0.0000377	0.0000254	1201	
		mwghuman3 OK#B:5965	XM_096695		1.5	3.2	5.361E-06	2.51921E-06	1211.5	
	C22orf4	mwghuman3 OK#B:9849	NM_014346.1	NP_055161.1	1.5	2.3	1.056E-05	1.33979E-05	1234	
	VSNL1	mwghuman3 OK#A:06227	NM_003385.3	NP_003376.2	2.2	13.8	0.0000215	0.0000254	1243.5	
		mwghuman3 OK#B:4922	XM_209550.5	XP_209550.4	2.0	10.5	0.0000141	0.00000899	1256.5	
	KIAA1598	mwghuman3 OK#A:10158	NM_018330.3	NP_060800.2	1.9	18.9	6.547E-05	8.56146E-07	1271	
		mwghuman3 OK#A:06319	NM_025007		2.0	5.7	3.162E-05	2.23862E-05	1285	
	DKFZP434 O047	mwghuman3 OK#A:08783	NM_015594.1	NP_056409.1	1.8	4.5	9.622E-06	4.13751E-05	1290.5	
		mwghuman3 OK#B:7389	NM_152367.1	NP_689580.1	1.9	4.0	9.5E-06	2.87228E-05	1291.5	
		mwghuman3 OK#A:02711	XM_372039.1	XP_372039.2	1.9	3.5	3.977E-05	1.73622E-05	1295.5	
		mwghuman3 OK#B:5745	XM_291269.3	XP_291269.2	1.6	2.4	2.655E-05	1.33979E-05	1313.5	
	PRIM1	mwghuman3 OK#A:07833	NM_000946.2	NP_000937.1	1.6	2.9	3.313E-05	5.24719E-05	1315	

Fig. 11 (continued)

81/102

Gene Name	HUGO	MWg oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
hypothetical protein BC001096 MCM2		mwghuman3 OK#B:6914	NM_138389.1	NP_612398.1	1.7	3.3	0.0000359	0.0000367	1318.5	
minichromosome maintenance deficient 2 gap junction protein, alpha 3 chromosome 11	MCM2	mwghuman3 OK#A:08834 mwghuman3 OK#A:04569	NM_004526.2	NP_004517.2	1.6	2.7	1.81E-06	0.0000045	1332	
open reading frame 30 similar to hypothetical protein FLJ30672	GJA3	mwghuman3 OK#A:10832	NM_021954.2	NP_068773.2	1.6	2.7	1.04E-06	0.00000252	1332.5	
Thy-1 co- transcribed (LOC94105) low density lipoprotein	C11orf30	mwghuman3 OK#B:9577	NM_020193.2	NP_064578.2	1.4	3.4	6.848E-07	1.00418E-06	1339	
receptor-related protein 3 LAG1 longevity assurance homolog 2 chromosome 18	THY1	mwghuman3 OK#A:07498	XM_376318.1	XP_376318.1	1.6	2.3	3.03E-05	2.53726E-05	1349	
open reading frame 8 zinc finger protein 81	LRP3	mwghuman3 OK#A:05066	NM_033209.2	NP_149986.1	1.5	3.4	1.262E-05	2.53726E-05	1353	
nuclear prelamin A recognition factor	LASS2	mwghuman3 OK#A:00827	NM_002333.1	NP_002324.1	1.5	2.1	1.068E-05	1.9727E-05	1358	
	C18orf8	mwghuman3 OK#A:07371 mwghuman3 OK#B:1067	NM_013384.3	NP_037516.3	1.7	4.6	0.0000173	0.0000224	1365	
	ZNF81		NM_013326.2	NP_037458.2	1.5	2.1	6.11E-06	0.00000899	1366.5	
	NARF	mwghuman3 OK#A:02301	NM_007137.1	NP_009068.1	1.5	2.2	2.599E-06	1.8667E-06	1387.5	
			NM_031968.1	NP_114174.1	1.5	2.5	8.752E-06	1.73622E-05	1391.5	

Fig. 11 (continued)

82/102

Gene Name	HUGO	MWVG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
methylenetetrahydrofolate dehydrogenase (NAD+ dependent)	MTHFD2	mwghuman3 OK#A:01688	NM_006636.2	NP_006627.1	2.4	8.4	0.0000861	0.00013	1392.5	
dihydrolipoamide branched chain transacylase E2	DBT	mwghuman3 OK#B:6654	NM_001918.1	NP_001909.1	1.6	2.3	4.015E-05	8.99315E-06	1398.5	
sialyltransferase 7D	SIAT7D	mwghuman3 OK#A:03286	NM_175040.1	NP_778205.1	1.7	7.9	3.17E-06	0.00000596	1400	
matrix metalloproteinase -like 1	MMPL1	mwghuman3 OK#A:02674	NM_004142.1	NP_004133.1	1.5	3.4	1.36E-06	2.91943E-06	1403	
kallikrein 11	KLK11	mwghuman3 OK#A:09721	NM_144947.1	NP_659196.1	1.5	2.3	0.0000159	0.0000153	1415.5	
karyopherin alpha 2	KPNA2	mwghuman3 OK#B:4036	NM_002266.1	NP_002257.1	1.6	3.3	9.792E-05	5.89923E-05	1426.5	
FGFR1 oncogene partner 2	FGFR1OP2	mwghuman3 OK#B:2210	NM_015633.1	NP_056448.1	1.5	5.0	1.338E-05	1.33979E-05	1427.5	
vimentin	VIM	mwghuman3 OK#A:02879	NM_003380.1	NP_003371.1	3.3	19.1	0.000123	0.0002	1451	
FLJ44108 protein poly(A)		mwghuman3 OK#B:0931	XM_379827.1	XP_379827.1	1.7	2.9	7.746E-05	2.53726E-05	1474	
polymerase gamma	PAPOLG	mwghuman3 OK#A:03836	NM_022894.2	NP_075045.2	2.7	36.2	0.0000757	0.0000932	1474.5	
formin homology 2 domain		mwghuman3								
containing 1	FHOD1	OK#A:05058	NM_013241.1	NP_037373.1	1.6	4.0	9.54E-06	0.00000187	1483.5	
RAS-like, family 12 (RASL12)	RASL12	mwghuman3 OK#A:07221	NM_016563.2	NP_057647.1	1.4	2.1	1.179E-05	2.23862E-05	1490.5	
high-mobility group nucleosomal binding domain 2	HMGN2	mwghuman3 OK#B:9113	NM_005517.2	NP_005508.1	1.6	2.7	0.0000826	0.0000367	1495.5	

Fig. 11 (continued)

83/102

Gene Name	HUGO	MWVG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
phosphatidylinositol transfer protein, membrane-associated 2	PITPNM2	mwghuman3 OK#B:8464	NM_020845	NP_06589	2.3	26.2	0.0000711	0.0000224	1497	
	DER1	mwghuman3 OK#A:01654	NM_024295.3	NP_077271.1	1.5	3.3	4.883E-05	5.24719E-05	1527	
	EPHA4	mwghuman3 OK#A:04433	NM_004438.3	NP_004429.1	1.5	3.1	0.0000113	0.0000743	1527.5	
V-set and immunoglobulin domain										
containing 1 regulator of G-protein signalling 5	VSIG1	mwghuman3 OK#B:6454	NM_182607.3	NP_872413.1	2.0	5.8	7.831E-05	3.24766E-05	1532.5	
KIAA1639 protein	RGS5	mwghuman3 OK#B:0128 mwghuman3 OK#B:4938 mwghuman3 OK#B:8571	NM_003617.2 XM_290923.2 NM_015503.1	NP_003608.1 XP_290923.3 NP_056318.1	1.8 1.9 2.2	6.3 11.5 13.2	0.0000417 2.676E-05 0.0000252	0.0000174 1.9727E-05 0.0000197	1534.5 1540.5 1556.5	
	SH2B									
	PGLYRP4	mwghuman3 OK#A:00688	NM_020393.1	NP_065126.1	1.5	3.2	2.991E-06	4.50136E-06	1566	
SH2-B homolog peptidoglycan recognition protein 4										
CDC45 cell division cycle 45-like	CDC45L	mwghuman3 OK#A:09331	NM_003504.3	NP_003495.1	1.8	2.9	6.316E-05	0.000129985	1567.5	
male sterility domain										
containing 1 hypothetical protein	MLSTD1	mwghuman3 OK#A:04600	NM_018099.3	NP_060569.3	1.9	10.0	6.279E-05	3.66781E-05	1585.5	
MGC11266 tumor necrosis factor receptor superfamily, member 13B		mwghuman3 OK#A:10595	NM_024322.1	NP_077298.1	1.5	3.4	5.16E-05	6.62502E-05	1608	
TNFRSF13B		mwghuman3 OK#A:00922	NM_012452.2	NP_036584.1	1.7	3.8	2.737E-05	6.62502E-05	1643	

Fig. 11 (continued)

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
neuroepithelial cell transforming gene 1	NET1	mwghuman3 OK#B:5122	S82401.1	AAB37683.1	1.4	2.1	8.678E-06	4.50136E-06	1657	
lipoma HMGIC fusion partner-like 5	LHFPL5	mwghuman3 OK#C:9217	NM_182548.2	NP_872354.1	1.7	9.5	5.419E-05	4.66206E-05	1661	
myxovirus (influenza virus) resistance 2	MX2	mwghuman3 OK#A:10346	NM_002463.1	NP_002454.1	1.6	9.3	0.0000739	0.000001	1680	
sphingosine kinase 1	SPHK1	mwghuman3 OK#C:2264	NM_182965.1	NP_892010.1	1.5	2.2	2.284E-06	5.18452E-06	1702	
ATP-binding cassette, sub- family G (WHITE), member 4	ABCG4	mwghuman3 OK#A:02044	NM_022169.3	NP_071452.2	1.7	8.3	0.000012	0.0000039	1702	
serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2	SERPINB2	mwghuman3 OK#A:10076	NM_002575.1	NP_002566.1	1.8	8.3	3.09E-05	2.50475E-05	1705.5	
UDP-N-acetyl- alpha-D- galactosamine:po lypeptide N- acetylgalactosami nyltransferase 10	GALNT10	mwghuman3 OK#A:10048	NM_017540.3	NP_060010.3	1.6	7.1	6.432E-05	2.23862E-05	1711	
leptin receptor MAX dimerization protein 4	LEPR	mwghuman3 OK#B:5260	NM_0010036 80.1	NP_0010036 80.1	1.6	2.8	2.176E-05	2.87228E-05	1715.5	
phosphoinositol 4-phosphate adaptor protein-2	MXD4	mwghuman3 OK#A:08296	NM_006454.2	NP_006445.1	1.7	4.1	0.0000111	0.0000134	1719.5	
nucleoporin 210	FAPP2	mwghuman3 OK#A:06904	NM_032639.2	NP_116028.1	1.5	3.3	1.563E-05	3.66781E-05	1725.5	
	NUP210	mwghuman3 OK#B:7411	NM_024923.2	NP_079199.2	1.6	2.8	6.528E-05	0.000104262	1728.5	

Fig. 11 (continued)

85/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
c-src tyrosine kinase	CSK	mwghuman3 OK#A:01629	NM_004383.1	NP_004374.1	1.5	5.1	7.283E-06	8.56146E-07	3601	
neuropilin 1	NRP1	mwghuman3 OK#A:03091	NM_003873.2	NP_003864.2	2.3	17.2	0.002761	0.004728544	6356	

Fig. 11 (continued)

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
neurtin 1 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase KIAA0100 gene product	NRN1	mwghuman3 OK#A:00658	NM_016588.2	NP_057672.1	3.0	17.6	4.78E-07	0.000000421	63	S
	MGAT1	mwghuman3 OK#A:09187	NM_002406.2	NP_002397.1	1.7	4.1	3.51E-07	0.00000395	165.5	S
		mwghuman3 OK#A:10762	NM_014680.2	NP_055495.2	1.6	2.5	1.74E-08	0.000000085	241	S
		mwghuman3 OK#B:9472	NM_022164.1	NP_071447.1	1.8	5.6	0.000015	0.0000271	436.5	S
lipocalin 7	LCN7	mwghuman3 OK#B:3555	NM_058199.2	NP_478106.1	1.8	6.9	3.39E-06	0.00000178	455	S
olfactomedin 1 bone morphogenetic protein 7 A midkine (neurite growth-promoting factor 2)	OLFM1	mwghuman3 OK#A:09963	NM_001719.1	NP_001710.1	1.7	4.1	2.96E-06	0.00000579	473	S
a disintegrin-like and metalloprotease (repolysin type) with	MDK	mwghuman3 OK#B:4650	NM_002391.2	NP_002382.1	1.8	4.8	4.98E-07	0.000000194	492.5	S
thrombospondin type 1 motif, 10	ADAMTS10	mwghuman3 OK#B:1355	NM_030957.1	NP_112219.2	1.9	6.9	0.0000442	0.0000379	569.5	S
pM5 protein tissue inhibitor of metalloproteinase 1	PM5	mwghuman3 OK#A:00608	NM_014287.2	NP_055102.3	1.6	2.5	0.000017	0.0000339	598.5	S
lumican	LUM	mwghuman3 OK#A:08048	NM_003254.1	NP_003245.1	1.7	3.2	0.0000185	0.0000107	611.5	S
		mwghuman3 OK#A:09199	NM_002345.2	NP_002336.1	2.5	19.1	0.000104	0.0000883	632	S

87/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
EGF-like-domain, multiple 6	EGFL6	mwghuman3 OK#A:07688	NM_015507.2	NP_056322.2	1.9	4.2	0.0000747	0.0000243	712	S
NODAL modulator 3	NOMO3	mwghuman3 OK#A:08071	NM_173614.1	NP_775885.1	1.5	3.0	1.71E-06	0.00000395	844.5	S
insulin-like growth factor	IGFBP5	mwghuman3 OK#C:1077	NM_000599.2	NP_000590.1	2.3	15.0	0.0000791	0.000284	859.5	S
binding protein 5 hexosaminidase A (alpha polypeptide)	HEXA	mwghuman3 OK#B:9777	NM_000520.2	NP_000511.1	1.5	3.1	0.0000386	0.0000718	903.5	S
serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1	SERPINH1	mwghuman3 OK#A:08615	NM_001235.2	NP_001226.2	1.5	3.2	0.0000043	0.0000107	1070.5	S
carboxypeptidase A6	CPA6	mwghuman3 OK#A:02979	NM_020361.2	NP_065094.2	1.4	3.2	0.0000154	0.0000271	1098.5	S
natriuretic peptide	NPPC	mwghuman3 OK#A:06602	NM_024409.1	NP_077720.1	1.5	3.1	8.17E-06	0.0000121	1134	S
precursor C protease, serine, 11	PRSS11	mwghuman3 OK#B:1274	NM_002775.2	NP_002766.1	1.4	2.6	0.0000125	0.0000523	1151.5	S
insulin-like growth factor	IGFBP7	mwghuman3 OK#A:03385	NM_001553.1	NP_001544.1	1.8	4.2	0.000239	0.000756	1222	S
binding protein 7 hypothetical protein		mwghuman3 OK#A:06273	NM_024579.1	NP_078855.1	1.5	2.8	0.000598	0.000375	1277.5	S
FLJ23221 protein disulfide isomerase related protein	ERP70	mwghuman3 OK#A:03979	NM_004911.3	NP_004902.1	1.5	3.9	0.000321	0.000215	1419	S

Fig. 12 (continued)

88/102

Gene Name	HUGO	MWVG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylglucosaminyltransferase 14 (GalNAc-T14) inter-alpha (globulin) inhibitor H3	GALNT14	mwghuman3 OK#B:4583	BC010659.1	AAH10659.1	1.4	2.4	0.000215	0.000312	1450.5	S
	ITIH3	mwghuman3 OK#B:7988	NM_002217.1	NP_002208.2	1.5	3.0	0.000317	0.000972	1504	S
pappalysin 2	PAPPA2	mwghuman3 OK#B:1636	NM_020318.1	NP_064714.1	1.5	2.8	0.000358	0.000584	1584	S
lysyl oxidase-like 1	LOXL1	mwghuman3 OK#A:07055	NM_005576.1	NP_005567.1	1.6	5.5	0.0001	0.000259	1598.5	S
secreted phosphoprotein 1	SPP1	mwghuman3 OK#A:09441	NM_000582.2	NP_000573.1	2.7	139.1	0.000577	0.00185	1789	S
tumor necrosis factor receptor superfamily, member 6b, decoy	TNFRSF6B	mwghuman3 OK#A:05069	NM_032945.2	NP_116563.1	2.0	6.8	0.001594	0.001244	1901.5	S
secreted protein, acidic, cysteine-rich (osteonectin)	SPARC	mwghuman3 OK#A:08092	NM_003118.2	NP_003109.1	1.7	4.5	0.000359	0.000895	2512	S
sulfatase 1	SULF1	mwghuman3 OK#B:8770	NM_015170.1	NP_055985.1	2.5	67.3	0.007144	0.000895	2581	S
microseminoprotein, beta	MSMB	mwghuman3 OK#B:4000	NM_002443.2	NP_002434.1	1.6	11.8	0.00535	0.042817	6739.5	S
tolloid-like 2 semaphorin sem2	TLL2	mwghuman3 OK#A:02932	NM_012465.2	NP_036597.1	1.9	29.2	0.036032	0.070205	8875.5	S
(LOC56920)	SEM2	mwghuman3 OK#A:05073	NM_020163.1	NP_064548.1	1.2	1.8	0.0172289	0.01761606	10677	S

Fig. 12 (continued)

89/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F	SEMA3F	mwghuman3 OK#A:07262	NM_004186.2	NP_004177.2	1.7	19.5	0.2804993	0.3890127	23988.5	S
	ENG	mwghuman3 OK#A:05668	NM_000118.1	NP_000109.1	1.9	3.7	2.76E-10	1.75E-09	37	
	CLDN6	mwghuman3 OK#A:08357	NM_021195.3	NP_067018.1	2.2	6.7	1.84E-07	0.000000881	59	
claudin 6										
prothymosin, alpha (gene sequence 28)	PTMA	mwghuman3 OK#B:9039	NM_002823.2	NP_002814.2	1.9	6.0	1.17E-07	0.000000031	77.5	
nipsnap homolog 1	NIPSNAP1	mwghuman3 OK#A:10699	NM_003634.1	NP_003625.1	2.0	4.0	3.08E-07	0.000000362	92.5	
arginine vasopressin receptor 2										
(nephrogenic diabetes insipidus)										
malignant fibrous histiocytoma	AVPR2	mwghuman3 OK#A:01219	NM_000054.2	NP_000045.1	1.7	3.7	1.2E-07	0.000000227	98	
amplified sequence 1	MFHAS1	mwghuman3 OK#A:04639	NM_004225.1	NP_004216.1	2.2	9.3	1.68E-09	2.62E-08	120	
homeo box A13 myxovirus (influenza virus) resistance 2	HOXA13	mwghuman3 OK#A:08971	NM_000522.2	NP_000513.2	1.9	6.4	7.15E-07	0.000000421	122	
	MX2	mwghuman3 OK#A:10346	NM_002463.1	NP_002454.1	1.9	6.6	1.42E-06	0.000000659	156.5	

Fig. 12 (continued)

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
similar to sodium- and chloride-dependent creatine transporter transmembrane protein 19 prostaglandin I2 (prostacyclin) receptor (IP) hypothetical protein xp_047287 hypothetical protein flj11871 proline synthetase co-transcribed homolog G protein-coupled receptor 32 hypothetical protein MGC34923	TMEM19	mwghuman3 OK#C:4265 mwghuman3 OK#B:7083	NM_198857.1 NM_018279.2	NP_942154.1 NP_060749.2	1.8 1.8	4.1 3.0	1.78E-06 3.14E-06	0.0000051 0.00000204	164 175	
	PTGIR	mwghuman3 OK#A:00268	NM_000960.3	NP_000951.1	2.1	9.9	4.88E-06	0.00000449	205	
		mwghuman3 OK#B:6955 mwghuman3 OK#A:10682	XM_047287 NM_025117		1.6 1.6	3.9 3.3	2.89E-07 6.94E-07	0.000000881 0.00000102	235 240.5	
	PROSC	mwghuman3 OK#B:0341	NM_007198.2	NP_009129.1	1.7	3.8	3.41E-07	0.00000233	270	
	GPR32	mwghuman3 OK#A:03297	NM_001506.1	NP_001497.1	2.4	21.8	0.0000154	0.0000216	322	
		mwghuman3 OK#C:4473 mwghuman3 OK#C:3953	NM_144717.2 NM_0010013 43.1	NP_653318.2 NP_0010013 43.1	1.5 2.6	2.7 10.4	0.0000015 0.0000214	0.00000117 0.0000243	323 333	
	NQO1	mwghuman3 OK#A:06176	NM_000903.1	NP_000894.1	2.6	17.7	7.17E-06	0.0000422	352.5	
	CKAP4	mwghuman3 OK#A:01860 mwghuman3 OK#A:03286	NM_006825.2 NM_175040.1	NP_006816.2 NP_778205.1	1.8 1.6	4.9 2.6	0.0000029 4.14E-09	0.00000233 6.34E-09	382 394	

Fig. 12 (continued)

Gene Name	HUGO	MWVG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
hypothetical protein BC001096		mwghuman3 OK#B:6914	NM_138389.1	NP_612398.1	1.6	3.6	1.99E-07	0.000000421	394	
3-phosphoinositide dependent protein kinase-1 phosphatidylinositol transfer protein, membrane-associated 2	PDPK1	mwghuman3 OK#A:10300	NM_002613.2	NP_002604.1	1.5	2.1	0.0000192	0.00000135	438	
regulator of mitotic spindle assembly 1 molecule interacting with Rab13	PITPNM2	mwghuman3 OK#B:8464	AB040890.2	BAA95981.2	2.1	7.8	0.0000309	0.00000579	448	
protease, serine, 15		mwghuman3 OK#A:09972	XM_040863		2.0	11.1	0.0000219	0.0000271	449.5	
porcupine homolog likely ortholog of mouse limb-bud and heart gene	MIRAB13	mwghuman3 OK#C:0021	NM_033386.1	NP_203744.1	1.5	3.0	2.16E-06	0.0000084	457.5	
mouse limb-bud and heart gene	PRSS15	mwghuman3 OK#A:03353	NM_004793.2	NP_004784.2	1.5	2.7	0.0000101	0.0000136	497	
sine oculis	PORCN	mwghuman3 OK#A:00520	NM_203476.1	NP_982302.1	1.6	3.4	7.61E-06	0.0000243	528	
homeobox homolog 6	LBH	mwghuman3 OK#B:7280	NM_030915.1	NP_112177.1	1.6	3.8	3.35E-07	0.000000266	534.5	
gap junction protein, beta 2A	SIX6	mwghuman3 OK#A:10145	NM_007374.1	NP_031400.1	1.5	2.4	0.0000131	0.00000949	538	
FLJ35784	GJB2	mwghuman3 OK#A:09852	NM_004004.3	NP_003995.2	1.6	4.1	0.0000164	0.0000977	541.5	
protein cell division cycle 2		mwghuman3 OK#C:4803	NM_198534.1	NP_940936.1	2.0	5.2	0.0000295	0.0000304	563.5	
	CDC2	mwghuman3 OK#A:05382	NM_033379.2	NP_203698.1	2.4	7.8	0.0000208	0.000284	582.5	

Fig. 12 (continued)

92/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
solute carrier family 37 (glycerol-3-phosphate transporter), member 3 sprouty homolog 4	SLC37A3	mwghuman3 OK#B:8722	NM_207113.1	NP_996996.1	1.5	3.8	7.99E-07	0.00000117	596	
	SPRY4	mwghuman3 OK#C:0553	NM_030964.2	NP_112226.2	1.5	3.1	3.13E-06	0.0000084	597.5	
	LHX3	mwghuman3 OK#A:02580	NM_178138.2	NP_835258.1	1.4	2.2	1.73E-06	0.00000049	608.5	
	C7orf27	mwghuman3 OK#B:2531	NM_152743.1	NP_689956.1	1.6	3.2	2.33E-06	0.00000102	648.5	
LDL receptor adaptor protein	ARH	mwghuman3 OK#B:2491	NM_015627.1	NP_056442.1	1.5	3.1	0.0000141	0.0000216	649	
solute carrier family 39 (zinc transporter), member 1	SLC39A1	mwghuman3 OK#A:02443	NM_014437.3	NP_055252.2	1.6	3.7	0.0000296	0.0000496	652	
zinc finger protein 307 (ZNF307)	ZNF307	mwghuman3 OK#A:08705	NM_019110.3	NP_061983.2	1.5	3.8	5.01E-06	0.00000743	658	
macrophage migration inhibitory factor	MIF	mwghuman3 OK#A:09347	NM_002415.1	NP_002406.1	1.6	3.6	0.0000719	0.0000977	681.5	
synuclein, alpha interacting protein	SNCAIP	mwghuman3 OK#A:08103	NM_005460.1	NP_005451.1	1.6	2.7	0.0000186	0.00000301	683	
bone marrow stromal cell antigen 2	BST2	mwghuman3 OK#B:4758	NM_004335.2	NP_004326.1	2.1	5.3	0.0000816	0.000236	737.5	
proline-serine-threonine phosphatase interacting protein 1	PSTPIP1	mwghuman3 OK#B:0578	NM_003978.2	NP_003969.2	1.6	3.3	2.22E-06	0.00000347	755	

Fig. 12 (continued)

93/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
topoisomerase (DNA) II alpha MCM2	TOP2A	mwghuman3 OK#B:7144	NM_001067.2	NP_001058.2	2.0	5.5	0.0000799	0.000161	760.5	
minichromosome maintenance										
deficient 2	MCM2	mwghuman3 OK#A:08834	NM_004526.2	NP_004517.2	1.5	2.3	4.21E-06	0.00000395	774.5	
SRY (sex determining										
region Y)-box 4	SOX4	mwghuman3 OK#A:07410	NM_003107.2	NP_003098.1	1.5	4.8	4.96E-06	0.00000449	789	
nuclear receptor		mwghuman3 OK#B:8592	NM_020967.1	NP_066018.1	1.6	2.8	0.0000122	0.00000223	792	
coactivator 5	NCOA5	mwghuman3 OK#B:2461	NM_025019.1	NP_079295.1	1.9	5.1	0.0000645	0.000161	793.5	
tubulin, alpha 4	TUBA4									
hypothetical protein		mwghuman3 OK#C:8001	NM_152385.1	NP_689598.1	1.5	2.9	0.0000327	0.0000121	804	
FLJ31438		mwghuman3 OK#C:8737	NM_145260.1	NP_660303.1	1.6	5.9	0.000131	0.0000523	813	
odd-skipped	ODD									
homolog										
solute carrier										
family 23										
(nucleobase transporters),										
member 2	SLC23A2	mwghuman3 OK#A:04621	NM_203327.1	NP_976072.1	1.8	4.7	0.0000069	0.000132	819.5	
split hand/foot										
malformation										
(ectrodactyly)										
type 1	SHFM1	mwghuman3 OK#A:05669	NM_006304.1	NP_006295.1	1.6	3.3	0.0000306	0.0000647	823.5	
SFRS protein		mwghuman3 OK#A:08606	NM_182692.1	NP_872634.1	1.6	6.4	0.0000197	0.0000339	848.5	
kinase 2	SRPK2									
chromosome 18										
open reading		mwghuman3 OK#A:07371	NM_013326.2	NP_037458.2	1.4	2.1	1.54E-06	0.00000347	856	
frame 8	C18orf8									
formin homology										
2 domain		mwghuman3 OK#A:05058	NM_013241.1	NP_037373.1	1.5	2.3	0.0000106	0.0000153	863.5	
containing 1	FHOD1									

Fig. 12 (continued)

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
receptor (calcitonin) activity modifying protein 2	RAMP2	mwghuman3 OK#A:02505	NM_005854.1	NP_005845.1	1.6	4.2	0.0000208	0.0000172	866.5	
2,3-bisphosphoglycerate mutase	BPGM	mwghuman3 OK#A:00673	NM_001724.3	NP_001715.1	1.6	4.1	0.000203	0.0000523	868	
		mwghuman3 OK#B:8571	NM_015503.1	NP_056318.1	1.7	5.7	0.0000461	0.0000647	906	
SH2-B homolog regulator of G-protein signalling 5	SH2B									
phosphoinositol 4-phosphate adaptor protein-2	RGS5	mwghuman3 OK#B:0128	NM_003617.2	NP_003608.1	1.8	12.8	0.0000299	0.000177	922.5	
coxsackie virus and adenovirus receptor	FAPP2	mwghuman3 OK#A:06904	NM_032639.2	NP_116028.1	1.4	2.3	0.0000188	0.0000647	932.5	
Meis1, myeloid ecotropic viral integration site 1 homolog 2	CXADR	mwghuman3 OK#A:00118	NM_001338.3	NP_001329.1	1.9	4.7	0.000165	0.000177	935.5	
tensin-like SH2 domain containing 1	MEIS2	mwghuman3 OK#A:08006	NM_002399.2	NP_002390.1	1.5	2.8	0.0000766	0.0000883	941	
		mwghuman3 OK#A:01929	NM_022748.6	NP_073585.6	1.5	3.1	0.0000869	0.000132	946.5	
snail homolog 2	TENS1	mwghuman3 OK#A:10656	NM_003068.3	NP_003059.1	1.8	17.9	0.0000524	0.0000339	960.5	
docking protein 3 carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2	SNAI2	mwghuman3 OK#B:2635	NM_024872.1	NP_079148.1	1.6	4.8	7.57E-06	0.00000049	967.5	
	DOK3									
		mwghuman3 OK#A:06174	NM_004267.2	NP_004258.2	1.7	5.2	9.87E-07	0.00000155	983	
nucleoside phosphorylase	CHST2	mwghuman3 OK#A:03762	NM_000270.1	NP_000261.1	1.5	4.1	0.0000189	0.0000271	996.5	
	NP									

Fig. 12 (continued)

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
visinin-like 1	VSNL1	mwghuman3 OK#A:06227	NM_003385.3	NP_003376.2	1.7	3.5	0.0000811	0.00012	1013	
v-yes-1										
Yamaguchi										
sarcoma viral	LYN	mwghuman3 OK#C:2653	NM_002350.1	NP_002341.1	1.6	3.5	0.0000593	0.000108	1013.5	
related oncogene										
homolog										
hepatocellular	HCA127	mwghuman3 OK#B:7758	NM_018684.1	NP_061154.1	1.3	2.0	0.0000442	0.0000797	1017	
carcinoma-										
associated										
antigen 127	SLC22A2	mwghuman3 OK#A:02704	NM_153191.1	NP_694861.1	2.3	12.5	0.000298	0.000535	1021	
solute carrier										
family 22										
(organic cation	MXD4	mwghuman3 OK#A:08296	NM_006454.2	NP_006445.1	1.4	2.5	5.21E-06	0.00000656	1025	
transporter),										
member 2										
MAX	THY1	mwghuman3 OK#A:07498	NM_033209.2	NP_149986.1	1.4	2.0	0.0000307	0.0000153	1032.5	
dimerization										
protein 4										
Thy-1 co-	LRFN3	mwghuman3 OK#A:01329	NM_024509.1	NP_078785.1	1.6	2.4	0.000225	0.0000419	1035.5	
transcribed										
(LOC94105)										
Thy-1 co-	FLJ22390	mwghuman3 OK#A:06789	XM_030144	NP_073583.2	1.9	12.3	0.000241	0.0000883	1040	
transcribed										
(LOC94105)										
leucine rich	FLJ22390	mwghuman3 OK#A:06789	NM_022746.2	NP_073583.2	1.5	2.4	0.0000373	0.0000172	1045.5	
repeat and										
fibronectin type										
III domain	FLJ22390	mwghuman3 OK#A:06789	NM_022746.2	NP_073583.2	1.5	2.4	0.0000373	0.0000172	1045.5	
containing 3										
h4 histone										
family, member g	FLJ22390	mwghuman3 OK#A:06789	NM_022746.2	NP_073583.2	1.5	2.4	0.0000373	0.0000172	1045.5	
hypothetical										
protein										
FLJ22390										

Fig. 12 (continued)

96/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
tribbles homolog 2	TRIB2	mwghuman3 OK#A:05272	NM_021643.1	NP_067675.1	1.7	4.1	0.0000616	0.000195	1058	
keratin, hair, acidic, 3B	KRTHA3B	mwghuman3 OK#A:02682	NM_002279.3	NP_002270.1	1.3	2.1	0.0000079	0.0000271	1071.5	
kinesin family member 21A	KIF21A	mwghuman3 OK#C:0043	NM_017641.2	NP_060111.2	1.7	3.1	0.000121	0.000108	1073	
high-mobility group										
nucleosomal		mwghuman3								
binding domain 2	HMGN2	OK#B:9113	NM_005517.2	NP_005508.1	1.5	2.9	0.000199	0.0000883	1075	
ankyrin repeat domain 17	ANKRD17	mwghuman3 OK#B:0250	NM_198889.1	NP_942592.1	1.5	2.6	0.000013	0.00000743	1089.5	
recombination		mwghuman3								
activating gene 1	RAG1	OK#A:09856	NM_000448.1	NP_000439.1	1.4	2.7	0.000114	0.0000797	1090	
nucleotide		mwghuman3								
binding protein 2	NUBP2	OK#C:1908	NM_012225.1	NP_036357.1	1.4	2.3	0.0000198	0.0000193	1097	
hypothetical protein		mwghuman3								
FLJ20489		OK#A:07462	NM_017842.1	NP_060312.1	1.4	2.7	3.49E-06	0.00000395	1100.5	
calcium/calmodulin-dependent										
serine protein kinase (MAGUK family)	CASK	mwghuman3 OK#A:01768	NM_003688.1	NP_003679.1	1.5	3.5	0.0000572	0.000161	1104.5	
huntingtin										
interacting protein 1	HIP1	mwghuman3 OK#A:05908	NM_005338.4	NP_005329.3	1.4	4.5	0.0000185	0.00000656	1110	
LAG1 longevity assurance		mwghuman3								
homolog 2	LASS2	OK#A:00827	NM_013384.3	NP_037516.3	1.5	2.3	0.0000311	0.000063	1111.5	
protein kinase C, delta binding		mwghuman3								
protein	PRKCDBP	OK#B:4639	NM_145040.2	NP_659477.2	1.6	3.5	6.96E-07	0.000000194	1123.5	

Fig. 12 (continued)

97/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
tyrosine kinase with immunoglobulin and epidermal growth factor homology domains chromosome 5 open reading frame 15 anillin, actin binding protein	TIE	mwghuman3 OK#A:05888	NM_005424.2	NP_005415.1	1.7	4.3	0.000266	0.000312	1126.5	
	C5orf15	mwghuman3 OK#A:10834	NM_020199.1	NP_064584.1	1.6	3.3	0.000144	0.000195	1131	
	ANLN	mwghuman3 OK#A:05280	NM_018685.2	NP_061155.2	2.2	6.5	0.000906	0.000332	1154	
	DER1	mwghuman3 OK#A:01654	NM_024295.3	NP_077271.1	1.4	3.1	0.000115	0.0000422	1160.5	
	CGI-72	mwghuman3 OK#C:2137	NM_016018.3	NP_057102.3	1.4	2.5	0.000047	0.000195	1165	
activin A receptor type II-like 1 ectonucleoside triphosphate diphosphohydrolase 8	ACVRL1	mwghuman3 OK#A:00470	NM_000020.1	NP_000011.1	1.4	2.3	0.000113	0.0000618	1178	
SH3 domain binding glutamic acid-rich protein like 3	ENTPD8	mwghuman3 OK#C:1422	NM_138793.2	NP_620148.1	1.4	2.2	0.0000121	0.0000379	1179.5	
SMC4 structural maintenance of chromosomes 4-like 1 (yeast)	SH3BGRL3	mwghuman3 OK#B:1593	NM_031286.2	NP_112576.1	1.5	2.5	0.000062	0.000177	1185.5	
NADH:ubiquinone oxidoreductase MLRQ subunit homolog	SMC4L1	mwghuman3 OK#A:05648	NM_0010027 99.1	NP_0010027 99.1	1.7	3.4	0.000271	0.000215	1190	
angiogenic factor VG5Q	VG5Q	mwghuman3 OK#B:1359 mwghuman3 OK#B:2180	NM_020142.3 99.1 NM_018046.3	NP_064527.1 NP_060516.2	2.2 1.4	17.8 2.8	0.000123 0.0000245	0.000249 0.0000582	1196 1226.5	

Fig. 12 (continued)

98/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
stathmin 1	STMN1	mwghuman3 OK#A:00925	NM_203401.1	NP_981946.1	1.9	11.6	0.0004	0.000342	1250	
lipidosin	BG1	mwghuman3 OK#A:08285	NM_015162.3	NP_055977.3	1.6	8.8	0.000221	0.00017	1267	
BCL2-like 11	BCL2L11	mwghuman3 OK#A:08369	NM_207003.1	NP_996886.1	1.4	2.5	0.0000689	0.000108	1271	
AMP-activated protein kinase family member 5	ARK5	mwghuman3 OK#B:9070	NM_014840.2	NP_055655.1	1.5	3.1	0.000345	0.0000647	1273.5	
pleckstrin homology domain containing, family A										
(phosphoinositide binding specific) member 4										
kalikrein 11	PLEKHA4	mwghuman3 OK#B:3447	NM_020904.1	NP_065955.1	1.4	2.6	6.69E-06	0.0000107	1278.5	
suppression of tumorigenicity 7 like	KLK11	mwghuman3 OK#A:09721	NM_144947.1	NP_659196.1	1.4	3.3	0.00024	0.000047	1332	
transducin-like enhancer of split 3	ST7L	mwghuman3 OK#A:01391	NM_138728.2	NP_620056.1	1.5	3.3	0.000161	0.000132	1376.5	
inter-alpha (globulin) inhibitor H5	TLE3	mwghuman3 OK#A:09092	NM_005078.1	NP_005069.1	1.3	2.1	0.0000102	0.0000084	1382.5	
regulator of G-protein signalling 11	ITIH5	mwghuman3 OK#A:10153	NM_032817.2	NP_116206.2	1.4	2.4	0.000205	0.000259	1387.5	
ankyrin repeat and SOCS box-containing 9	RGS11	mwghuman3 OK#A:09250	NM_183337.1	NP_899180.1	1.5	2.8	0.0000268	0.0000379	1400.5	
	ASB9	mwghuman3 OK#A:01131	NM_024087.1	NP_076992.1	1.4	2.5	0.000131	0.000146	1418.5	

Fig. 12 (continued)

99/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
chromosome 6 open reading frame 69 transmembrane 7 superfamily member 3	C6orf69	mwghuman3 OK#C:0854	NM_173562.3	NP_775833.2	1.4	2.7	0.0000737	0.000195	1436	
TM7SF3		mwghuman3 OK#A:09485	NM_016551.1	NP_057635.1	1.6	3.0	0.000278	0.000535	1437	
secernin 3	SCRN3	mwghuman3 OK#A:00384	NM_024583.2	NP_078859.2	1.4	2.7	0.0000977	0.000215	1452	
cryptochrome 1	CRY1	mwghuman3 OK#A:06219	NM_004075.2	NP_004066.1	1.5	3.7	0.000377	0.000259	1457.5	
plexin A1 UDP-N-acetyl-alpha-D-galactosamine:p-olypeptide N-acetylglactosaminyltransferase 10 (GalNAc-T10)	PLXNA1	mwghuman3 OK#B:8739	NM_032242.2	NP_115618.2	1.4	3.2	0.000107	0.000108	1474	
gap junction protein, alpha 4 hypothetical protein	GALNT10	mwghuman3 OK#B:6489	NM_017540.3	NP_060010.3	1.4	2.0	4.42E-06	0.000000659	1479.5	
DKFZp434G1415	GJA4	mwghuman3 OK#A:07540	NM_002060.1	NP_002051.1	1.4	2.8	0.000427	0.000284	1488.5	
WD repeat and SOCS box-containing 2A cytidine deaminase phosphoribosylglycinamide formyltransferase		mwghuman3 OK#C:3525	NM_031292.2	NP_112582.2	1.4	2.9	0.0000627	0.000156	1501	
	WSB2	mwghuman3 OK#B:1353	NM_018639.3	NP_061109.1	1.4	2.5	0.0000652	0.0000523	1505	
	CDA	mwghuman3 OK#A:07490	NM_001785.1	NP_001776.1	1.6	3.0	0.0000477	0.0000271	1538.5	
	GART	mwghuman3 OK#A:10142	NM_000819.3	NP_000810.1	1.4	2.2	0.0000428	0.000146	1560	
histone 1, H1b	HIST1H1B	mwghuman3 OK#A:05716	NM_005322.2	NP_005313.1	1.5	4.0	0.0000929	0.000236	1578.5	

Fig. 12 (continued)

100/102

Gene Name	HUGO	MWG oligo #	NCBI mRNA ref seq	Protein ref seq	mean fold change	max fold change	T-test	Wilcoxon test	Summated rank	Serum
zinc metalloproteinase (STE24)		mwghuman3 OK#A:09568	NM_005857.2	NP_005848.2	1.5	3.9	0.000166	0.000236	1653.5	
homolog. yeast) transmembrane protein 33	ZMPSTE24	mwghuman3 OK#A:01542	NM_018126.1	NP_060596.1	2.9	31.9	0.000365	0.002513	1669.5	
glucose phosphate isomerase hypothetical	TMEM33	mwghuman3 OK#B:1465	NM_000175.2	NP_000166.2	1.4	2.6	0.000153	0.000236	1670.5	
protein FLJ11000 hypothetical	GPI	mwghuman3 OK#B:4538	NM_018295.1	NP_060765	1.6	5.1	0.000203	0.000448	1687.5	
protein MGC5576 calcium/calmodulin-dependent		mwghuman3 OK#A:06786	NM_024056.2	NP_076961.1	1.6	11.7	0.000735	0.000312	1710	
protein kinase ID protein tyrosine phosphatase, non-receptor type 21	CAMK1D	mwghuman3 OK#A:00327	NM_020397.1	NP_065130.1	1.4	2.6	0.00034	0.000423	1719	
eukaryotic translation initiation factor 2C	PTPN21	mwghuman3 OK#A:09269	NM_007039.2	NP_008970.1	1.4	2.4	0.000571	0.000259	1723.5	
WD repeat domain 18	EIF2C2	mwghuman3 OK#C:2287	NM_012154.2	NP_036286.2	1.4	2.5	0.00011	0.0000243	1730	
tensin	WDR18	mwghuman3 OK#B:3546	NM_024100.2	NP_077005.2	1.4	3.2	0.0000511	0.0000582	1748.5	
c-src tyrosine kinase	TNS	mwghuman3 OK#B:8493	NM_022648.2	NP_072174.2	1.3	2.0	0.0000393	0.000177	1753.5	
ubiquitin-conjugating enzyme E2C	CSK	mwghuman3 OK#A:01629	NM_004383.1	NP_004374.1	1.4	1.9	1.05E-06	0.0000107	1935.5	
neuropilin 1	UBE2C	mwghuman3 OK#A:01776	NM_181803.1	NP_861519.1	2.1	8.9	0.001146	0.003908	2155	
	NRP1	mwghuman3 OK#A:03091	NM_003873.2	NP_003864.2	1.9	6.0	0.003291	0.003636	2941	

Fig. 12 (continued)

101/102

control	number	TCC	number
other urological cancer	35	Ta grade 1	9
benign prostate hyperplasia	10	Ta grade 2	28
miscellaneous non malignant urological disease	10	T1 stage 2	4
TCC surveillance (no cancer)	47	Tis stage 1	1
urinary tract infection	21	Tis stage 2	1

Fig. 13

Area under curve (%)				
TCC characteristic	HoxA13	HoxA13/LTB4DH	IGFBP5	IGFBP5/LTB4DH
Stage Ta (grades 1-2)	64	67	61	70
Stage Ta (grade 1)	66	69	73	81
Grade 1 (all stages)	66	69	73	81
Grade 2 (all stages)	62	62	55	63
Grade 1-2 (all)	64	64	60	68

Fig. 14

102/102

BTM	Overall		
	Sensitivity	stage Ta	grade 1&2
cdc2 Hoxa13, MDK	0.61	0.41	0.42
cdc2, Hoxa13, MDK, LTB4DH	0.63	0.44	0.43
cdc2 Hoxa13, IGFBP5, MDK	0.61	0.44	0.44
cdc2 Hoxa13, IGFBP5, MDK, LTB4DH	0.62	0.46	0.45
cdc2, IGFBP5, MDK	0.61	0.44	0.45
cdc2, IGFBP5, MDK, LTB4DH	0.62	0.46	0.45
Hoxa13, IGFBP5, MDK, Top2a	0.61	0.44	0.45
Hoxa13, IGFBP5, MDK, Top2a, LTB4DH	0.63	0.47	0.46
Hoxa13, IGFBP5, MDK	0.61	0.44	0.45
Hoxa13, IGFBP5, MDK, LTB4DH	0.62	0.46	0.45
HoxA13, MDK	0.62	0.42	0.42
HoxA13, MDK, LTB4DH	0.64	0.45	0.44
IGFBP5, MDK	0.62	0.44	0.45
IGFBP5, MDK, LTB4DH	0.63	0.47	0.45
cdc2, IGFBP5, MDK, Top2a	0.62	0.45	0.45
cdc2, IGFBP5, MDK, Top2a, LTB4DH	0.64	0.48	0.46

Fig. 15